

CURRICULUM VITAE*Arturo Casadevall***PERSONAL DATA**

W. Harry Feinstone Department of Molecular Microbiology and Immunology
 Johns Hopkins Bloomberg School of Public Health
 615 N. Wolfe Street, E5132
 Baltimore, MD 21205
 Phone: 410-955-3457
 FAX: 410-955-0105
 E-Mail: acasad1@jhu.edu

EDUCATION AND TRAINING*Degree/Year Institution and Field Postdoctoral Training Medical or Other Licensure*

Year	Degrees/Certificate	Discipline	Institution
Undergraduate			
1979	B.A. (Magna Cum Laude)	Chemistry	Queens College, CUNY
Doctoral/graduate			
1983	M.S.	Biochemistry	New York University
1984	Ph.D.	Biochemistry	New York University
1985	M.D.	Medicine	New York University
Postdoctoral			
1985-1988	Bellevue Hospital - NYU Medical Center Internship and Residency in Internal Medicine		
1988-1989	Albert Einstein/Montefiore Medical Center Fellowship in Infectious Diseases		
1989-1991	Postdoctoral Fellowship with Dr. Matthew D. Scharff of Cell Biology, Albert Einstein College of Medicine		
1991	Cold Spring Harbor Course on Yeast Genetics		

Medical Board or Other Certification

2013-2023	American Board in Internal Medicine Certified in the Subspecialty of Infectious Diseases American Board in Internal Medicine Specialist in Internal Medicine	
1990	Diplomate in the Subspecialty of Infectious Diseases	
1988	Diplomate in the Specialty of Internal Medicine	
1986	National Board of Medical Examiners Diploma	

PROFESSIONAL EXPERIENCE (*annotate as appropriate*)

Alfred & Jill Sommer Prof. & Chair	2015-Present	JH Bloomberg Sch. of Public Health Dept of Molecular, Microbiol. & Immunol
Visiting Prof of Med. & Microbiol. & Immunol.	2015-present	Albert Einstein College of Medicine
Director, Ctr for Immunological Sciences	2013-15	Albert Einstein College of Medicine
Leo and Julia Forchheimer Professorship	2006-15	Albert Einstein College of Medicine
Chair, Dept of Microbiology & Immunology	2006-15	Albert Einstein College of Medicine
Interim Chair, Dept of Microbiol. & Immunol.	2005-06	Albert Einstein College of Medicine
Selma and Jacques Mitrani Professorship	2002-06	Albert Einstein College of Medicine

Director, Division of Infectious Diseases	2000-06	Montefiore Medical Ctr-Albert Einstein
Professor, Med. & Microbiol. & Immunology	2001-15	Albert Einstein College of Medicine
Assoc. Prof, Med. & Microbiol. & Immunol.	1996-01	Albert Einstein College of Medicine
Asst. Prof. Med. & Microbiol. & Immunol.	1992-96	Albert Einstein College of Medicine

PROFESSIONAL ACTIVITIES

American Association for the Advancement of Science
 American Association of Immunologists
 American Society for Clinical Investigation
 American Society for Microbiology
 Medical Mycology Society of the Americas
 Fellow, Infectious Disease Society of America
 Harvey Society
 Interurban Clinical Club
 Practitioner's Society
 National Academy of Medicine
 American Academy of Arts and Sciences

Service to Scientific Societies

1998-2000	Vice-President, New York Mycology Society
2000-02	President of New York Mycology Society
1998, 2002	Nominating committee for American Society for Microbiology (ASM) Division F officers
1998-2000	Councilor, New York Society for Infectious Diseases
2005	ASM Division F Chair Elect
2005	Nominated as Candidate for President of ASM
2006-09	Chair, ASM Career Development Committee
2004-07	ASM Abbot Award Selection Committee
2007-10	ASM Committee on Awards
2008-11	ASM Membership Election committee
2008-11	ASM Communications Committee
2008-11	ASM Minority Recruitment Committee
2008-present	ASM Minority Affairs Committee
2014-16	American Association of Immunology Minority Affairs Committee
2008-09	Medical Mycology Society of America President
2011-14	Elected Member-at-Large, AAAS Section on Medical Sciences
2014-16	American Association for Immunology Minority Affairs Committee
2012-15	Research Committee of the IDSA
2016-19	Elected Chair of the Board of Governors of the American Academy of Microbiology
2017	Elected Member of the American Academy of Arts and Sciences

Conference Organizer, Session Chair

1997	13th Congress of the International Society of Human and Medical Mycology, Parma Italy. Convener of symposium titled: Cell-mediated versus antibody mediated-protection mechanisms in fungal diseases: an ongoing dilemma.
1997	Program committee: The Fourth NIAID Workshop in Medical Mycology, Lake Tahoe
1999	Scientific Committee: Fourth International Meeting on Cryptococcus and Cryptococcosis, London
2000	Organizer, Bacteriology and Mycology Horizons for the 21 st century. A symposium in honor of Dr. William Branche, NIH, Shannon Building
2001	Convener, Symposium Host defense against fungi: application toward therapeutics and vaccine development. American Society of Microbiology, Orlando

2002 Scientific Committee: Fifth International Meeting on Cryptococcus and Cryptococcosis, Adelaide, Australia

2005 Scientific Committee: Six International Meeting on Cryptococcus and Cryptococcosis, Boston

2005 United States National Organizing Committee. International Union of Microbiological Societies Meeting. Representative for the American Society of Microbiology. San Francisco

2004 IDSA Program Committee

2006 IDSA Program Chair

2006 Scientific Committee. 13th Congress of the International Society of Human and Medical Mycology, Paris, France

2006 Scientific Committee. ASM Biodefense Meeting, Baltimore

2007 Co-chair, ASM colloquium on 'The fungal kingdom: diverse and essential roles in the earth's ecosystem' Developer of Division F program for ASM General meeting

2009, 2010 ASM Colloquium Advisory Committee

2010, 2012, 2015, 2017 Organizing committee for Model Host Meeting, Crete

2011 Gordon Conference on Chemical & Biological Terrorism Defense 2011 organizing committee

2010-2013 Keystone Symposia Scientific Advisory Board

2013-16 ASM General Meeting Program Chair

Consultantships

2006-11 Consultant, Pain Therapeutics

2012-14 Pfizer Resident Professors Program

Research Program Building / Leadership

2000-06 Director, Div. of Infectious Diseases Montefiore Medical Ctr-Albert Einstein
I was responsible for: 1) supervising clinical activities of the Division of Infectious Diseases in two hospitals (Montefiore and Weiler); 2) recruitment physician scientists; 3) mentoring faculty and fellows.

2006-14 Chair, Dept of Microbiology & Immunology Albert Einstein College of Medicine
I was responsible for: 1) supervising basic science department; 2) recruited six new faculty scientists; 3) mentored faculty, fellows and graduate students.

2015-present Chair and Alfred and Jill Sommer Professor, Bloomberg Distinguished Professor, W. Harry Feinstone Department of Molecular Microbiology & Immunology Johns Hopkins Bloomberg School of Public Health

EDITORIAL ACTIVITIES

1994 Journal of Medical and Veterinary Mycology, Guest Section Editor

1995-1997 Journal of Medical and Veterinary Mycology, Associate Editor

1995-2001 International Journal of Infectious Diseases, Editor

1997-2005 Infection and Immunity - Editorial Board

2005-2009 Infection and Immunity, Editor

1997-present Revista Iberoamericana de Micologia, Editorial Board

1996-present Emerging Infections Disease Editorial Board

2000 Section Editor-Host-Pathogen Interactions. Current Opinion in Microbiology

2004-present Expert Opinion on Emerging Drugs, Editorial Board

2005-present BMC Infectious Diseases, Editorial Board

Future Microbiology – Editorial Board

Faculty of 1000 Contributor

2003-present Nature Reviews in Microbiology – Highlights Advisor

2007-present Journal of Experimental Medicine – Editorial Board

2004-2012 Journal of Clinical Investigation – Editorial Board

2012-present Journal of Infectious Diseases Editorial Board
2010-present mBio – Founding Editor and EIC
2013 Section Editor-Host-Pathogen Interactions. Current Opinion in Microbiology

Journal Reviewer (partial list)

Antimicrobial Agents and Chemotherapy

American Journal of Epidemiology

American Journal of Pathology

Canadian Journal of Microbiology

Cell

Cellular Immunology Clinical Microbiology Reviews

Clinical Infectious Diseases

Emerging Infectious Diseases

FEMS Immunology and Medical Microbiology

Fungal Genetics and Biology

Genes and Development

Journal Clinical Investigation

Journal of Experimental Medicine

Journal of Infectious Diseases

Infection and Immunity

Immunity

Journal of Clinical Microbiology

Journal of Molecular Evolution

J. Immunological Methods

Journal of Immunology

Journal of Medical and Veterinary Mycology

J. Neuroimmunology

International Journal of Infectious Diseases

Immunity

Infectious Diseases in Clinical Practice

Lancet

Microbes and Infection

Journal of Molecular Biology

Nature Medicine

Revista Iberoamericana de Micologia

Molecular and Cellular Biology

Laboratory Investigation

Life Sciences

Microbes and Infection

New England Journal of Medicine

J. Dental Res.

Pediatric Infectious Diseases

PNAS

Trends in Microbiology

Advisory Committees, Review Groups/Study Sections

1994 National Cooperative Drug Discovery Group Study Section

1995, 1996 (Member 1996-2000); Chair 1998-2000NIH Bacteriology and Mycology 2 Study Section

1995 NSF Outside Reviewer

1998 Italian AIDS Program outside Reviewer

1996, 1997, 1998, 1999, 2003 Burroughs Wellcome Trust (United Kingdom) Outside Reviewer

1998	VA Merit Review outside Reviewer
1999	AIDS Study Section AAR1 Ad hoc Reviewer
2000	USDA SBIR Ad hoc Reviewer
1999	NIAID Strategic Plan Task Force
2000-15	St. Jude Fellowship for Pediatric Infectious Diseases
2002-07	Burroughs Wellcome Fund Advisory Committee
2001-5	NIH MIDRC (Microbiology and Infectious Diseases Research Committee) Study Section
2002	NIAID Blue Panel on Bioterrorism Research
2002-05	City University of New York Jonas Salk Award reviewer
2002	Ad Hoc Consultant to Board of Scientific Counselors for NCI
2002	Ad Hoc Consultant to Board of Scientific Counselors for NIAID
2003	National Research Council Workshop on Biotechnology and Bioterrorism
2004	Chair, Expert Panel for NIAID Invasive Aspergillosis Animal Models contract
2004	External Advisory Comm. for Pathomics Strategic Initiative, Lawrence Livermoreational Lab
2004	CDC Advisory panel on Anthrax Immune Globulin
2004-06	Scientific Advisory Board for the NIAID Immune Epitope Database contract
2004-07	Abbot Laboratories Award in Clinical and Diagnostic Immunology Selection Committee
2007-10	NIAID Board of Scientific Counselors 2005-2010; Co-Chair
2005-14	National Science Advisory Board for Biosecurity (NSABB)
2005	Chair, NAS Workshop 'NEW DIRECTIONS IN THE STUDY OF ANTIMICROBIAL THERAPEUTICS – IMMUNOMODULATORS
2005	Chair, NHLBI Working group Innate Immunity HIV & HIV-related Lung Infections
2007	Army Basic Research Review
2009	External Reviewer University of Colorado Department of Microbiology 2009
2011	Keystone Symposia SAB (ad hoc) 2009; Member 2010-2013; Chair Immunology section
2010-16	National Academy Sci Committee on Science Technology and Law
2009-11	National Academy Sci Committee to Review the FBI Investigation of the 2001 Bacillus anthracis Mailings
2010	NIAID Genomics Blue Ribbon Panel
2012	Pioneer Award Review Panel
2012-17	Co-Chair, N IAID Board of Scientific Counselors
2013	Review of Boston University Microbiology Program
2013-17	Scientific Council Institut Pasteur, Paris, France
2014	Co-Chair, Committee on the Future Direction of the NIAID Intramural Research Program
2014	NIH Advisory Council to the Director on long-term planning for the NIH intramural research program
2014	Review of Washington University Department of Microbiology
2014	Advisory Comm to the (NIH) Director Long-Term Intramural Research Program (LT-IRP)
2015	Review of Jefferson University Department of Microbiology
2015-2016	National Academy of Sciences Comm of Federal Regulations and Reporting requirement
2015-present	National Commission Forensic Science Board, Commissioner
2016	External Advisory Committee for the Mount Sinai Department of Microbiology
2016-present	National Academy of Sciences Committee on Dual Use Research of Concern: Options for Limited Communication 2016
2018	Advisory Board Center for Integrity in Forensic Science

HONORS AND AWARDS

Awards, Honors

1979	Stanley Konkol Memorial Award
1979	Chemistry Department Service Award

1979-83	Salk Scholarship
1979-85	Medical Scientist Training Program Fellowship
1989	Montefiore Fellow of the Year Award
1990	Pfizer Postdoctoral Fellowship Award
1992	James S. McDonnell Scholar Award
1996	Burroughs Wellcome Trust Fund Developmental Therapeutics Award
1997-98	Foundation for Microbiology Lectures Program
1999	Elected to the American Society for Clinical Investigation
1999	Melini Award
2001	Leo M. Davidoff Society (for outstanding teaching)
2001	Sam Rosen Award for outstanding teaching in Pre-Clinical Curriculum
2002	Alpha Omega Alpha
2002	Elected to Fellowship in American Academy of Microbiology
2002	Burroughs Wellcome Visiting Professorship to University of Wisconsin
2004	Elected to American Association of Physicians
2005	Solomon A Berson Medical Alumni Achievement Award in Basic Science -NYU Sch. of Med
2006	Elected AAAS Fellow
2006	Maxwell L. Littman Award (mycology award)
2007	Rhoda Benham Award from Medical Mycology Society of America
2007	NIH Merit Award
2008	ASM William Hinton Award (for mentoring scientists from underrepresented groups)
2008	Albert Einstein College of Medicine Faculty Mentoring Award
2010	Elected to the Interurban Club
2014	Commencement Speech, Albert Einstein College of Medicine graduation
2014	ASM Founders Award Distinguished Service Award
2014	Elected to Institute of Medicine of the National Academy of Sciences
2015	Delta Omega Alpha Chapter

Invited Talks, Panels

NAMED LECTURES

2008	IDSA Kass Lecturer
2009	14 th Farness Lecturer, U. Arizona 2009
2010	Marshall S. Horwitz Faculty Achievement Award 2010
2010	Nelson Lecture, Bozeman, Montana
2010	Theobald Smith Lecture at Albany
2010	Arthur White Lecture, U Indiana
2011	Louis Weinstein Lecture, Tufts University
2012	Jessie Boden Lloyd Visiting Professor for 2012 and gave the Jessie Boden Lloyd Lecture in Immunology, Calgary.
2012	ICAAC Lecturer
2012	Jenner Lecture, St Georges Hospital, London
2013	Michael Apicella Lecture, Iowa
2013	NIAID Kinyoun Lecture, Bethesda, MD
2013	Faculty of Science 50th Anniversary Speaker, University of British Columbia, Vancouver CA
2014	Bernard Fields Lecture Scripps, CA
2014	American Association of Immunology Minority Affairs Committee Guest Lecture
2015	McGinnis Memorial Lecture at Duke University, NC
2015	McCollum Colloquium Speaker, Dartmouth (student invited speaker)
2015	Douglas D. McGregor Research Lecture, Cornell University, Ithaca
2016	Naff Lecture, Case Western Reserve, Cleveland
2016	Robert McGhee Distinguished Lecture, University of Arkansas

- 2016 Medoff Lecture, Washington University Division of Infectious Disease
- 2016 Karling Lecture, Mycology Society of America
- 2017 Harry Smith Memorial Lecturer, Birmingham, United Kingdom
- 2017 Westmere Lecturer, Birmingham, United Kingdom
- 2017 Brown-Williamson Lecturer, Queens College, The City University of New York

PUBLICATIONS (813)

1. Baker AD, **Casadevall A**, Gafney HD, Gellender M (1980) Photochemical Reactions of Tris (Oxalato) Iron III. *J. Chem. Ed.* 57:314-315.
2. Baker AD and **Casadevall A** (1980) A Clock Reaction with Paraquat. *J. Chem. Ed.* 57:515-516.
3. **Casadevall A**, Day LA (1982) DNA Packing in the Filamentous Viruses fd, xφ, φφ1, and φφ3. *Nucleic Acids Res.* 10:2467-2481.
4. **Casadevall A**, Day LA (1983) Silver and Mercury Probing of Deoxyribonucleic Acid Structures in the Filamentous Viruses fd, φφ1, φKe, φφ, φφ1, and φφ3. *Biochem.* 22:4831-4842.
5. Putterman DG, **Casadevall A**, Boyle PD, Yang H-L, Frangione B, Day LA. (1984) Major Coat Protein and Single-Stranded DNA-binding Protein of the Filamentous Virus φφ3. *PNAS* 81:699-703.
6. **Casadevall A**, Day LA (1985) The Precursor Complex of the φφ3 Bacteriophage. *Virology* 45:260-272.
7. Day LA, **Casadevall A**, Prescott B, Thomas GJ (1988) Raman Spectroscopy of Mercury (II) Binding to Two Filamentous Viruses: φφ (fd, M13, φφ) and φφ1. *Biochem.* 27:706-711.
8. **Casadevall A**, Day LA (1988) Thermal Differences Circular Dichroism of φφ1 Filamentous Virus and Effects of Mercury (II) Silver (I), and Copper (II). *Biochem.* 27:3599-3602.
9. Day LA, Marzec CJ, Reisberg SA, **Casadevall A**. (1988) DNA Packing in Filamentous Bacteriophages. *Ann. Rev. Biophys. Biophysical Chem.* 17:509-539.
10. **Casadevall A**, Pirofski L, Catalano MT (1990) Primary Group A Streptococcal Peritonitis in Adults. *Am. J. Med.* 88:5-63N-64N.
11. Pirofski L, **Casadevall A**. (1990) Mixed Staphylococcal and Cryptococcal Epidural abscess in a patient with AIDS. *Rev. Infect. Dis.* 12:964-965.
12. Pirofski L, **Casadevall A**, Rodriguez L, Zuckier L, Scharff MD (1991) Current State of the Hybridoma Technology. *J. Clin. Immunol.*, 10, No. 6 (November Supplement), 5S-14S.
13. **Casadevall A**, Scharff MD (1991) The Mouse Antibody Response to Infection with *Cryptococcus neoformans*: V_H and V_L Usage in Polysaccharide Binding Antibodies. *J. Exp. Med.* 174:151-160.
14. Pettoello-Mantovani M, **Casadevall A**, Kollmann TR, Rubinstein A, Goldstein H. (1992) Enhancement of HIV-1 Infection by the Capsular Polysaccharide of *Cryptococcus neoformans*. *Lancet* 339:21-23.
15. **Casadevall A**, Mukherjee J, Devi S, Schneerson R, Robbins J, Scharff, M.D. (1992) Antibodies elicited by a *Cryptococcus neoformans* -tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. *J. Infect. Dis.* 165:1086-93.
16. **Casadevall A**, Dobroszycki J, Small C, Pirofski, L. (1992) *Haemophilus Influenzae* Type b Bacteremia in Adults with AIDS and at Risk for AIDS. *Am. J. Med.* 92:587-590.

17. **Casadevall A**, Freundlich LF, Pirofski L. (1992) Septic shock from *Pseudomonas paucimobilis*. Clin. Infect. Dis. 14:784.
18. **Casadevall A**, Freundlich L, Marsh L, Scharff MD. (1992) Extensive Allelic Variation in *Cryptococcus neoformans*. J. Clin. Microbiol. 30:1080-1084.
19. **Casadevall A**, Mukherjee J, Scharff MD. (1992). Monoclonal antibody based ELISAs for Cryptococcal polysaccharide. J. Immunol. Methods. 154:27-35.
20. Mukherjee J, Scharff MD, **Casadevall A** (1992). Protective murine monoclonal antibodies to *Cryptococcus neoformans*. Infection and Immunity 60:4534-4541.
21. Mukherjee J, **Casadevall A**, Scharff, MD (1993) Molecular characterization of the humoral responses to *Cryptococcus neoformans* infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med. 177:1105-1116.
22. **Casadevall A**, Fan M. (1992) The *URA5* gene of *Cryptococcus neoformans* var. *gattii*: Evidence for a close phylogenetic relationship between *C. neoformans* var. *gattii* and *C. neoformans* var. *neoformans*. J. Gen. Appl. Microbiol. 38:491-495.
23. Spitzer, ED, Spitzer S, Freundlich L, **Casadevall A**. (1993) Persistence of initial infection in recurrent *Cryptococcus neoformans* meningitis. Lancet 341:595-596.
24. **Casadevall A**, Dobroszycki J Small C, Pirofski, L. (1993) Bacteremic *H. influenzae* type b infection and HIV. Am. J. Med. 95:119.
25. Mukherjee J, Pirofski L, Scharff MD, **Casadevall A**. (1993) Antibody mediated protection in mice with lethal intracerebral *Cryptococcus neoformans* infection. PNAS 90:3636-3640.
26. **Casadevall A**, Spitzer ED, Webb D, Rinaldi MG (1993) Susceptibilities of serial *Cryptococcus neoformans* isolates from patients with recurrent cryptococcal meningitis to Amphotericin B and fluconazole. Antimicrobial Agents. Chemotherapy 37:1383-1386.
27. Mukherjee J, **Casadevall A**, Scharff MD (1993) Mu switch region deletion is associated with both T cell independent and T cell dependent responses. Molecular Immunology 30:1049-1055.
28. Currie BP, Freundlich LF, Soto MA, **Casadevall A** (1993) False negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture positive cryptococcal meningitis. J. Clin. Microbiol. 31:2519-2522.
29. **Casadevall A** (1993) Cryptococcosis: The case for immunotherapy. CliniGuide to Fungal Infections 4:1-5.
30. **Casadevall A** (1993) *Cryptococcus neoformans*: Ecology and Pathogenesis. CliniGuide to Fungal Infections 4:1-5.
31. Mantovani MP, **Casadevall A**, Goldstin H, (1993) The Presence of Cryptococcal Capsular Polysaccharide Increases the Sensitivity of HIV-1 Coculture in Children. Annals New York Academy of Sciences 693:281-283.

32. Mukherjee S, Lee S, Mukherjee J, Scharff, MD, **Casadevall A** (1994). Monoclonal antibodies to *Cryptococcus neoformans* capsular polysaccharide modify the course of intravenous infection in mice. *Infect. Immun.* 62:1079-1088.
33. Mukherjee J, Zuckier, L, Scharff, MD, and **Casadevall A** (1994). Therapeutic efficacy of monoclonal antibodies to *Cryptococcus neoformans* Glucuaonoxylomannan alone and in combination with amphotericin B. *Antimicrob. Agents Chemotherap.* 38:580-587.
34. Currie BP, Freundlich LF, **Casadevall A** (1994) Restriction fragment length polymorphism analysis of *Cryptococcus neoformans* isolates from environmental (pigeon excreta) and clinical sources in New York City. *J. Clin. Microbiol.* 32:1188-1192.
35. Fan M, Currie BP, Guttell R, Ragan M, **Casadevall A** (1994). The 16S-like, 5.8S, and 23-S-like rRNAs of the two varieties of *Cryptococcus neoformans*: sequence, secondary structure, and phylogenetic analysis and restriction fragment polymorphisms. *J. Med. Vet. Mycology* 32:163-180.
36. **Casadevall A**, Scharff, M.D. (1994). Serum Therapy Revisited: Animal models of infection and the development of passive antibody therapy. *Antimicrob. Agents Chemotherap.* 38:1695-1702.
37. Lee SC, Dickson DW, Brosnan CF, **Casadevall A** (1994) Human astrocytes inhibit *Cryptococcus neoformans* by a nitric oxide-mediated mechanism. *J. Exp. Med.* 180:365-369.
38. Wang Y, **Casadevall A** (1994) Susceptibility of melanized and non-melanized *Cryptococcus neoformans* to nitrogen and oxygen-derived oxidants. *Infect. Immun.* 62:3004-3007.
39. **Casadevall A**, DeShaw M, Fan M, Dromer F, Kozel TR, Pirofski L. Molecular and idiotypic analysis of antibodies to *Cryptococcal neoformans* Glucuronoxylomannan. *Infect. Immun.* 62:3864-3872.
40. Zebedee SL, Koduri RJ, Mukherjee J, Mukherjee S, Lee S, Sauer DF, Scharff MD, **Casadevall A** (1994) Mouse-Human chimeric Immunoglobulin G1 Chimeric antibodies with activities against *Cryptococcus neoformans*. *Antimicrob. Agents Chemotherap.* 38:1507-1514.
41. Ghannoum MA, Spellberg BJ, Ibrahim AS, Ritchie JA, Currie BP, Spitzer E, Edwards J, **Casadevall A** (1994) Sterol composition of *Cryptococcus neoformans* in the presence and absence of fluconazole. *Antimicrob. Agents Chemotherap.* 38:2029-2033.
42. Currie BP, **Casadevall A** (1994) Estimation of the prevalence of *Cryptococcus neoformans* infections among patients infected with the Human Immunodeficiency Virus in New York City. *Clin. Infect. Dis.* 19:1029-1033.
43. Pettoello-Mantovani M, **Casadevall A**, Goldstein H. (1994) Enhancement of HIV-1 Infectivity *in Vitro* by Capsular Polysaccharide of *Cryptococcus neoformans* and *Haemophilus influenzae*. *AIDS Research and Human Retroviruses* 10:1079-1087.
44. **Casadevall A**, Mukherjee J, Yuan R, Perfect J. (1994) Management of injuries caused by *Cryptococcus neoformans*-contaminated needle. *Clin. Infect. Dis.* 19:951-3.
45. Brosnan CF, Battistini L, Raine CS, Dickson DW, **Casadevall A**, Lee SC. (1994). Reactive nitrogen intermediates in human neuropathology: an overview. *Developmental Neuroscience* 16:152-161.

46. Cleare W, Mukherjee J, Spitzer ED, **Casadevall A** (1994) Prevalence in *Cryptococcus neoformans* strains of a polysaccharide epitope which can elicit protective antibodies. Clin. Diagn. Lab. Immunol. 1:737-740.
47. Wang, Y. and **Casadevall A** (1994) Decreased susceptibility of melanized *C. neoformans* to ultraviolet light. Appl.Environ.Microbiol. 60:3864-3866.
48. Spira, G, Ruirong, Y, Paizi, M, Weisendal M, **Casadevall A** (1994) Simultaneous expression of kappa and lambda light chains in a murine IgG3 anti-*Cryptococcus neoformans* hybridoma cell line. Hybridoma 13:531-535.
49. Mukherjee J, Scharff MD, **Casadevall A** (1994) *Cryptococcus neoformans* infection can elicit protective antibodies in mice. Can.J.Microbiol. 40:888-892.
50. Wang Y, **Casadevall A** (1994) Growth of *Cryptococcus neoformans* in the presence of L-dopa decreases its susceptibility to Amphotericin B. Antimicrobial Agents Chemoth. 38:2648-2650.
51. Goldman D, Lee SC, **Casadevall A** (1994) Pathogenesis of pulmonary cryptococcosis in the rat Infect. Immun. 62:4755-4761.
52. Mukherjee J, Nussbaum G, Scharff MD, **Casadevall A** (1995) Protective and non-protective antibodies to *C. neoformans* originating from one B cell. J. Exp. Med. 181:405-409.
53. Mukherjee S, Lee SC, **Casadevall A** (1995) Antibodies to *Cryptococcus neoformans* glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573-579.
54. Ruirong Y, **Casadevall A**, Spira G, Scharff MD (1995) Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to *Cryptococcus neoformans* to a protective antibody. J. Immunol. 154:1810-1816.
55. Mukherjee S, **Casadevall A** (1995) Sensitivity of sandwich ELISAs for *Cryptococcus neoformans* polysaccharide antigen is dependent on the isotype of the capture and detection antibodies. J. Clin. Microbiol. 33:765-768.
56. Mozaffarian N, Berman JW, **Casadevall A** (1995) Crosslinking of Fc-gamma receptors increases nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774.16 cells. J.Leukocyte Biol. 57:657-662.
57. Cherniak R, Morris LC, Belay T, Spitzer ED, **Casadevall A** (1995) Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent Cryptococcal Meningitis. Infect. Immun. 63:1899-1905
58. **Casadevall A** (1995) Antibody Immunity and *Cryptococcus neoformans*. Can.J.Bot. 73:s1180-1186.
59. **Casadevall A**, Scharff MD (1995) Return to the past: the case for the re-introduction of passive antibody therapy. Clin. Infect. Dis. 21:150-161.
60. Nussbaum G, Yuan R, **Casadevall A**, Valadon P, Scharff MD (1995) Vaccination elicits protective and non-protective antibodies to *Cryptococcus neoformans*. Vaccines 95. Cold Spring Harbor Press. Cold Spring Harbor, NY. p.231-235.

61. Kristensson K, Glasser SM, **Casadevall A**, Scharff MD, Zebedee SL, Huse WD (1995) Humanization of a murine antibody against *Cryptococcus neoformans* polysaccharide using a novel approach. *Vaccines* 95. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. p.39-43.
62. Mukherjee J, Cleare W, **Casadevall A** (1995) Monoclonal antibody mediated capsular reactions (quellung) in *Cryptococcus neoformans*. *J. Immunol. Methods* 184:139-143.
63. Currie BP, Ghannoum M, **Casadevall A** (1995) Decreased fluconazole susceptibility of a relapse *Cryptococcus neoformans* isolated after fluconazole treatment. *Infect.Dis.Clin.Pract.* 4:318-319.
64. Fan M, Chen L.-C, Ragan MA, Guttell RR, Warner JR, Currie BP, **Casadevall A** (1995) The 5S rRNA and the rDNA intergenic spacer of the two varieties of *Cryptococcus neoformans*. *J. Med. Vet. Mycology* 33:215-221.
65. Mukherjee J, Scharff MD, Feldmesser M, **Casadevall A** (1995) Monoclonal antibodies to *Cryptococcus neoformans* glucuronoxylomannan enhance fluconazole efficacy. *Antimicrob. Agents. Chemotherap.* 39:1398-1405.
66. Wang Y, Aisen P, **Casadevall A** (1995) *Cryptococcus neoformans* melanin and Fungal Virulence: Mechanism of Action. *Infect. Immun.* 63:3131-3136.
67. Goldman D, Lee SC, **Casadevall A** (1995) Tissue localization of *Cryptococcus neoformans* glucuronoxylomannan in the presence and absence of specific antibody. *Infection and Immunity* 63:3448-3453.
68. Lee SC, Kress Y, Dickson DW, and **Casadevall A** (1995) Human microglia mediate anti-*Cryptococcus neoformans* activity in the presence of specific antibody. *J. Neuroimmunology* 62:43-52.
69. Edelman M, Birkenhauer MC, Steinberg JJ, Dickson DW, **Casadevall A**, Lee SC. (1996) Microglial nodule encephalitis: limited CNS infection despite disseminated systemic Cryptococcosis. *Clinical Neuropathology* 15:30-33.
70. Mukherjee J., Scharff MD, and **Casadevall A** (1995) Variable efficacy of passive antibody administration against diverse *Cryptococcus neoformans* strains. *Infection and Immunity* 63:3353-3359.
71. Currie BC, Sanati H, Ibrahim AS, Edwards JE, **Casadevall A** and Ghannoum MA. (1995) The sterol composition and susceptibility to amphotericin B of environmental *Cryptococcus neoformans* are changed by murine passage. *Antimicrob. Agents Chemotherap.* 39:1934-1937.
72. Gordon M. and **Casadevall A** (1995) Serum therapy for cryptococcal meningitis. *Clin. Infect. Dis.* 21:1477-9.
73. Chen F, Currie BP, Chen L, Spitzer S, Spitzer ED, **Casadevall A** (1995) Genetic relatedness of *Cryptococcus neoformans* clinical isolates Grouped with repetitive DNA Probe CNRE-1. *J. Clin. Microbiol* 33:2818-2822.
74. **Casadevall A** (1995) Antibody immunity and fungal infections. *Infection and Immunity* 63:4211-4218.
75. Lee SC, Kress Y, Zhao ML, Dickson DW, **Casadevall A** (1995) *Cryptococcus neoformans* survive and replicate in human microglia. *Laboratory Investigation* 73:871-879.

76. Feldmesser M, Mukherjee J, **Casadevall A** (1996) Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine *Cryptococcus neoformans* infections and *in vitro*. J. Antimicrobial. Therap. 37:617-622.
77. Lee SC, **Casadevall A**, and Dickson, DW (1996) Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningitis. Amer. J. of Pathol. 148:1267-1274.
78. Pirofski L, **Casadevall A** (1996). *Cryptococcus neoformans*: Paradigm for the role of antibody immunity against fungi? Zentralblatt fur Bakteriologie 284:475-495.
79. Goldman D, Chao Y, Zhao M-L, **Casadevall A**, Lee, S.C. (1996) Expression of inducible nitric oxide synthase in rat pulmonary *Cryptococcus neoformans* granuloma. Amer. J. Pathol 148:1275-1282.
80. Nussbaum G, Yuan R, **Casadevall A**, Scharff MD. (1996) Immunoglobulin G3 to the Fungal Pathogen *Cryptococcus neoformans*. J. Exp. Med. 183:1905-1909.
81. Mukherjee S, Feldmesser M, **Casadevall A** (1996) J774 Murine macrophage cell interactions with *C. neoformans* in the presence and absence of opsonins. J. Infect. Dis. 173:1222-1231.
82. Lee SC, **Casadevall A** (1996) Polysaccharide antigen in brain tissue of patients with cryptococcal meningitis. Clin. Infect. Dis. 23:194-195.
83. Wang Y, **Casadevall A** (1996) Susceptibility of melanized and non-melanized *Cryptococcus neoformans* to the melanin-binding compounds trifluoperazine and chloroquine. Antimicrobial Agents and Chemotherapy 40:541-545.
84. Lee SC, Dickson DW, **Casadevall A** (1996) Pathology of cryptococcal meningoencephalitis. Analysis of 27 patients with pathogenic implications. Human Pathology 27:839-847.
85. Fries BC, Chen F, Currie BP, and **Casadevall A** (1996) Karyotype instability in *C. neoformans* J. Clin. Microbiol. 34:1531-1534.
86. **Casadevall A** Antibody-based therapies for emergent pathogens (1996) Emergent Infectious Diseases. Emergent Infectious Diseases 2:200-208.
87. Wang Y, Aisen P, and **Casadevall A** (1996) Melanin, melanin ghosts, and melanin composition of *Cryptococcus neoformans*. Infection and Immunity 64:2420-2424.
88. Spira G, Paizi M, Nussbaum G, Mukherjee S, **Casadevall A** (1996) Generation of biologically active anti *Cryptococcus neoformans* IgG, IgE, and IgA isotype-switch variant antibodies by acridine orange mutagenesis. Clin. Exp. Immunol. 105:436-442.
89. Chen L, Blank E, **Casadevall A** (1996) Extracellular proteinase activity of *C. neoformans*. Clin. Diagn. Lab. Immunol. 3:570-574.
90. **Casadevall A** (1996) Crisis in Infectious disease: Time for a new paradigm? Clin. Infect. Dis. 1996:23:790-794.
91. Feldmesser M, Harris C, Reichberg S, Khan S, and **Casadevall A** (1996) Serum Cryptococcal antigen in Patients with AIDS. Clin. Infect. Dis. 23:827-30.

92. Glatman-Freedman A, Martin JM, Riska, PF, Bloom BR, **Casadevall A** (1996) Monoclonal antibodies to surface antigens of *Mycobacterium tuberculosis* and their use in a modified ELISA spot assay for the detection of mycobacteria. J. Clin. Microbiol. 34:2795-2802.
93. Goldman DL, **Casadevall A**, ChoY, Lee SC (1996) Cryptococcus meningitis in the rat. Laboratory Investigation 75:759-770.
94. **Casadevall A** (1997) Antibodies and fungi: an evolving paradigm with opportunities for the development of new antifungal therapies and vaccines. Revista Iberoamericana de Micologia 14:2-3.
95. Feldmesser M, **Casadevall A** (1997) Effect of Serum IgG1 to *Cryptococcus neoformans* glucuronoxylomannan alters the course of murine pulmonary infection J. Immunol. 158:790-799.
96. Belay T, Cherniak R, Kozel T.R., **Casadevall A** (1997) Reactivity patterns and epitope specificities of anti-*Cryptococcus neoformans* antibodies by Enzyme-linked immunosorbent assay and dot blot assay. Infection and Immunity 65:718-728.
97. Nussbaum G, Cleare W, **Casadevall A**, Scharff MD, Valadon P (1997) Epitope location in the *Cryptococcus neoformans* capsule is a determinant of antibody efficacy. J. Exp. Med 185:685-694.
98. Franzot S and **Casadevall A** (1997) Pneumocandin L-743,872 enhances the activity of amphotericin b and fluconazole against *Cryptococcus neoformans in vitro*. Antimicrob. Agents Chemotherap. 41:331-336.
99. Lukashok S, **Casadevall A** (1997) Persistent vancomycin-resistant *Enterococcus faecium* bacteremia. Infec. Dis. Clin. Pract. 6:250-255.
100. Nosanchuck J and **Casadevall A** (1997) The cellular charge of *C. neoformans*: contributions from polysaccharide capsule, melanin, and monoclonal antibody binding. Infect. Immun. 65:1836-1841.
101. Ruirong Y, **Casadevall A**, Scharff MD (1997) T cells cooperate with passive antibody to modify *Cryptococcus neoformans* infective in mice. PNAS 94:2483-2488.
102. Feldmesser M, **Casadevall A**, Kress Y, Spira G, and Orlofsky A (1997) Eosinophil-*Cryptococcus neoformans* interactions *in vitro* and *in vivo*. Infection and Immunity 65:1899-1907.
103. Goldman DL, **Casadevall A**, Zuckier LS (1997) Pharmacokinetics and biodistribution of a monoclonal antibody to *Cryptococcus neoformans* capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy. J. Med. Vet. Mycol. 35:271-8.
104. Chen L-L, Pirofski L, **Casadevall A** (1997) Extracellular proteins of *C. neoformans* and the host antibody response. Infection and Immunity 65:2599-2605.
105. Rosas AL, **Casadevall A** (1997) Melanization affects susceptibility of *Cryptococcus neoformans* to heat and cold stress. FEMS Microbiology Letters 153:265-272.
106. Franzot S, Hamdan J, Currie BP, **Casadevall A** (1997). Molecular epidemiology of *Cryptococcus neoformans* in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J. Clin. Microbiol. 35:2243-2251.

107. Mozaffarian N, Berman JW, **Casadevall A** (1997) Enhancement of macrophage nitric oxide synthesis represents an additional mechanism of action for amphotericin B. *Antimicrob. Agents Chemotherap.* 41:1825-1829.
108. Blackstock R and **Casadevall A** (1997) Presentation of Cryptococcal Capsular polysaccharide (GXM) on activated antigen-presenting cells inhibits the T suppressor response and enhances delayed-type hypersensitivity and survival. *Immunology* 92:334-339.
109. **Casadevall A**, Goldman DL, Feldmesser MF (1997) Antibody-based therapies for infectious diseases: Renaissance for an abandoned arsenal? *Ann. Pasteur. Inst.* 95:247-257.
110. Pirofski L and **Casadevall A** (1998) The use of licenced vaccines for active immunization of the immunocompromised host. *Clin. Microbiol. Rev.* 11:1-26.
111. Podwall D, Yador E, Mille, S, Pena J, Franzot SP, **Casadevall A**, Steinberg JJ (1998) Interstrain variation in the deoxynucleotide composition of *Cryptococcus neoformans*. *J. Med. Vet. Mycol.* 36:1-5.
112. Young A, Valadon P, **Casadevall A**, Scharff MD, Sacchatini J (1997) The three dimensional structures of a polysaccharide binding antibody to *Cryptococcus neoformans* and its complex with a peptide from a phage display library: implications for the identification of peptide epitopes. *J. Mol. Biol.* 274:622-634.
113. Vecchiarelli A, Monan C, Retini C, Pietrella D, Palazetti B, Pitzurra L, and **Casadevall A** (1998) *Cryptococcus neoformans* differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. *Eur. J. Immunol.* 28:114-121.
114. Franzot SP, Mukherjee J, Cherniak R, Chen L, Hamdam JS, and **Casadevall A** (1998) Microevolution of a standard strain of *Cryptococcus neoformans* resulting in differences in virulence and other phenotypes. *Infect. Immun.* 66:89-97.
115. Vecchiarelli A, Retini C, Monari C and **Casadevall A** (1998) Specific antibody to *Cryptococcus neoformans* alters human leukocyte cytokine expression and promotes T cell proliferation. *Infect. Immun.* 66:1244-1247.
116. Glattman-Freedman A and **Casadevall A** (1998) Serum therapy for tuberculosis revisited: A critical reappraisal of the role of antibody-mediated immunity against *Mycobacterium tuberculosis*. *Clin. Microbiol. Rev.* 11:514-542.
117. Yuan R, Spira G, Oh J, Paizi M, **Casadevall A**, Scharff MD, (1998). Isotype switching increases antibody protective efficacy to *Cryptococcus neoformans* infection in mice. *Infect. Immun.* 66:1057-1062.
118. Lendvai N, **Casadevall A**, Liang Z, Goldman DL, Mukherjee J, Zuckier L, (1998) Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. *J. Infect. Dis.* 177:1647-1659.
119. Feldmesser M, Kress Y, **Casadevall A** (1998) Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with *Cryptococcus neoformans*. *J. Infect. Dis.* 177:1639-1646.

120. Murphy JW, Schafer F, **Casadevall** A (1998) Antigen-induces protective and nonprotective cell-mediated immune components against *Cryptococcus neoformans*. *Infection and Immunity* 66:2632-2639.
121. Cleare W and **Casadevall** A (1998) The different binding patterns of two immunoglobulin M monoclonal antibodies to *Cryptococcus neoformans* serotype A and D strains correlate with serotype classification and differences in functional assays. *Clin. Diagn. Lab. Immunol.* 5:125-128.
122. **Casadevall** A (1998) Antibody-mediated protection against intracellular pathogens. *Trends in Microbiology* 6:102-107.
123. Feldmesser M and **Casadevall** A (1998) Mechanism of action of antibody to capsular polysaccharide in *Cryptococcus neoformans* infection *Frontiers in Bioscience*, 3:d136-151.
124. **Casadevall** A (1998) Antibody-based therapies as anti-infective agents *Expert Opinion on Investigational Drugs*, 7:307-321.
125. **Casadevall** A, Cleare W, Feldmesser M, Glatman-Freedman A, Goldman DL, Kozel TR, Lendvai N, Mukherjee J, Pirofski L, Rivera J, Rosas AL, Scharff MD, Valadon P, Westin K, Zhong Z (1998) Characterization of a murine monoclonal antibody to *Cryptococcus neoformans* polysaccharide that is a candidate for human therapeutic studies. *Antimicrob. Agents Chemotherap.* 42:1437-1446.
126. **Casadevall** A. (1998) Cryptococcosis in Alabama. *Ann. Epidemiol.* 8:209-211.
127. Dixon DM, **Casadevall** A, Klein B, Mendoza L, Travassos L, Deepe GS (1998) Development of vaccines and their use in prevention of fungal infections *Medical Mycology* 36 (suppl):57-67.
128. **Casadevall** A, Cassone A, Bistoni, F., Cutler, J.E., Magliani, W., Murphy, J.W., Polonelli, L., Romani, L. Antibody - and/or cell mediated immunity - protective mechanisms in fungal disease: and ongoing dilemma or an unnecessary dispute? (1998) *Medical Mycology* 36 (suppl):95-105.
129. Franzot SP, Fries BC, Cleare W, **Casadevall** A (1998) Genetic relationship between *Cryptococcus neoformans* var. *neoformans* strains of serotypes A and D. *J. Clin. Microbiol.* 36 :2200-2204.
130. Nosanchuk JD, Rosas AL, **Casadevall** A (1998) The antibody response to fungal melanin in mice *J. Immunol.* 160:6026-6031.
131. Vecchiarelli A, Retini C, **Casadevall** A, Monari C, Pietrella D, Kozel TR (1998) Involvement of C3a and C5a in Interleukin-8 secretion by human polymorphonuclear cells in response to capsular polysaccharide material of *Cryptococcus neoformans*. *Infect. Immun.* 66:4324-4330,.
132. Dong F, Feldmesser M, **Casadevall** A, Rubin CS (1998) Molecular characterization of a cDNA that encodes six isoforms of a novel murine A kinase anchor protein. *J.Biol.Chem.* 273:6533-6541.
133. Vecchiarelli A and **Casadevall** A (1998) Antibody-mediated effects against *Cryptococcus neoformans*: evidence for interdependency and collaboration between humoral and cellular immunity. *Res.Immunol.* 149:321-333.
134. Mukherjee J, Kozel TR, **Casadevall** A (1998) Monoclonal antibodies Reveal Additional Epitopes of Serotype D *Cryptococcus neoformans* capsular Glucuronoxylomannan that Elicit Protective Antibodies. *J. Immunol.* 161:3557-3568.

135. Rivera J, Feldmesser M, Cammer M, **Casadevall A** (1998) Organ dependent variation of capsule thickness in *Cryptococcus neoformans* during experimental murine infection. Infect. Immun. 66:5027-5030.
136. Fries BC and **Casadevall A** (1998) Serial isolates of *Cryptococcus neoformans* from patients with AIDS differ in virulence for mice. J. Infect. Dis. 178:1761-1766
137. Goldman DL, Fries, BC, Franzot SP, Montella L, **Casadevall A** (1998) Phenotypic switching in the human pathogenic fungus *Cryptococcus neoformans* is associated with changes in virulence and pulmonary inflammatory responses in rodents. PNAS 95:14967-14972.
138. Teitelbaum R, Glatman-Freedman A, Chen B, Robbins JB, Unanue E, **Casadevall A**, Bloom BR (1998) A Mab recognizing a surface antigen of *Mycobacterium tuberculosis* enhances host survival. PNAS 95:15688-15693.
139. Heitman J, **Casadevall A**, Lodge JK, and Perfect JR (1999) The *Cryptococcus neoformans* genome sequencing project. Mycopathologia 148:1-7.
140. Nosanchuk J, Valadon P, Feldmesser M, **Casadevall A** (1999) Melanization of *Cryptococcus neoformans* in murine infection. Mol.Cell Biol. 19:745-750.
141. Cleare W and **Casadevall A** (1999) Scanning electron microscopy of encapsulated and non-encapsulated *Cryptococcus neoformans* and the effect of glucose on capsular polysaccharide release. Medical Mycology 7(4):235-43.
142. Retini C, **Casadevall A**, Pietrella D, Monari C, Palazatti B, Vecchiarelli A (1999) Specific activated T cells regulate interleukin-12 production by human monocytes stimulated with *Cryptococcus neoformans*. J. Immunol. 162:1618-1623.
143. Nosanchuk J, Cleare W, Franzot SP, **Casadevall A** (1999) Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of *Cryptococcus neoformans* at subinhibitory concentrations. Antimicrob. Agents Chemother. 43:233-239.
144. Franzot SP, Salkin IF, **Casadevall A** (1999) *Cryptococcus neoformans* var. *grubii*: separate varietal status for *Cryptococcus neoformans* serotype A isolates. J. Clin. Microbiol. 37:838-840.
145. Chen LC and **Casadevall A** (1999) Labeling of proteins with [³⁵S]-methionine and/or [³⁵S]-cysteine in the absence of cells. Analytical Biochem. 269:179-188.
146. Chen LC and **Casadevall A** (1999) Variants of a *Cryptococcus neoformans* strain elicit different inflammatory responses in mice. Clin.Diagn.Lab.Immunol.6:266-268.
147. Doering TL, Nosanchuk KD, Roberts KW **Casadevall A** (1999) Melanin as a potential cryptococcal defense against microbicidal proteins. Med.Mycol. 7(3):175-81.
148. Chen L, Goldman DA, Doering TL, Pirofski L, **Casadevall A** (1999) The antibody response to *Cryptococcus neoformans* in rodents and humans. Infect. Immun. 67:2218-2224.

149. Monari C, **Casadevall** A, Retini C, Baldelli F, Bistoni F, Vecchiarelli A (1999) Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against *Cryptococcus neoformans*. *AIDS* 13:653-660.
150. Cleare W, Cherniak RL, **Casadevall** A (1999). In vitro and in vivo stability of a *Cryptococcus neoformans* glucuronoxylomannan epitope that elicits protective antibodies. *Infect. Immun.* 67(6):3096-107.
151. Lendvai N, **Casadevall** A (1999) Monoclonal Antibody-mediated toxicity in *Cryptococcus neoformans* infection: mechanism and relationship to antibody isotype. *J. Infect. Dis.* 180:791-801.
152. **Casadevall** A, Pirofski L (1999) Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. *Infect. Immun.* 67:3703-3713.
153. Monari C, Kozel TR, **Casadevall** A, Pietrella D, Palazzetti B, Vecchiarelli A (1999) B7 co-stimulatory ligand regulates development of the T cell response to *Cryptococcus neoformans*. *Immunology* 98:27-35.
154. Nussbaum GJ, Anadasabapthy S, Mukherjee J, Fan M, **Casadevall** A, Scharff MD (1999) Molecular and idiotypic analysis of the antibody response to *Cryptococcus neoformans* glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice. *Infect. Immun.* 67(9):4469-76.
155. Cleare W, Brandt ME, **Casadevall** A (1999) Monoclonal antibody 13F1 produces annular immunofluorescence patterns on *Cryptococcus neoformans* serotype AD isolates. *J. Clin. Microbiol.* 37:3080.
156. **Casadevall** A (1999) Passive antibody therapies: progress and continuing challenges. *Clin. Immunol.* 93(1):5-15.
157. Nosanchuk J, Rudolf J, Rosas AL, **Casadevall** A (1999) Evidence that *Cryptococcus neoformans* is melanized in pigeon excreta: implications for pathogenesis. *Infect. Immun.* 67:5477-9.
158. Monari C, **Casadevall** A, Pietrella D, Bistoni F, Vecchiarelli A (1999) Neutrophils from Patients with Advanced Human Immunodeficiency Virus Infection have impaired complement receptor function and preserved FCY Receptor Function. *J. Infect. Dis.* 180:1542-9.
159. Fries BC, Goldman DL, Cherniak R, Ju R, **Casadevall** A (1999) Phenotypic Switching in *Cryptococcus neoformans* strain 24067A is associated with changes in virulence, polysaccharide structure and cellular morphology. *Infect. Immun.* 67:6076-83.
160. Goldman DL, Lee SC, Mednick AJ, Montell L, **Casadevall** A (2000) Persistent *Cryptococcus neoformans* pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide expression and altered antibody responsiveness to cryptococcal polysaccharide. *Infect. Immun.* 68:832-838.
161. Glatman-Freeman, Mednick A, Lendvai N, **Casadevall** A (2000) Clearance and organ distribution of *Mycobacterium tuberculosis* lipoarabinomannan (LAM) in the presence and absence of LAM-specific Immunoglobulin M. *Infect. Immun.* 68:335-341.
162. Cox GM, Mukherjee J, Cole GT, **Casadevall** A, Perfect JR (2000). Urease as a virulence factor in experimental cryptococcosis. *Infect. Immun.* 68:443-8.

163. Nosanchuk JD, Shoham S, Fries BC, Shapiro DS, Levitz SM, **Casadevall A** (2000) Evidence for zoonotic transmission of *Cryptococcus neoformans* from a pet cockatoo to an immunocompromised patient. *Ann.Intern.Med.*2000: 132; 205-208.

This article was featured in the Science section of the New York Times

<http://partners.nytimes.com/library/national/science/health/020800hth-animal-fungus.html>

164. Rosas A, Nosanchuk JD, Feldmesser M, Cox, McDade HC, and **Casadevall A** (2000) Synthesis of polymerized melanin by *Cryptococcus neoformans* in rodents. *Infect. Immun.* 68:2845-2853.

165. Lendvai N, Xiao-Wu Q, Hsueh W, **Casadevall** (2000) Mechanism for the isotype dependence of antibody-mediated toxicity in *Cryptococcus neoformans* infected mice. *J. Immunol.* 164:4367-4374.

166. Feldmesser M, Rivera J, Kress Y, Kozel TR, **Casadevall A** (2000) Antibody interactions with the capsule of *Cryptococcus neoformans*. *Infect. Immun.* 68:3642-3650.

167. Steenbergen J and **Casadevall A** (2000) Prevalence of *cryptococcus neoformans* var. *neoformans* (Serotype D) and *cryptococcus neoformans* var. *grubii* (Serotype A) isolates in New York City. *J. Clin. Microbiol.* 38:1974-1976.

168. Nosanchuk JD, Rosas AL, Lee SC, **Casadevall A** (2000) Melanization of *Cryptococcus neoformans* in human brain tissue. *Lancet* 355:2049-2050.

169. Tracy C, MacGill RS, MacGill A, **Casadevall A**, Kozel TR (2000) Biological correlates of capsular (quellung) reactions of *Cryptococcus neoformans*. *J. Immunol.* 164:4835-4842.

170. **Casadevall A**, Rosas AL, Nosanchuk JD (2000) Melanin and virulence in *Cryptococcus neoformans*. *Current Opinion in Microbiology* 3:354-358



171. Feldmesser M, Kress Y, Novikoff P **Casadevall A** (2000). *Cryptococcus neoformans* is a facultative intracellular pathogen in murine pulmonary infection. *Infect. Immun.* 68:4225-4237.

172. Mozaffarian N, **Casadevall A**, Berman JW (2000) Inhibition of human endothelial cell chemokine production by the opportunistic fungal pathogen *Cryptococcus neoformans*. *J. Immunol.* 165:1541-1547.

173. Rosas AL, Nosanchuk JD, Gomez BL, Edens WA, Henson JM, **Casadevall A** (2000) Isolation and serological analyses of fungal melanins. *J. Immunol. Methods* 244:69-80.

174. **Casadevall A** (2000) Host-microbe interactions: fungi. *Recent Progress in understanding host-fungal interactions. Current Opinion in Microbiology* 3:337-338.

175. Monari C, **Casadevall A**, Baldelli F, Francisci D, Pietrella D, Bistoni F, Vecchiarelli A (2000) Normalization of anti-cryptococcal activity and interleukin-12 secretory function of polymorphonuclear leukocytes from HIV-infected patients after highly active antiretroviral therapy. *AIDS* 14:2699-2708.

176. Vecchiarelli A, Monari C, Palazzetti B, Bistoni F, **Casadevall A** (2000) Dysregulation of IL-12 secretion by neutrophils from infected patients. *Clin.Exp.Immunol.* 121:311-319.
177. **Casadevall A**, Pirofski L (2000) Host-Pathogen Interactions. The basic concepts of microbial commensalism, colonization, infection and disease. *Infect. Immun.* 68:6511-6518.
178. Feldmesser M, Kress Y, **Casadevall A** (2000) The Effect of the Echinocandin Analog Caspofungin on Cell Wall Glucan Synthesis by *Cryptococcus neoformans*. *J. Infect. Dis.* 182:1791-1795.
179. Cox GM, McDade HC, Chen SC, Tucker SC, Gottfredsson M, Wright LC, Sorrell T, Leidich SD, **Casadevall A**, Ghannoum MS, Perfect JR (2001) Extracellular Phospholipase Activity is a Virulence Factor for *Cryptococcus neoformans* *Mol.Micro.* 39:166-175.
180. Garcia-Rivera J, **Casadevall A** (2001) Melanization of *Cryptococcus neoformans* reduces its susceptibility to the antimicrobial effects of Silver Nitrate. *Medical Mycology* 39:353-357.
181. Tabora C, **Casadevall A** (2001). Immunoglobulin M efficacy against *Cryptococcus neoformans*: mechanism, dose dependence and prozone-like effects in passive protection experiments. *J. Immunol.* 166:2100-2107.
182. Luberto C, Toffaletti DL, Wills EA, Tucker SC, **Casadevall A**, Perfect JR, Hannun YU, Del Poeta M (2001). Roles for inositol-phosphoryl ceramide synthase 1 (*IPC1*) in pathogenesis of *Cryptococcus neoformans*. *Genes & Development* 15:201-212.
183. Schwebach JR, Jacobs WR Jr, **Casadevall A** (2001) Sterilization of *Mycobacterium tuberculosis* Erdman Samples by Antimicrobial Fixation in the BSL-3 Laboratory. *J. Clin. Microbiol.* 39:769-771.
184. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, Niang R, **Casadevall A** (2001) Serologic Evidence for *Cryptococcus neoformans* Infection in Early Childhood. *Pediatrics* 107; E66. (Published in electronic pages - full text at <http://www.pediatrics.org/cgi/content/full/107/5/e66>)
185. McClean GR, Nakouzi A, **Casadevall A**, Green NS (2000). Human and murine immunoglobulin expression vector cassettes. *Mol.Immunol.* 37:837-845.
186. Nosanchuk JD, Ovalle R, **Casadevall A** (2001). Glyphosate Inhibits Melanization of *Cryptococcus neoformans* and Prolongs Survival of Mice following Systemic Infection. *J. Infect. Dis.* 183:1093-1099.
187. Goldman D, Song X, Kitai R, **Casadevall A**, Zhao M, and Lee SC (2001) *Cryptococcus neoformans* induces MIP-1alpha and MIP-1alpha in human microglia: The role of specific antibody and soluble capsular polysaccharide. *Infect. Immun.* 69:1808-1815.
188. San-Blas G, Travassos LR, Fries BC, Goldman DS, **Casadevall A**, Carmona AK, Barros TF, Puccia R, Hostetter MK, Shanks SG, Copping VMS, Knox Y, Gow NAR (2001) Fungal morphogenesis and virulence. *Med.Mycol.* 38(Suppl 1):79-86.
189. Stevens DA, Kullberg BJ, Brummer E, **Casadevall A**, Netea MG (2001) Combined treatment: antifungal drugs with antibodies and cytokines. *Med Mycol* 38(Suppl 1):305-315.
190. Polonelli L, **Casadevall A**, Adriani D, Bernardis F, Boccanera M, Burnie JP, Cassone A, Conti S, Cutler JE, Frazzi R, Gregory C, Han Y, Hodgetts S, Illidge C, Kirkland TN, Magliani W, Matthews RC, Rigg G, Santoni G (2001) The efficacy of acquired humoral and cellular immunity in the prevention and

therapy of experimental fungal infections. *Med. Mycol.* 38(Suppl 1):281-292.


191. Feldmesser M, Kress Y, **Casadevall** A (2001) Intracellular crystal formation as a mechanism of cytotoxicity in murine pulmonary *Cryptococcus neoformans* infection. *Infect. Immun.* 69:2723-2727.

192. Wills EA, Roberts IS, del Poeta M, Cox GM, Rivera J, **Casadevall** A, Perfect JR (2001) Identification and characterization of the *Cryptococcus neoformans* phosphomannose isomerase-encoding gene, *MAN1*, and its impact on pathogenicity. *Mol. Micro.* 40:610-620.

193. Nakouzi A, Valadon P, Nosanchuk J, Green N, **Casadevall** A (2001) Molecular basis for IgM specificity to epitopes in *Cryptococcus neoformans* that elicit protective and non-protective antibodies. *Infect. Immun.* 69:3398-3409.

194. Rosas AL, Nosanchuk J, **Casadevall** A (2001) Passive Immunization with Melanin-Binding Monoclonal Antibodies Prolongs Survival in Mice with Lethal *Cryptococcus neoformans* Infection *Infect. Immun.* 69:3410-3412.

195. Feldmesser M, Tucker S, **Casadevall** A (2001) Intracellular parasitism of macrophages by *Cryptococcus neoformans*. *Trends in Microbiology* 9:273-278.



196. **Casadevall** A, Pirofski L (2001) Host-pathogen interactions: the attributes of virulence. *J. Infect. Dis.* 184:337-344.

197. Feldmesser M, Kress Y, **Casadevall** A (2001) Dynamic changes in the morphology of *Cryptococcus neoformans* during infection. *Microbiology* 147:2355-2365.

198. **Casadevall** A, Pirofski L (2001) Adjunctive immune therapy for fungal infections. *Clin. Infect. Dis.* 33:1048-1056.

199. Gomez BL, Nosanchuk JD, Diez S, Youngchim S, Aisen P, Cano LE, Restrepo A, **Casadevall** A, Hamilton AJ (2001) Detection of melanin-like pigments in the dimorphic fungal pathogen *Paracoccidioides brasiliensis* *in vitro* and during infection. *Infect. Immun.* 69:5760-5767.

200. Schwebach JR, **Casadevall** A, Schneerson R, Dai Z, Wang Z, Robbins JB, Glatman-Freedman A (2001) Expression of a *Mycobacterium tuberculosis* arabinomannan antigen *in vitro* and *in vivo*. *Infect. Immun.* 69:5671-5678.

201. Zhu X, Gibbons J, Garcia-Rivera J, **Casadevall** A, Williamson PR (2001) Laccase of *Cryptococcus neoformans* is a cell wall associated virulence factor. *Infect. Immun.* 69:5589-5596.
F1000 Recommended <http://f1000.com/prime/1052866#recommendations>

202. Rosas AL, **Casadevall** A (2001) Melanization decreases the susceptibility of *Cryptococcus neoformans* to enzymatic degradation. *Mycopathologia* 151:53-56.


203. Martinez LR, Garcia-Rivera J, **Casadevall A** (2001) *C. neoformans* serotype D strains are more susceptible to heat than serotype A strains. J. Clin. Microbiol. 39:3365-3367.
204. Beenhouwer DO, Shapiro S, Feldmesser M, **Casadevall A**, Scharff MD (2001) Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against *Cryptococcus neoformans*. Infect.Immun.69:10) 6445-6455
205. McFadden DC, **Casadevall A** (2001) Capsule and melanin synthesis in *Cryptococcus neoformans*. Med. Mycol. 39:19-30.
206. Fries BC, Tarborda CP, Serfass E, **Casadevall A** (2001) Phenotypic switching of *Cryptococcus neoformans* occurs in vivo and influences the outcome of infection. J. Clin. Invest. 108:1639-1648.
207. Steenbergen J, Shuman H, **Casadevall A** (2001). *Cryptococcus neoformans* interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. PNAS 98:15245-15250.
F1000 Recommended Must read <http://f1000.com/prime/1004027#recommendations>
Paper was discussed in PNAS commentary <http://www.pnas.org/content/98/26/14760.extract>
Editor's choice. Science, <http://www.sciencemag.org/content/295/5553/235.2.full.pdf?sid=3c9abfcd-cf2e-42a1-a014-c5fe82017a7b>
208. Rosas AL, McGill RS, Nosanchuk JD, Kozel TR, **Casadevall A** (2002) Activation of the alternative complement pathway by fungal melanins. Clin.Dian.Lab.Immunol. 9:144-148
209. Westin Kwon K, Lendvai N, Morrison S, Trinh KR, **Casadevall A** (2002) Biological activity of a mouse-human chimeric immunoglobulin G2 antibody to *Cryptococcus neoformans* polysaccharide. Clin. Diagn. Lab. Immunol. 9:201-204.
210. Feldmesser M, Mednick A, **Casadevall A** (2002). Antibody-mediated protection in murine *Cryptococcus neoformans* infection is associated with subtle pleiotrophic effects on cytokine and leukocyte response. Infect. Immun. 70:1571-1580.
211. **Casadevall A**, Pirofski L (2002) What is a pathogen? Annals of Medicine 34:2-4.
212. Tucker SC, **Casadevall A** (2002) Replication of *Cryptococcus neoformans* in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. PNAS 99:3165-3170.
213. Schwebach JR, Glatman-Freedman A, Gunther-Cummins L, Dai Z, Robbins JB, Schneerson R and **Casadevall A** (2002) Glucan is a Component of the *Mycobacterium tuberculosis* Surface That is Expressed *in vitro* and *in vivo*. Infect. Immun. 70:2566-2577.
214. Shapiro S, Beenhouwer DO, Feldmesser M, Taborda C, Carroll MC, **Casadevall A**, Scharff MD (2002) Immunoglobulin G monoclonal antibodies to *Cryptococcus neoformans* protects mice deficient in complement component C3. Infect. Immun. 70:2598-2604.
215. **Casadevall A** (2002) Antibodies for defense against biological attack. Nature Biotechnology 20:114.
216. Rivera J, Mukherjee J, Weiss LM, **Casadevall A** (2002) Antibody efficacy in murine pulmonary *Cryptococcus neoformans* infection: a role for nitric oxide. J. Immunol. 168:3419-3427.

217. Vecchiarelli A, Pietrella D, Bistoni F, Kozel TR, **Casadevall** A (2002) Antibody to *Cryptococcus neoformans* capsular glucuronoxylomannan promotes expression of IL2Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells. Immunology 106:267-72.

218. **Casadevall** A, Feldmesser M, and Pirofski L (2002) Induced humoral immunity and vaccination against major human fungal pathogens. Curr. Opin. Microbiol. 5:386.

219. **Casadevall** A (2002) Passive antibody administration ('immediate immunity') as a specific defense against biological weapons. Emerg. Infect. Dis. 8:833-41

220. McLean G, Torres M, Elguezabal N, Nakouzi A, **Casadevall** A (2002) Isotype can affect the specificity of an antibody for a polysaccharide antigen. J. Immunol. 169:1379-86.



221. Taborda C, **Casadevall** A (2002) CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement independent antibody-mediated phagocytosis of *Cryptococcus neoformans*. Immunity 16:791-802 *F1000 Must Read* <http://f1000.com/prime/1030371#recommendations>

222. Schwebach JR, Chen B, Glatman-Freedman, **Casadevall** A, McKinney J, Bloom BR, Jacobs WR Jr. (2002) Infection in mice with aerosolized *Mycobacterium tuberculosis*: use of a nose-only apparatus for delivery of low-innocula and design of an ultra-safe facility. Applied Environ. Microbiol. 68:4646-4649

223. Song X, Shapiro S, Goldman DL, **Casadevall** A, Scharff M, Lee SC (2002) FcgammaRI_ and FcgammaRIII_ mediated MIP_1alpha induction in primary human and murine microglia. Infect. Immun. 70:5177-84

224. Nosanchuk JD, Gomez BL, Diez S, Youngchim S, Aisen P, Restrepo A, **Casadevall** A, Hamilton AJ (2002). *Histoplasma capsulatum* synthesizes melanin_like pigments in vitro and during mammalian infection. Infect. Immun. 70:5124-31 **A. Casadevall** And A.J. Hamilton shared senior authorship

225. Van Duin D, **Casadevall** A, Nosanchuk JD (2002) Melanization of *Cryptococcus neoformans* and *Histoplasma capsulatum* Reduces Their Susceptibilities to Amphotericin B and Caspofungin. Antimicrob. Agents Chemotherap. 46:3394-400.

226. Pirofski L, **Casadevall** A (2002). The meaning of microbial exposure, infection, colonization, and disease in clinical practice. Lancet Infect. Dis. 2(10):628-35.

227. Fries BC, Goldman DL, **Casadevall** A (2002) Phenotypic switching in *Cryptococcus neoformans*. Microbes Infect. 4:1345-1352.

228. Perfect JR, **Casadevall** A (2002) Cryptococcosis. Infect. Dis. Clin. North Am. 16(4):837-74, v-vi.

229. Cox GM, Harrison, TS, McDade HC, Taborda CP, Heinrich G, **Casadevall A**, Perfect, JR (2003) Superoxide dismutase influences the virulence of *Cryptococcus neoformans* by affecting growth within macrophages. Infect. Immun. 71:173-80.
230. He W, **Casadevall A**, Lee SC, Goldman MD (2003) Phagocytic activity and monocyte chemotactic protein (MCP-1) expression by pulmonary macrophages in persistent pulmonary cryptococcosis. Infect. Immun. 71(2):930-6.
231. Wang F, Nakouzi A, Angeletti RH, **Casadevall A** (2003) Site-specific characterization of the N-linked oligosaccharides of a murine immunoglobulin M by high-performance liquid chromatography/electrospray mass spectrometry. Anal. Biochem. 314:266-280.
232. Nosanchuk JD, **Casadevall A** (2003) 'The contribution of melanin in microbial pathogenesis. Cell. Microbiol 5:203-205.
233. Navoa JA, Laal S, Pirofski LA, McLean GR, Dai Z, Robbins JB, Schneerson R, **Casadevall A**, Glatman-Freedman A. (2003) Specificity and diversity of antibodies to Mycobacterium tuberculosis arabinomannan. Clin. Diagn. Lab. Immunol. 2003:88-94.
234. Taborda C, Rivera J, Zaragoza O, **Casadevall A** (2003) More is not necessarily better: 'prozone-like' effects in passive immunization with immunoglobulin. G. J. Immunol. 170:3621-3630.
235. **Casadevall A**, Pirofski L (2003) Virulence is an outcome of the host-interaction. Trends in Microbiol. 11:157-8.
236. Steenbergen JN and **Casadevall A** (2003) The origin and maintenance of virulence for the human pathogenic fungus *Cryptococcus neoformans*. Microbes Infect. 5:667-675.
237. Nosanchuk JD, Mednick A, Shi L, **Casadevall A** (2003). Experimental murine infection results in contamination of bedding with *Cryptococcus neoformans*. Contemporary Trends in Laboratory and Animal Sciences 42:9-12.
238. Morris-Jones R, Youngchim S, Gomez B, Aisen P, Hay R, Nosanchuk, J, **Casadevall A**, Hamilton AJ (2003) Synthesis of melanin-like pigments by *Sporothrix schenckii* *in vitro* and during mammalian infection. Infection and Immunity 71:4026-33.
239. Mednick AJ, Feldmesser M, Rivera J, **Casadevall A** (2003). Neutropenia alters lung cytokine production in mice and reduces their susceptibility to murine cryptococcosis. Eur. J. Immunol. 33:1744-53.
240. Monari C, Retini C, **Casadevall A**, Netski D, Bistoni F, Kozel TR, Vecchiarelli A (2003) Differences in outcome of the interaction between *Cryptococcus neoformans* glucuronoxylomannan and human monocytes and neutrophils. Eur J Immunol. 33:1041-1051.
241. Nosanchuk JD, **Casadevall A** (2003) Budding of melanized *Cryptococcus neoformans* in the presence or absence of L-dopa. Microbiology 149:1945-1951
242. Zaragoza, O., Taborda, C., **Casadevall A** (2003) Localization of C3 affects complement-mediated phagocytosis of C. neoformans. Eur. J. Immunol. 33:1957-67.

243. **Casadevall A** (2003) Antibody-mediated immunity against intracellular pathogens; two dimensional thinking comes full circle. *Infect. Immun.* 71:4225-8.

244. **Casadevall A**, Nosanchuk JD, Steenbergen JN (2003) 'Ready-made' virulence and 'dual-use' virulence factors in pathogenic environmental fungi - the *Cryptococcus neoformans* paradigm. *Current Opinion in Microbiol.* 6:332-337.

245. Tian S, Garcia-Rivera J, Yan B, **Casadevall A**, Stark RE (2003) Unlocking the Molecular Structure of Fungal Melanin Using ¹³C Biosynthetic Labeling and Solid-State NMR. *Biochem.* 42:8105-9.

246. **Casadevall A** and Pirofski L (2003) Exploiting the redundancy of the immune system: vaccines can mediate protection by eliciting 'unnatural' immunity. *J. Exp. Med.* 197:1401-1404.

247. Nakouzi A and **Casadevall A** (2003) The function of conserved amino acids in or near the complementarity determining regions for related antibodies to *Cryptococcus neoformans* glucuronoxylomannan. *Mol. Immunol.* 40:351-361.

248. Steenbergen J, Nosanchuk JD, Malliaris S, and **Casadevall A** (2003) *Cryptococcus neoformans* virulence is enhanced after intracellular growth in the genetically malleable host *Dictyostelium discoideum*. *Infect. Immun.* 71:4862-72.

249. **Casadevall A** and Pirofski L (2003) Antibody-mediated regulation of cellular immunity and the inflammatory response. *Trends Immunol.* 24:474-478.

250. Dadachova E, Nakouzi A, Ryan RA, **Casadevall A** (2003) Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. *PNAS* 100:10942-10947.
[F1000 Recommended] <http://f1000.com/prime/1015868#recommendations>

251. **Casadevall A** and Pirofski L (2003) The 'damage-response' framework of microbial pathogenesis. *Nature Microbiology Reviews* 1:17-24.

252. Pietrella D, Fries B, Lupo P, Bistoni F, **Casadevall A**, Vecchiarelli A (2003) Phenotypic switching of *Cryptococcus neoformans* can influence the outcome of the human immune response. *Cell Microbiol.* 5:513-22.

253. Vecchiarelli A, Pietrella D, Lupo P, Bistoni F, McFadden D, **Casadevall A** (2003) The polysaccharide capsule of *Cryptococcus neoformans* interferes with human dendritic cell maturation and activation. *J. Leukoc. Biol.* 74:370-378.

254. Datta K, Jain N, Sethi S, Rattan A, **Casadevall A**, Banerjee U. (2003) Fluconazole and itraconazole susceptibility of clinical isolates of *Cryptococcus neoformans* at a tertiary care centre in India: a need for care. *J. Antimicrob. Agents Chemotherap.* 52:682-683.

255. Sweeney DA, Caserta, MT, Kornoos D, **Casadevall A**, Goldman DL. (2003) A 10 year old boy with a pulmonary nodule secondary to *Cryptococcus neoformans*: A case report and review of the literature. *Ped. Infect. Dis.* 1089-1093.

256. **Casadevall A**, Pirofski L (2003) 'Anti-virulence' genes – further muddling the lexicon? *Trends Microbiol.* 11:413-5.

257. Nosanchuk JD, Steenbergen JN, Deepe GS, **Casadevall A** (2003) Antibodies to a cell surface histone-like protein protect against *Histoplasma capsulatum*. J. Clin. Invest. 112:1164-1175.
258. Zaragoza O, Fries BC, **Casadevall A** (2003). Induction of capsule growth in *Cryptococcus neoformans* by mammalian serum and CO₂. Infect. Immun. 71:6155-6164.
259. Hassani M, Tanowitz HB, Levi MH, Smolkin M, Wasi F, **Casadevall A**, (2004) Extrapulmonary Nonmeningela Coccidioidomycosis. Infections in Medicine 21:245-248.
260. Dadachova E, Howell RW, Bryan RA, Frenkel A, Nosanchuk JD, **Casadevall A** (2004) Susceptibility of human pathogens *Cryptococcus neoformans* and *Histoplasma capsulatum* to gamma radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J. Nuclear Med. 45:313-320.
261. Garcia-Rivera J, Chang YC, Kwon-Chung KJ, **Casadevall A** (2004) *Cryptococcus neoformans* CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryotic Cell 3:385-392.
262. McFadden D. **Casadevall A** (2004) Unexpected diversity in the fine specificity of monoclonal antibodies that use the same variable region gene to glucuronoxylomannan of *Cryptococcus neoformans*. J. Immunol. 172:3670-3677.
263. Dadachova E, Burns T, Bryan RA, Apostolidis C, Brechbiel MW, Nosanchuk JD, **Casadevall A**, Pirofski L. (2004) Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob. Agents Chemotherap. 48:1624-1629.
264. Dadachova E, Bryan RA, Frenkel A, Zhang T, Apostolidis C, Nosanchuk JS, Nosanchuk JD, **Casadevall A** (2004) Evaluation of acute hematological and long-term pulmonary toxicity of radioimmunotherapy of *Cryptococcus neoformans* infection in murine models. Antimicrob. Agents Chemotherap. 48:1004-1006.
265. Pirofski L, **Casadevall A** (2004) 'Good', 'bad', and 'neutral' antibodies – the adjective depends on the context of the host-microbe interaction. Trends in Immunology 25:167-168.
266. Steenbergen J, Nosanchuk JD, Malliaris S, **Casadevall A** (2004). The interaction of *Blastomyces dermatitidis*, *Sporothrix schenckii*, and *Histoplasma capsulatum* with *Acanthamoeba castellanii*. Infect. Immun 72:3478-88.
267. Malliaris S, Steenbergen J and **Casadevall A** (2004) *Cryptococcus neoformans* variety *gattii* can exploit *Acanthamoeba castellanii* for growth. Med. Mycol. 42:149-158.
268. Martinez L, Moussai D, **Casadevall A** (2004) Antibody to *Cryptococcus neoformans* glucuronoxylomannan inhibits the release of capsular antigen. Infect. Immun. 72:3674-9.
269. **Casadevall A** (2004) What is the latest approach to pulmonary cryptococcosis? J. Resp. Dis. 25:5:188-199.
270. Zaragoza O and **Casadevall A** (2004) Experimental modulation of capsule size in *Cryptococcus neoformans*. Biol. Proc. Online 6:10-15.
271. van Duin D, Cleare W, Zaragoza O, **Casadevall A**, Nosanchuk J (2004) Effects of Voriconazole on *Cryptococcus neoformans*. Antimicrob. Agents Chemotherap. 48:2014-2020.
F1000 Recommended <http://f1000.com/prime/1020742#recommendations>

272. McFadden DC, Zaragoza O, **Casadevall A** (2004) The immunoreactivity of cryptococcal antigen is not stable under prolonged incubations in human serum. *J. Clin. Microbiol.* 42:2786-8.
273. **Casadevall A**, Pirofski L (2004). The weapon potential of a microbe. *Trends Microbiol.* 12:259-263.
274. Morris-Jones R, Hextall JM, Youngchim S, Morris-Jones SD, Hay RJ, Nosanchuk JD, **Casadevall A**, Hamilton AJ (2004) *Scytalidium dimidiatum* causing recalcitrant subcutaneous lesions produces melanin. *J. Clin. Microbiol.* 42:3789-94.
275. Glatman-Freedman A, **Casadevall A**, Dai Z, Jacobs Jr, WR Li A, Morris SL, Navoa JAD, Piperdi S, Robbins JB, Schneerson R, Schwebach JR, Shapiro M. (2004) Antigenic evidence of prevalence and diversity of *Mycobacterium tuberculosis* arabinomannan. *J. Clin. Microbiol.* 42:3225-31.
276. Zaragoza O, **Casadevall A** (2004) Antibodies produced in response to *Cryptococcus neoformans* pulmonary infection in mice have characteristics of non-protective antibodies. *Infect. Immun* 42:2786-8
277. Banerjee U, Datta K, **Casadevall A** (2004) Serotype distribution of *Cryptococcus neoformans* in patients in a tertiary care center in India. *Med. Mycol* 181-186.
278. **Casadevall A** (2004) The methodology for determining the efficacy of antibody-mediated immunity. *J. Immunol. Methods.* 291:1-10.
279. **Casadevall A**, Dadachova E, Pirofski L (2004) Passive antibody therapy for infectious diseases. *Nature Microbiol. Rev.* 2:695-703.
280. **Casadevall A**, Pirofski L. New concepts in antibody-mediated immunity (2004) *Infect. Immun.* 72:6191-6196.
281. Monari C, Bistoni F, **Casadevall A**, Pericolini E, Pietrella D, Kozel TR, Vecchiarelli A (2004) Glucuronylmannan, a microbial compound, regulates expression of co-stimulatory molecules and cytokines in macrophages. *J. Infect. Dis.* 191:127-137.
282. Nosanchuk JD, van Duin D, Mandal P, Aisen P, Legendre AM, **Casadevall A** (2004) *Blastomyces dermatitidis* produces melanin in vitro and during infection. *FEMS Microbiol. Lett.* 239:187-93.
283. Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, **Casadevall A** (2004) Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. *PNAS* 101:14865-70.
Paper featured in Science daily <http://www.sciencedaily.com/releases/2006/12/061208101603.htm>
284. Fries BD, Cook E, Wang C, **Casadevall A** (2005) Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of *Cryptococcus neoformans*. *Antimicrob. Agents. Chemotherap.* 49:350-7.
285. Capitelli F, Vicini S, Piaggio P, Abbruscato P, Princi E, **Casadevall A**, Nosanchuk JD, Zanardini E (2005) Investigation of fungal deterioration of synthetic paint binders using vibrational spectroscopic techniques. *Macromolec. Biosci.* 5:49-57.
286. Rivera J, **Casadevall A** (2005) 'Antibody-mediated protection against *Cryptococcus neoformans* pulmonary infection is dependent on B cells. *Infect. Immun.* 73:1141-50.

287. Larsen RA, Pappas PG, Perfect J, Aberg J, **Casadevall A**, Cloud GA, James R, Filler S, Dismukes WE. (2005) A Phase I evaluation of the safety and activity of a murine derived anti-cryptococcal antibody in subjects with treated cryptococcal meningitis. *Antimicrob. Agents Chemotherap.* 49:952-8.

288. **Casadevall A** (2005). Fungal virulence, vertebrate endothermy and dinosaur extinction: is there a connection? *Fungal Genetics and Biol* 42:98-106.

F1000 Must read <http://f1000.com/prime/13578958#recommendations>

Boston Globe interview

http://www.boston.com/news/globe/health_science/articles/2005/02/22/were_the_dinosaurs_done_in_by_fungus/


Live Science Interview

<http://www.livescience.com/11705-theory-mammals-fungus-explains-bat-plague.html>

289. McLean GR, Torres M, Trotter B, Nosedá M, Bryson S, Pai EF, **Casadevall A** (2005) A point mutation in the CH3 domain of human IgG3 inhibits antibody secretion without affecting antigen specificity. *Mol. Immunol.* 42:1111-1119.

290. Fries B, **Casadevall A**, Goldman DA (2005) Phenotypic switching of *Cryptococcus neoformans* can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitis. *Infect. Immun.* 73:1779-1787.

291. Bryan RA, Zaragoza O, Zhang T, Ortiz G, **Casadevall A**, Dadachova E (2005) Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of *Cryptococcus neoformans*. *Eukaryotic Cell* 4:465-475.



292. Mednick A, Nosanchuk JD, **Casadevall A** (2005) Melanization of *Cryptococcus neoformans* affects lung inflammatory responses during cryptococcal infection. *Infect. Immun.* 73:2012-2019.

293. Eisenman HC, Nosanchuk JD, Webber JBW, Emerson RJE, Camesano TA, **Casadevall A** (2005). The microstructure of cell-wall associated melanin in the human pathogenic fungus *Cryptococcus neoformans*. *Biochem.* 44:3683-3693.

294. Torres M, May R, Scharff MD, **Casadevall A** (2005) Variable region identical antibodies differing in isotype demonstrate differences in fine specificity and isotype. *J. Immunol.* 174:2132-2142.

295. Monari C, Pericolini E, Bistoni G, **Casadevall A**, Kozel TR, Vecchiarelli, A (2005) *Cryptococcus neoformans* capsular glucuronoxylomannan induces expression of Fas ligand in macrophages. *J. Immunol* 174:3461-3468. *F1000 Recommended*

296. Garcia-Rivera J, Tucker SC, Feldmesser M, Williamson PR, **Casadevall A** (2005) Laccase Expression in Murine Pulmonary *Cryptococcus neoformans* infection. *Infect. Immun.* 73:3124-7.

297. Luo, Y, Tucker, SC, **Casadevall A** (2005) Fc- and Complement-Receptor Activation Stimulates Cell Cycle Progression of Macrophage Cells from G1 to S. *J. Immunol.* 174:7226-7233.

298. Oscarson S, Alpe M, Svahnberg P, Nakouzi A, and **Casadevall A** (2005) Synthesis and immunological studies of glycoconjugates of *Cryptococcus neoformans* capsular glucuronoxylomannan oligosaccharide structures. *Vaccine* 23:3961-3972.
299. Rivera, J, **Casadevall A** (2005) Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against *C. neoformans*. *J. Immunol.* 174:8017-8026.
300. **Casadevall A** (2005) The host as a variable: model hosts approach the immunological asymptote. *Infect. Immun.* 73:3829-3832.
301. **Casadevall A**, Pirofski, L (2005) Insights into mechanisms of antibody-mediated immunity from studies with *Cryptococcus neoformans*. *Current Molecular Medicine.* 5:421-433.
302. Nielsen, K, Cox GM, Litvintseva AP, Mylonakis E, Malliaris SD, Benjamin DK Jr, Giles SS, Mitchell TG, **Casadevall A**, Perfect, JR, Heitman J (2005) *C. neoformans* alpha strains preferentially disseminate to the central nervous system during co-infection. *Infect. Immun* 73:4922-33.
303. Wang W, Nakouzi A, Alvarez M, Zaragoza O, Angeletti RH, **Casadevall A** (2005) Structural and functional characterization of glycosylation in an immunoglobulin G1 to *Cryptococcus neoformans* glucuronoxylomannan. *Mol. Immunol.* 43:987-998.
304. Morris-Jones R, Gomez BL, Diez S, Uran M, Morris-Jones SD, **Casadevall A**, Nosanchuk JD, Hamilton AJ (2005). Synthesis of melanin pigment by *Candida albicans* in vitro and during infection. *Infect. Immun.* 73:6147-6150.
305. Shao X, Mednick A, Alvarez M, van Rooijen N, **Casadevall A**, Goldman DL (2005) An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. *J. Immunol.* 175:3244-3251.
306. Mandal, P, Banerjee U, **Casadevall A**, Nosanchuk JD (2005) Dual infections with pigmented and albino strains of *Cryptococcus neoformans* in patients with and without human immunodeficiency virus infection in India. *J. Clin. Microbiol.* 43:4766-4772.
307. Martinez LR, **Casadevall A** (2005) Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. *Infect. Immun.* 73:6350-6362.
308. McClellan EE, Perrine WT, Potts WK, **Casadevall A** (2005) The relationship of virulence factor expression to evolved virulence in mouse-passaged *Cryptococcus neoformans* strains. *Infect. Immun.* 73:7047-50.
309. Zaragoza O, Mihu C, **Casadevall A**, and Nosanchuk JD (2005) Effect of amphotericin B on capsule and cell size in *Cryptococcus neoformans* during murine infection. *Antimicrobial Agents Chemotherap.* 49:4358-61.
310. **Casadevall A** and Pirofski L (2005) The potential of antibody-mediated humoral immunity against biological weapons. *Expert Opinion on Biological Therapy* 5:1359-1372.
311. Da Silva MB, Marques AF, Nosanchuk JD, **Casadevall A**, Travassos LR, Taborda CP (2005) Melanin in the dimorphic fungal pathogen *Paracoccidioides brasiliensis*: effects on phagocytosis, intracellular resistance, and drug susceptibility. *Microbes Infect.* 8:197-205.

312. Shao X, Rivera J, Niang R, **Casadevall A**, Goldman DL (2005) A dual role for TGF-beta1 in the control of fungal pneumonia. J. Immunol. 175:6757-63.

313. Jain N, Wickes BL, Keller SM, Fu J, **Casadevall A**, Jain P, Ragan MA, Banerjee U, Fries BC (2005) The molecular epidemiology of clinical *Cryptococcus neoformans* strains from India. J. Clin. Microbiol. 43:5733-5742.

314. Garcia-Rivera J, Nosanchuk JD, Aisen P, Zaragoza O, Moadel T, Dadachova E, **Casadevall A** (2005) Comparative analysis of *Cryptococcus neoformans* acid-resistant particles generated from pigmented cells grown in different laccase substrates. Fungal Genetics and Biol. 42:989-998.



315. Dadachova E, **Casadevall A** (2005) Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Exp. Opin. Drug. Deliv. 2:1075-1084.

316. **Casadevall A**, Pirofski L (2005) Feasibility and prospects for a vaccine to prevent cryptococcosis. Med. Mycol 43:667-80.

317. Pericolini E, Cenci E, Monari C, DeJesus M, Bistoni F, **Casadevall A**, Vecchiarelli A (2005) *Cryptococcus neoformans* capsular polysaccharide component galactoxylomannan induces apoptosis of human T cells through caspase 8 activation. Cellular Microbiology 8:267-75.

318. Dadachova E, **Casadevall A** (2005) Melanin as a potential target for radionuclide therapy of metastatic melanoma. Future Oncology 1:541-9.

319. **Casadevall A** (2006) The cards of virulence and the global virulome. Microbe 1:359-364.

320. McFadden D, DeJesus M, **Casadevall A** (2006) The physical properties of the capsular polysaccharides from *Cryptococcus neoformans* suggest features for capsule construction. J. Biol. Chem. 281:1868-75.


321. **Casadevall A**, Pirofski L (2006) Polysaccharide-containing conjugate vaccines for fungal diseases. Trends in Molecular Medicine 12:6-9.

322. Zaragoza O, Telzak A, Bryan R, Dadachova E, **Casadevall A** (2006) The polysaccharide capsule of the pathogenic fungus *Cryptococcus neoformans* enlarges by distal growth and is rearranged during budding. Mol.Microbiol. 59:67-83.
F1000 Recommended <http://f1000.com/prime/1030371#recommendations>

323. Frases S, Chaskes S, Dadachova E, **Casadevall A** (2006) Induction by *Klebsiella aerogenes* of a melanin-like pigment in *Cryptococcus neoformans*. Applied and Environmental Microbiol. 72:1542-50.

324. Martinez L, **Casadevall A** (2006) Susceptibility of *Cryptococcus neoformans* biofilms to antifungal agents in vitro. Antimicrob. Agents Chemotherap. 50:1021-33.

325. McClellan E, Bernhardt D, **Casadevall A** (2006) Estimating the relative contribution of virulence factors for pathogenic microbes. *Infect. Immun.* 74:1500-1504.
326. Goldman D, Davis J, Bommartio F, Shao X, **Casadevall A** (2006) Enhanced allergic inflammation and airway responsiveness in rats with chronic *Cryptococcus neoformans* infection suggests a potential role for fungal pulmonary infection in the pathogenesis of asthma. *J. Infect. Dis.* 193:1178-86.
F1000 Recommended 'Must Read' <http://f1000.com/prime/1069772#recommendations>
327. **Casadevall A** (2006) The third age of antimicrobial therapy. *Clin. Infect. Dis.* 42:1414-6.
328. Dadachova E, Bryan RA, Apostolidis C, Morgenstern A, Zhang T, Moadel T, Torres M, Huang X, Revskaya E, **Casadevall A** (2006) Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy of experimental infection. *J. Infect. Dis.* 193:1427-1436.
329. Zaragoza O, McClelland E, Telzak A, **Casadevall A** (2006) Equatorial ring-like channels in the *Cryptococcus neoformans* polysaccharide capsule. *FEMS Yeast Research* 6:662-666.
330. Dadachova E, Moadel T, Schweitzer AD, Bryan RA, Zhang T, Mints L, Revskaya E, Huang X, Ortiz G, Nosanchuk JS, **Casadevall A** (2006). Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. *Cancer Biother Radiopharm* 21:117-29.
331. Martinez LR, Bryan RA, Apostolidis C, Morgenstern A, **Casadevall A**, Dadachova E (2006) Antibody-guided alpha radiation effectively damages fungal biofilms. *Antimicrob Agents Chemother* 50:2132-6.
332. McClelland E, Bernhardt, D, **Casadevall A** (2006) Coping with multiple virulence factors: which is most important? *PLOS Pathogens* 1:4:287-288.
333. Li L, Zaragoza O, **Casadevall A**, Fries B (2006) Characterization of a flocculation-like phenotype in *Cryptococcus neoformans* and its effect on pathogenesis. *Cellular Microbiol.* 8(11):1730-1739.
334. Martinez, L, Christaki E, **Casadevall A** (2006) Specific antibody to *Cryptococcus neoformans* glucuronoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitro. *J. Infect. Dis.* 194:261-266
335. Paolo WF, Jr, Mandal P, Dadachova E, **Casadevall A**, Szaniszlo PJ and Nosanchuk JD (2006) Effects of disrupting the polyketide synthase gene WdPKS1 in *Wangiella [Exophiala] dermatitidis* on melanin production and resistance to killing by antifungal compounds, enzymatic degradation, and extremes in temperature. *BMC Microbiology* 6(1):55.
336. Rivera J, Nakouzi A, Abboud N, Revskaya E, Goldman D, Collier RJ, Dadachova E, **Casadevall A** (2006) A monoclonal antibody to *Bacillus anthracis* protective antigen defines a neutralizing epitope on domain one. *Infect. Immun.* 74(7):4149-4156.
337. Zaragoza O, **Casadevall A** (2006) Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus *Cryptococcus neoformans* by both classical pathway activation and steric hindrance. *Cell Microbiol* 8:1862-1876.



338. Dadachova E, **Casadevall A** (2006) Treatment of infection with radiolabeled antibodies. QJ Nucl.Med Mol. Imaging 50:193-204.
339. Luo Y, Cook E, Fries BC, **Casadevall A** (2006) Phagocytic efficacy of macrophage-like cells as a function of cell cycle and Fcgamma receptors (FcgammaR) and complement receptor (CR)3 expression. Clin Exp Immunol. 145:380-7.
340. Mavrogiorgos N, Zaragoza O, **Casadevall A**, and Nosanchuk JD (2006) Efficacy of voriconazole in experimental *Cryptococcus neoformans* infection. Mycopathologia 162:111-114.
341. Pirofski LA, **Casadevall A**. (2006) Immunomodulators as an antimicrobial tool. Curr Opin Microbiol. Oct;9(5):489-95. Epub 2006 Aug 22. Review. PMID: 16931122
342. **Casadevall A**, Pirofski L (2006) A reappraisal of humoral immunity based on mechanism of antibody-mediated protection against intracellular pathogens. Advances in Immunology 91:1-44.
343. Maxson MM, Cook E, **Casadevall A** (2006). The volume and hydration of the *Cryptococcus neoformans* polysaccharide capsule. Fungal Genetics and Biology 44(3):180-6.



344. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, **Casadevall A**, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Graziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T. (2006) Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis. Oct 15;43(8):1031-9. Epub Sep 13. Clin Infect Dis. 2007 Mar 15;44(6):894. PMID: 16983616.

345. McFadden D, Zaragoza O, **Casadevall A** (2006) The capsular dynamics of *Cryptococcus neoformans*. *Trends in Microbiol.* 14:497-505.
346. Okoli I, Oyeka C, Kwon-Chung K, Theelen B, Robert V, Groenewald J, McFadden D, **Casadevall A**, Boekhout T (2006) *Cryptotrichosporon anacardii* gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar. *FEMS Yeast Research.* 7(2):339-50.
347. Martinez L, **Casadevall A** (2006) *Cryptococcus neoformans* cells in biofilms are less susceptible to antimicrobial molecules produced by the innate immune system than planktonic cells. *Infec. Immun.* 74(11):6118-6123.
348. Nosanchuk J, **Casadevall A** (2006). Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. *Antimicrob. Agents Chemotherap.* 50(11):3519-3528.
349. Capittelli F, Nosanchuk JD, **Casadevall A**, Toniolo L, Brusetti L, Florio S, Principi P, Borin S, Sorlini C (2006) Synthetic consolidants attacked by melanin-producing fungi: the study case of biodeterioration of the Milan Cathedral (Italy) marble treated with acrylics. *Appl Environ Microbiol* 72:271-277.
350. Nosanchuk JD, Yu J, Hung C, **Casadevall A**, Cole GT (2006). *Coccidioides posadasii* produces melanin in vitro and during infection. *Fungal Genetics and Biology* 44(6):517-20.
351. Monari C, Kozel TR, Paganelli F, Pericolini E, Perito S, Bistoni F, **Casadevall A**, Vecchiarelli A (2006). Microbial immune suppression mediated by direct engagement of inhibitory Fc receptor. *J. Immunol.* 177:6842-6851.
352. Alvarez M, Casadevall A (2006) Phagosome extrusion and host cell survival after *Cryptococcus neoformans* phagocytosis by macrophages. *Current Biology* 16:2161-2165.
F1000 Recommended Must Read <http://f1000.com/prime/1069772#recommendations>
353. Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, **Casadevall A**, Goldstein H (2006) Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. *PLOS Medicine* 3:e427. [*Drs Casadevall and Goldstein shared senior authorship*]
F1000 Recommended <http://f1000.com/prime/1052866#recommendations>
Featured in Science Daily <http://www.sciencedaily.com/releases/2008/06/080616115744.htm>
Featured in Scientific American <http://www.scientificamerican.com/article.cfm?id=kill-the-virus-stop-the-cancer>
354. Barbosa FM, Fonseca FL, Figueiredo RT, Bozza MT, **Casadevall A**, Nimrichter L, Rodrigues ML (2007) Binding of glucuronoxylomannan to CD14 receptor in human A549 alveolar cells induces IL-8. *Clin. Vaccine Immunol.* 14:94-98.
355. Frases S, **Casadevall A** (2007) *Cryptococcus neoformans* can utilize the bacterial melanin precursor homogentisic acid for fungal melanogenesis. *Appl Environ Microbiol.* 73:615-621.
356. Maxon MM, Dadachova E, **Casadevall A**, Zaragoza O (2007) Radial mass density, charge, and epitope distribution in the *Cryptococcus neoformans* capsule. *Eukaryotic cell* 6:95-109.

357. Rodrigues ML, Nimrichter L, Oliveira DL, Frases S, Miranda K, Zaragoza O, Alvarez M, Nakouzi A, Feldmesser M, **Casadevall A** (2007) Vesicular polysaccharide export in *Cryptococcus neoformans* is an eukaryotic solution to the problem of fungal trans-cell wall transport. *Eukaryotic Cell* 6:48-59.
F1000 Recommended <http://f1000.com/prime/1069772#recommendations>
358. **Casadevall A**, Pirofski L (2006) The weapon potential of human pathogenic fungi. *Medical Mycology* 44:689-696.
359. Dadachova E., **Casadevall A** (2007) Renaissance of targeting molecules for melanoma. *Cancer Radiother. Biopharm* 21:545-52.
360. Macura N, Zhang T, **Casadevall A** (2007) The dependence of macrophage phagocytic efficacy on antibody concentration. *Infect. Immun.* 75:1904-15.
361. Torres M, Fernandez-Fuentes N, Fiser A, **Casadevall A** (2007) The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. *J. Biol. Chem* 282:13917-27.
F1000 Recommended <http://f1000.com/prime/1082953#recommendations>
362. De Jesus M, Hackett E, Durkin M, Connolly P, **Casadevall A**, Petraitiene R, Walsh, TJ, Wheat LJ (2007) Galactoxylomannan (GalXM) does not Exhibit Cross-Reactivity with *Aspergillus* Galactomannans. *Clin. Vaccine Immunol.* 14:624-7.
F1000 Recommended <http://f1000.com/prime/1086020#recommendations>
363. Zaragoza O, Alvarez M, Telzak A, Rivera J, **Casadevall A** (2007). The relative susceptibility of mouse strains to pulmonary *Cryptococcus neoformans* infection is associated with pleiotropic differences in immune response. *Infect. Immun.* 75:2729-39.
364. **Casadevall A**, Goldstein H, Dadachova E (2007) Targeting host cells harboring viruses with radiolabeled antibodies. *Expert Opinion in Biological Therapy* 7:595-7.
365. Martinez LR, **Casadevall A** (2007) Biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and ultraviolet light. *Appl Environ Microbiol* 73(14):4592-601.
366. Dadachova E, Bryan RA, Huang X, Moadel T, Schweitzer AD, Aisen P, Nosanchuk JD, **Casadevall A** (2007) Ionizing radiation changes the electronic properties of melanin and enhances the growth of melanized fungi. *PLoS ONE*. 2:e457.
F1000 Rated Exceptional <http://f1000.com/prime/1086966#recommendations>
This paper received widespread coverage in many journals and newspapers. Some sample articles:
National Geographic <http://news.nationalgeographic.com/news/2007/05/070522-fungi.html>
Science Daily <http://www.sciencedaily.com/releases/2007/05/070522210932.htm>
Fox News <http://www.foxnews.com/story/0,2933,276196,00.html>
Scientific American <http://www.scientificamerican.com/article.cfm?id=radiation-helps-fungi-grow>
Astrobiology Magazine <http://www.astrobio.net/pressrelease/2349/soaking-up-radiation>
Cosmos Magazine <http://www.cosmosmagazine.com/node/2095/full>
Yahoo Voices <http://voices.yahoo.com/scientists-discover-radiation-eating-fungi-362074.html>
Nasa http://solarsystem.nasa.gov/news/display.cfm?News_ID=21175
Nature <http://www.nature.com/news/2007/070521/full/news070521-5.html>
Nature Micro Rev O'Connell D, Fungal Physiology: Radiation Jukes Nature Reviews Microbiology5, 475-475 doi:10.1038/nrmicro1694


Natural History <http://www.naturalhistorymag.com/samplings/141343/radiation-its-whats-for-dinner>

367. Davis, J, Zheng WY, Glatman-Freedman A, Ng JN, Pagcatipunan MR, Lessin H, **Casadevall A**, Goldman, DL. (2007) Serological evidence for differences in cryptococcal infection. *Ped. Infect. Dis* 26:549-51.

368. Achkar JM, **Casadevall A**, Glatman-Freedman A (2007) Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches. *Expert Rev. Anti. Infect. Ther.* 5:461-7.

369. Nimrichter L, Frases S, Cinelli LP, Viana NB, Nakouzi A, Travassos LR, **Casadevall A**, Rodriguez ML (2007) Self-aggregation of *Cryptococcus neoformans* capsular polysaccharide is dependent of divalent ions. *Eukaryotic Cell* 16:1400-10. [Drs **Casadevall** and Rodriguez shared senior authorships]

370. McFadden D, Fries BC, Wang F, **Casadevall A** (2007) Capsule structural heterogeneity and antigenic variation in *Cryptococcus neoformans*. *Eukaryotic Cell* 6:1464-73.



372. Dadachova E, Wang XG, **Casadevall A** (2007) Targeting the virus with radioimmunotherapy in virus-associated cancers. *Cancer Biother. Radiopharm.* 22:303-308.

372. Mylonakis E., **Casadevall A**, Ausubel FM (2007) Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. *PLoS Pathog.* 3:e101.

373. Alvarez M, **Casadevall A** (2007) Cell-to-cell spread and massive vacuole formation after *Cryptococcus neoformans* and infection of murine macrophages. *BMC Immunology* 8:16.
F1000 Recommended <http://f1000.com/prime/1086966#recommendations>

374. **Casadevall A**, Pirofski L, (2007) Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. *Infect. Immun.* 75(11):5074-8.


375. Dadachova, E, Bryan RA, Huang X, Ortiz G, Moadel T, **Casadevall A** (2007) Comparative evaluation of capsular polysaccharide-specific IgM and IgG antibodies and F(ab')₂ and Fab fragments as delivery vehicles for radioimmunotherapy of fungal infection. *Clin Cancer Res.* 13:5629s-5635s.

376. Al-Sayyed B, Piperdi S, Yuan X, Li A, Besra GS, Jacobs WR, **Casadevall A**, Glatman-Freedman A (2007). Monoclonal antibodies to *Mycobacterium tuberculosis* CDC 1551 reveal subcellular localization of MPT51. *Tuberculosis (Edinb).* 87:489-97.

377. Schweitzer AD, Rakesh V, Revskaya E, Datta A, **Casadevall A**, Dadachova E. (2007) Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to the metastatic melanoma tumors with wide range of melanin concentrations. *Melanoma Res.* 17:291-303.

378. Martinez LR, Ntiamoah P, **Casadevall A**, Nosanchuk JD (2007) Caspofungin reduces the incidence of fungal contamination in cell culture. *Mycopathologia.* 164(6):279-86.

379. Howell RC, Revskaya E, Pazo V, Nosanchuk JD, **Casadevall A**, Dadachova E (2007) Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. *Bioconjug Chem.* 18(6):1739-48.
380. Martinez LR, Ntiamoah P, Gacser A, **Casadevall A**, Nosanchuk JD (2007) Voriconazole Inhibits Melanization in *Cryptococcus neoformans*. *Antimicrob Agents Chemother.* 51:4396-400.
381. **Casadevall A**, Pirofski L (2007) Accidental Virulence, cryptic pathogenesis, martians, lost hosts, and the pathogenicity of environmental microbes. *Eukaryotic Cell* 6:2169-74.
F1000 Recommended 'Must Read' <http://f1000.com/prime/1098373#recommendations>
382. Saha Dc, Goldman DL, Shao X, **Casadevall A**, Husain S, Limaye AP, Lyon M, Somani J, Pursell K, Pruett TL, Singh N (2007) Voriconazole Inhibits Melanization in *Cryptococcus neoformans*. *Antimicrob Agents Chemother.* 51:4396-400.
383. **Casadevall A** (2007) Determinants of virulence in the pathogenic fungi. *Fungal Biology Reviews* 21(4):130-132.
384. Wang XG, Revskaya E, Bryan RA, Strickler HD, Burk RD, **Casadevall A**, Dadachova E (2007) Treating cancer as an infectious disease-viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. *PLoS ONE.* 2(10):e1114.
385. Chaskes S, Frases S, Cammer M, Gerfen G, **Casadevall A** (2008) Growth and Pigment Production by *Cryptococcus gattii*, *Cryptococcus neoformans*, and *Candida albicans* from D-Tryptophan. *J Clin Microbiol.* 46:255-64.
386. Eisenman HC, **Casadevall A**, McClellan EE (2007) New Insights on the Pathogenesis of Invasive *Cryptococcus neoformans* Infection. *Curr. Infect. Dis. Rep.* 9:457-64.
387. Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, Almeida IC, **Casadevall A** (2007) Extracellular vesicles produced by *Cryptococcus neoformans* contain protein components associated with virulence. *Eukaryot Cell.* 7:58-67.
388. Eisenman HC, Mues M, Weber SE, Chaskes S, Frases S, **Casadevall A** (2007) *Cryptococcus neoformans* laccase catalyzes melanin synthesis from both D- and L-DOPA. *Microbiology* 153(Pt 12):3954-62.
389. Torres M, Fernandez-Fuentes N, Fiser A, **Casadevall A**. (2007) Exchanging murine and human immunoglobulin constant chains affects the kinetics and thermodynamics of antigen binding and chimeric antibody autoreactivity.
PLoS One. Dec 12;2(12):e1310. PMID: 18074033
390. Zhuang D, Hage C, DeJesus M, Hackett M, Durkin M, Davis TE, **Casadevall A**, Wheat LJ (2007) Cryptococcal glucuronoxylomannan does not exhibit cross reactivity in the MVista™ *Histoplasma* antigen assay immunoassay. *Clin Vaccine Immunol* 15:392-3.
391. Rodrigues ML, Alvarez M, Fonseca FL, **Casadevall A** (2008) Binding of the wheat germ lectin to *Cryptococcus neoformans* suggests an association of chitin-like structures with yeast budding and capsular glucuronoxylomannan. *Eukaryot Cell.* 7:602-9.



392. Frases S, Nimrichter L, Viana NB, Nakouzi A, **Casadevall A** (2008) *Cryptococcus neoformans* capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. *Eukaryot. Cell* 7:319-27.
393. Torres M, **Casadevall A** (2008) The immunoglobulin constant region contributes to affinity and specificity. *Trends in Immunology* 29:91-7.
394. Dadachova E, **Casadevall A**. (2008) Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases. *Curr Opin Investiga Drugs*. Feb: 9(2):184-8. PMID: 18246521
395. Zarebski LM, Vaughan K, Sidney J, Peters B, Grey H, Janda KD, **Casadevall A**, Sette A. (2008) Analysis of epitope information related to *Bacillus anthracis* and *Clostridium botulinum*. *Expert Rev Vaccines*. Feb;7(1):55-74. doi: 10.1586/14760584.7.1.55. PMID: 18251694
396. Maglione P.J., Xu J., **Casadevall A**, Chan J (2008) Fcγ receptors regulate immune activation and susceptibility during *M. tuberculosis* infection. *J. Immunol* 180:3329-38.
397. De Jesus M; Park CG, Su Y; Goldman D; Steinman RM; **Casadevall A** (2008) Spleen deposition of *Cryptococcus neoformans* capsular Glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1. *Med. Mycol* 46:153-62.
398. Howell RC, Schweitzer AD, **Casadevall A**, Dadachova EA (2008) Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins. *Nucl Med. Biol* 35:335-7.
399. Zhong J, Frases-Carvajal S, Hsin W, **Casadevall A**, Stark RE (2008) Following Fungal Melanin Biosynthesis with Solid-State NMR: biopolymer molecular structures and possible connections to cell-wall polysaccharides. *Biochem.* 47:4701-10.
400. Bryan RA, Huang X, Morgenstern A, Bruchertseifer F, **Casadevall A**, Dadachova E. (2008) Radiofungicidal effects of external gamma radiation and antibody-targeted beta and alpha radiation on *Cryptococcus neoformans*. *Antimicrob Agents Chemother.* 52(6):2232-5.
401. Alvarez M, Saylor C, **Casadevall A** (2008) Antibody action after phagocytosis promotes *Cryptococcus neoformans* and *Cryptococcus gattii* macrophage exocytosis with biofilm-like microcolony formation. *Cell Microbiol* 10:1622-33.
402. Albuquerque PC, Nakayasu ES, Rodrigues ML, Frases S, **Casadevall A**, Zancoppe-Oliveira RM, Almeida IC, Nosanchuk JD. (2008) Vesicular transport in *Histoplasma capsulatum*: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes. *Cell Microbiol.* 10:1695-710.

403. Dadachova E, Bryan RA, Howell RC, Schweitzer AD, Aisen P, Nosanchuk JD, **Casadevall A** (2008) The radioprotective properties of fungal melanin are a function of its chemical composition, stable radical presence and spatial arrangement. *Pigment Cell Melanoma Res.* 21(2):192-9
404. Goldman DL, Zeng W, Rivera J, Nakouzi A, **Casadevall A** (2008) Human serum contains a protease that protects against cytotoxic activity of *Bacillus anthracis* lethal toxin in vitro. *Clin Vaccine Immunol.* Jun 15(6):970-3.
405. Abboud N, **Casadevall A** (2008) The Immunogenicity of *Bacillus Anthracis* Protective Antigen Domains and the Efficacy of Elicited Antibody Responses Depend on host Genetic Background. *Clin Vaccine Immunol.* 15:1115-23.
406. Vicencio AG, Narain S, Du Z, Zeng WY, Ritch J, **Casadevall A**, Goldman DL (2008) Pulmonary cryptococcosis induces chitinase in the rat. *Respir Res.* 15:9:40.
407. Goldman DL, **Casadevall A** (2008) Anthrax-associated shock. *Front Biosci.* May 1(13):4009-14.
408. Dadachova E, Revskaya E, Sesay MA, Damania H, Boucher R, Sellers RS, Howell RC, Burns L, Thornton GB, Natarajan A, Mirick GR, Denardo SJ, Denardo GL, **Casadevall A** (2008) Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with (188)Re against experimental human metastatic melanoma in nude mice. *Cancer Biol Ther.* 9:1116-27.
409. Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, Rodriguez-Tudela JL, **Casadevall A** (2008) 'Capsule enlargement in *C. neoformans* confers resistance to oxidative stress suggesting a mechanism for intracellular survival'. *Cell Microbiol* 10:2043-57.
410. Martinez LR, Ibom DC, **Casadevall A**, Fries BC (2008) Characterization of phenotypic switching in *Cryptococcus neoformans* biofilms. *Mycopathologia* 66:175-80.
411. Nicola A, **Casadevall A**, Goldman DA (2008) Fungal killing by mammalian phagocytic cells. *Current Opinion in Microbiology* 11:313-7.
412. Rakesh V, Schweitzer, A, Zaragoza O, Bryan R, Wong, K, Ashim, D, **Casadevall A**, Dadachova E (2008) 'Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of *Cryptococcus neoformans*. *J. Phys. Chem. B*: 8514-22.
413. **Casadevall A**, Fang FC (2008) Descriptive Science. *Infect. Immun.* 76:3835-6.
414. Rodriguez ML, Nimrichter L, Oliveira DL, Nosanchuk JD, **Casadevall A** (2008). Vesicular trans cell wall transport in fungi: a mechanism for delivery of virulence-associated macromolecules? *Lipid Insights* 2:27-40.
415. **Casadevall A** (2008) Evolution of intracellular pathogens. *Annual Reviews in Microbiology* 62:19-33
416. Luo Y, Alvarez M, **Casadevall A** (2008) The Outcome of Phagocytic Cell Division with Infectious Cargo Depends on Single Phagosome Formation. *PlosOne* e3219.
417. Dam TK, Torres M, Brewer CD, **Casadevall A** (2008) Isothermal titration calorimetry reveals differential binding thermodynamics of variable region-identical antibodies differing in constant region for a univalent ligand. *J. Biol. Chem.* 283:31366-70.


418. Nakouzi A, Rivera J, Rest RF, **Casadevall A** (2008) Passive administration of monoclonal antibodies to Anthrolysin O prolong survival in mice lethally infected with *Bacillus anthracis*. *BMC Microbiology* 8:159.

419. Pirofski L, **Casadevall A** (2008) The damage-response framework of microbial pathogenesis and infectious diseases. *Adv Exp Med Biol* 635:135-46.

420. Dadachova E, Rivera J, Revskaya E, Nakouzi A, Cahill SM, Blumenstein M, Xiao D, **Casadevall A** (2008) In vitro evaluation, biodistribution and scintigraphic imaging in mice of radiolabeled anthrax toxins. *Nuclear Medicine and Biology* 35:755-61.

421. Dadachova E, **Casadevall A** (2008) Ionizing radiation: how fungi cope, adapt and exploit with the help of melanin. *Curr Opin Microbiol.* 11:525-31.

422. De Jesus M, Nicola AM, Rodrigues ML, Janbon G, **Casadevall A** (2008) Capsular localization of the *Cryptococcus neoformans* polysaccharide component galactoxylomannan. *Eukaryotic Cell* 8:96-103.



423. **Casadevall A**, Ehrlich SA, Franz DR, Imperiale MJ, Keim PS. (2008) Biosecur Bioterror. 2008 Dec;6(4):291-2. doi: 10.1089/bsp.2008.1114. PMID: 19090664

424. Bliska JB, **Casadevall A** (2009) Intracellular pathogenic bacteria and fungi – a case of convergent evolution? *Nat. Rev. Microbiol.* 7:165-171.

425. Bryan, RA, Jiang Z, Huang X, Morgestem A, Bruchertseifer F, Sellers R, **Casadevall A**, Dadachova E. (2009) Radioimmunotherapy is effective against high-inoculum *Cryptococcus neoformans* infection in mice and does not select for radiation-resistant cryptococcal cells. *Antimicrob. Agents Chemother.* 53:1679-82.

426. Frases S, Pontes B, Nimrichter L, Viana NB, Rodrigues ML, **Casadevall A** (2009) The capsule of *Cryptococcus neoformans* grows by enlargement of polysaccharide molecules. *PNAS* 106:1228-33.

427. Fang FC, **Casadevall A** (2009) NIH Peer Review Reform – Change we need, or Lipstick on a Pig. *Infect. Immun.* 77:929-32

428. Nosanchuk JD, Nimrichter L, **Casadevall A**, Rodrigues ML (2009) A role for vesicular transport of macromolecules across cell walls in fungal pathogenesis. *Commun. Integr. Biol* 1:37-39.

429. Dadachova E, **Casadevall A** (2009) Radioimmunotherapy of Infectious Diseases *Semin Nucl Med* 39:146-53.

430. Pirofski L, **Casadevall A** (2009) Rethinking T cell immunity in oral candidiasis. *J. Exp. Med* 206:269-73.

431. Panepinto J, Komperda K, Frases S, Park Y, Djordjevic JT, **Casadevall A**, Williamson PR (2009) Sec6-dependent sorting of fungal extracellular exosomes and laccase of *Cryptococcus neoformans*. *Mol. Micro* 71:1165-76.
432. **Casadevall A**, Fang FC (2009) Is peer review censorship. *Infect. Immun.* 77:1273-4.
433. Robertson EJ, **Casadevall A** (2009) Antibody-mediated immobilization of *Cryptococcus neoformans* promotes biofilm formation. *Appl. Environ. Microbiol* 75:2528-33.
434. Alvarez, Burns T, Luo Y, Pirofski L, **Casadevall A** (2009) The outcome of *Cryptococcus neoformans* intracellular pathogenesis in human monocytes. *BMC Microbiology* 5:51.
435. Fonseca F, Frases S, **Casadevall A**, Fischman-Gompertz O, Nimrichter L. (2009) The Structural and functional properties of the *Trichosporon asahii* glucuronoxylomannan. *Fungal Genet. Biol.* 46:496-505.
436. Revskaya E, Jongco AM, Sellers RS, Howell RC, Koba W, Guimaraes AJ, Nosanchuk JD, **Casadevall A**, Dadachova E. (2009) Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. *Clin Cancer Res.* Apr 1;15(7):2373-9. doi: 10.1158/1078-0432.CCR-08-2376. Epub 2009 Mar 17. PMID: 19293257
437. **Casadevall A**, Nosanchuk JD, Williamson P, Rodrigues ML. (2009) Vesicular transport across the fungal cell wall. *Trends Microbiol.* Apr;17(4):158-62. doi: 10.1016/j.tim.2008.12.005. Epub 2009 Mar 18. PMID: 19299133
438. Rodrigues ML, Fonseca FL, Frases S, **Casadevall A**, Nimrichter L. (2009) The still obscure attributes of cryptococcal glucuronoxylomannan. *Med Mycol.* Dec;47(8):783-8. doi: 10.3109/13693780902788621. PMID: 19343609
439. Pericolini E, Gabrielli E, Cenci E, De Jesus M, Bistoni F, **Casadevall A**, Vecchiarelli A (2009) Involvement of glyco-receptors in galactoxylomannan-induced T cell death. *J. Immunol.* 182:6003-10.
440. Zaragoza O, Rodrigues ML, De Jesus MD, Frases S, Dadachova E, **Casadevall A** (2009) The Capsule of fungal pathogen *Cryptococcus neoformans*. *Adv Appl. Microbiol.* 68:133-216.
441. Nakouzi A, Zhang T, Oscarson S, **Casadevall A** (2009) The common *Cryptococcus neoformans* glucuronoxylomannan M2 motifs elicits non-protective antibodies. *Vaccine* 27:3513-9.
442. Nicola A, Frases S, **Casadevall A** (2009) Lipophilic dye staining of *Cryptococcus neoformans* extracellular vesicles and capsule. *Eukaryotic Cell* 8:1373-80.
443. **Casadevall A** (2009) The case for pathogen specific therapy. *Expert Opinion of emerging drugs* 10:1699-703.
444. **Casadevall A**, Fang F (2009). Mechanistic science. *Infect. Immun.* 77:3717-19.
F1000 Recommended 'Must Read' <http://f1000.com/prime/1163707#recommendations>
445. Fonseca FL, Nimrichter L, Cordero RJB, Frases S, De Siqueira JR, Goldman DL, Andruszkiewicz R, Milewski S, Travassos LR, **Casadevall A**, Rodrigues ML (2009). A role for chitin and chito oligomers in the capsular architecture of *Cryptococcus neoformans*. *Eukaryotic Cell* 8:1543-53.

446. Abboud N, DeJesus M, Nakouzi A, Cordero RJB, Puhato M, Fiser A, Rivera J, and **Casadevall A** (2009) Identification of linear epitopes in *Bacillus anthracis* protective antigen bound by neutralizing antibodies. *J. Biol. Chem.* 284:25077-86.
447. Luo Y, Isaac BM, **Casadevall A**, Cox D (2009) Phagocytosis inhibits F-actin enriched membrane protrusions stimulated by fractalkine (CX3CL1) and colony-stimulating factor-1. *Infect. Immun.* 77:4487-95.
448. **Casadevall A**, Fang F (2009). Important Science. *Infect. Immun* 77:4177-80.
449. DeJesus M, Nicola AM, Frases S, Lee IR, Mieses S, **Casadevall A** (2009) Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage. *J. Immunol* 183:3885-94.
450. Frases S, Pontes B, Nimrichter L, Rodrigues ML, Viana NB, **Casadevall A** (2009) The elastic properties of the *Cryptococcus neoformans* capsule. *Biophysical J.* 97:937-45.
451. Rivera J, Nakouzi AS, Morgenstern A, Bruchertseifer F, Dadachova E, **Casadevall A** (2009). Radiolabeled antibodies to *Bacillus anthracis* toxins are bactericidal and partially therapeutic in experimental murine anthrax. *Antimicrobiol. Agents. Chemotherapy.* 53:4860-8.
452. **Casadevall A**, Pirofski L (2009) Virulence factors and their mechanisms of action: the view from a damage-response framework. *J Water Health* 7 Suppl 1:S2-S18. doi: 10.2166/wh.2009.036. Review. PMID: 19717929
453. Silva MB, Thomaz L, Marques AF, Svidzinski AR, Nosanchuk JD, **Casadevall A**, Travassos LR, Taborda CP (2009) Resistance of melanized yeast cells of *Paracoccidioides brasiliensis* to antimicrobial oxidants and inhibition of phagocytosis using carbohydrates and monoclonal antibody to CD18. *Mem Inst Oswaldo Cruz* 104:644-8.
454. Eisenman H, Frases S, Nicola AM, Rodrigues ML, **Casadevall A** (2009) Vesicle-associated melanization in *Cryptococcus neoformans*. *Microbiology* 155:3860-7. PMCID: PMC2889422
455. Oliveira D, Nimrichter L, Miranda K, Frases S, Faull K, **Casadevall A** (2009) *Cryptococcus neoformans* cryoimmunoelectronmicroscopy and vesicle fractionation reveals an intimate association between membrane lipids and glucuronoxylomannan. *Fungal Genetics Biol* 46:956-63.
456. Schweitzer AD, Howell RC, Jiang Z, Bryan RA, Gerfen G, Chen CC, Mah D, Cahill S, **Casadevall A**, Dadachova E. (2009) Physico-chemical evaluation of rationally designed melanins as novel nature-inspired radioprotectors. *PLOS One* e7229 PMCID: PMC2749938
457. Martinez LR, Mihi MR, Han G, Frases S, Cordero RJB, **Casadevall A**, Friedman AJ, Friedman JM, and Nosanchuk (2009) The use of chitosan to damage *Cryptococcus neoformans* biofilms. *Biomaterials* 31:669-79. PMCID: PMC2783412
458. Robert VA, **Casadevall A**. (2009) Vertebrate endothermy restricts most fungi as potential pathogens. *J Infect Dis.* 2009 Nov 15;200(10):1623-6. doi: 10.1086/644642. PMID: 19827944
459. Saylor C, Dadachova E, **Casadevall A**. (2009) Monoclonal antibody-based therapies for microbial diseases.

Vaccine. 2009 Dec 30;27 Suppl 6:G38-46. doi: 10.1016/j.vaccine.2009.09.105. Review. PMID: 20006139

460. Franz DR, Ehrlich SA, **Casadevall A**, Imperiale MJ, Keim PS (2010) The 'nuclearization' of biology is a threat to health and security. *Biosecur. Bioterror.* 7:243-4.

461. Saylor C, Dadachova E, **Casadevall A** (2010) Murine IgG1 and IgG3 isotype switch variants promote phagocytosis of *Cryptococcus neoformans* through different receptors. *J. Immunol.* 184:336-43.

462. Luo Y, Pollard JW, **Casadevall A** (2010) Fcγ receptor crosslinking stimulates cell proliferation of macrophages via the ERK pathway. *J. Biol. Chem* 285:4232-42.

463. Fang FC, **Casadevall A** (2010) Lost in translation – basic science in the era of translational research. *Infect. Immun.* 78:563-6. PMCID: PMC2812192

464. Biron CA, **Casadevall A**. (2010) On immunologists and microbiologists: ground zero in the battle for interdisciplinary knowledge. *MBio.* 1(5). pii: e00260-10. PMID: 21714147

465. De Jesus M, Chow S., Cordero R.J.B., Frases S, **Casadevall A** (2010) Galactoxylomannans from *Cryptococcus neoformans* varieties *neoformans* and *grubii* are structurally and antigenically variable. *Eukaryotic Cell* 9:1018-28.

466. **Casadevall A**, Relman DA (2010) Microbial threat lists: obstacles in the quest for biosecurity? *Nature Micro. Reviews* 8:149-54.

467. Guimaraes AJ, Frases S, Cordero RJB, Nimrichter L, **Casadevall A**, Nosanchuk JD (2010). *Cryptococcus neoformans* responds to mannitol by increasing capsule size in vitro and in vivo. *Cell. Microbiol.* 12:740-53. PMCID: PMC289187

468. Achkar JM, Jenny-Avital E, Yu X, Burger S, Leibert E, Bilder PW, Almo SC, **Casadevall A**, Laal S (2010) Antibodies against immunodominant antigens of *M. tuberculosis* in tuberculosis suspects in the US: a comparison by HIV status. *Clin.Vaccine Immunol* 17:384-92. PMCID: PMC2837951

469. Phaeton R, Wang XG, Einstein MH, Goldberg GL, **Casadevall A**, Dadachova E (2010). The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of 188Re-labeled anti-E6 C1P5 antibody in cervical cancer in mice. *Cancer* 20:1067-1074. PMCID: PMC2820134

470. Oliveira DC, Freire-de-Lima CG, Nosanchuk JD, **Casadevall A**, Rodrigues ML, Nimrichter L. (2010) Extracellular vesicles from *Cryptococcus neoformans* modulate macrophage functions. *Infect. Immun.* 78:1601-9. PMCID: PMC2849392

471. Luke TC, **Casadevall A**, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. (2010) Hark back: passive immunotherapy for influenza and other serious infections. *Crit. Care Med.* 38 (4 Suppl), e66-73.

472. Frager SZ, Chrisman CJ, Shakked R, **Casadevall A** (2010) Paramecium species ingest and kill the cells of the human pathogenic fungus *Cryptococcus neoformans*. *Med Mycol.* 48:775-9.

473. Janda A, **Casadevall A** (2010) Circular Dichroism Reveals Evidence of Coupling between Immunoglobulin Constant and Variable Region Secondary Structure. *Molecular Immunology* 47:1421-5. PMCID: PMC2872143

474. McClelland EE, Nicola AM, Prados-Rosales, R, **Casadevall A** (2010). Humoral immunity can modulate fungal metabolism. *J. Clin. Invest.* 120:1355-61.
Paper was accompanied by a JCI commentary: <http://www.ncbi.nlm.nih.gov/pubmed/20335652>
475. Winterroth L, Rivera J, Nakouzi AS, Dadachova E, **Casadevall A** (2010). A neutralizing monoclonal antibody to edema toxin and its effect on murine anthrax. *Infection and Immunity* 78(6):2890-8 .
476. Scheweitzer AS, Revskaya E, Chu P, Pazo V, Friedman M, Nosanchuk JK, Cahill S, Frases S, **Casadevall A**, Dadachova E. (2010) Melanin-covered nanoparticles for protection of bone marrow during radiation therapy of cancer. *Int J. Radiat. Oncol. Biol. Phys* 78(5):1494-502.
Paper was featured in Science Daily
<http://www.sciencedaily.com/releases/2010/04/100426182022.htm>
477. **Casadevall A** (2010) Cryptococci at the brain gate: break and enter or use a Trojan horse. *J. Clin. Invest* 210:1689-92. PMCID: PMC2860912
478. Fonseca FL, Nohara LL, Cordero JB, Frases S, **Casadevall A**, Almeida I, Nimrichter L, Rodrigues ML (2010) Immunomodulatory effects of serotype B glucuronoxylomannan from *Cryptococcus gattii* correlate with polysaccharide diameter. *Infect. Immun.* 78:3861-70.
479. Oliveria DL, Nakayasu ES, Joffe LS, Guimaraes AJ, Sobreira TJ, Nosanchuk JD, Cordero RJ, Frases S, **Casadevall A**, Almeida IC, Nimrichter L, Rodrigues ML (2010) Characterization of yeast extracellular vesicles: evidence for the participation of different pathways of cellular traffic in vesicle biogenesis. *PLOS One* e11113. PMCID: PMC2885426
480. **Casadevall A**, Imperiale MJ (2010). Destruction of Microbial Collections in Response to Select Agent and Toxin List Regulations. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science*. Vol 8:151-4.
This paper was the subject of an NPR Morning Edition program
<http://www.npr.org/player/v2/mediaPlayer.html?action=1&t=1&islist=false&id=133066108&m=133071625>
481. Zaragoza O, Garcia-Rodas R, Nosanchuk JD, Cuenca-Estrella M, Rodriguez-Tudela JL, **Casadevall A** (2010) Fungal cell gigantism during mammalian infection. *PLOS Pathogens* e1000945. PMCID: PMC2887474 *F1000 Recommended 'Must Read'* <http://f1000.com/prime/7063956#recommendations>
482. Bryan RA, Jiang Z, Howell RC, Morgenstern A, Bruchertseifer R, **Casadevall A**, Dadachova E. (2010) Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. *J. Infect. Dis.* 202:633-7.
F1000 Recommended <http://f1000.com/prime/4145956#recommendations>
483. Muehlbauer SM, Lima Hr Jr, Goldman DL, Jacobson L, Rivera J, Goldberg MF, Palladino MA, **Casadevall A**, Brojatsch J (2010) Proteosome inhibitors prevent caspase-1-mediated disease in rodents challenged with anthrax lethal toxin. *Am. J. Pathol* 177(2):735-43.
484. Chrisman CJ, Alvarez M, **Casadevall A** (2010). Phagocytosis and non-lytic exocytosis of *Cryptococcus neoformans* by and from *Acanthamoeba castellanii*. *Appl Environ Microbiol.* 76:6065-62.
485. **Casadevall A**. (2010) ASM Launches mBio. *MBio*. 2010 May 18;1(1). pii: e00120-10. doi: 10.1128/mBio.00120-10.
PMID: 20689741

486. Garcia-Solache MA, **Casadevall A** (2010) Global warming will bring new fungal diseases for mammals. *mBio* 1:e00061-10.

In 2016 this paper was the subject of a Wall Street Op Ed raising the specter that fungi could cause devastating epidemics. <http://www.wsj.com/articles/what-comes-after-zika-1457132252>

487. Ostrosky-Zeichner L, **Casadevall A**, Galgiani JN, Odds FC, Rex JH (2010) An insight into the antifungal pipeline: selected molecules and beyond. *Nat. Rev. Drug. Discov.* 9:719-27.

488. Luo Y, **Casadevall A** (2010). Intracellular cryptococci suppress Fc-mediated cyclin D1 elevation. *Commun. Intergr. Biol.* 3:390-1.

489. Pericolini E, Gabrielle E, Bistoni G, Cenci E, Perito S, Chow SK, Riuzzi F, Donato R, **Casadevall A**, Vecchiarelli A (2010) Role for CD45 signalling pathway in galactoxylomannan-induced T cell damage. *PLOS One* e12720.

490. Phaeton R, Harris M, Jiang Z, Wang XG, Einstein MH, Goldberg GL, **Casadevall A**, Dadachova E. (2010) Radioimmunotherapy with antibody to HPV16 E6 oncoprotein is effective in experimental cervical tumor expressing low levels of E6. *Cancer Biol Ther.* 10:1041-7.

491. Casadevall A, Fang F (2010) Reproducible Science. *Infect. Immun* 78:4972-5.

492. Lye LF, Kang SO, Nosanchuk JD, **Casadevall A**, Beverley SM (2010) Phenylalanine hydroxylase (PAH) from the lower eukaryote *Leishmania major*. *Mol. Biochem. Parasitol.* 175:58-67.

493. Abboud N, Chow S, Ravetch J, Scharff MD, **Casadevall A** (2010). A requirement for FcR in antibody-mediated bacterial toxin neutralization. *J. Exp. Med* 2010:207; 2395-405.

494. Rivera J, Cordero RJB, Nakouzi AS, Frases S, Nicola A, **Casadevall A** (2010) *Bacillus anthracis* produces membrane-derived vesicles containing biologically active toxins. *PNAS* 107:19002-7. *This paper was rated F1000 Must Read* <http://f1000.com/prime/717992089#recommendations>

495. Siev M, Yu X, Prados-Rosales R, Martiniuk FT, **Casadevall A**, Achkar JM. (2011) Correlation between serum and plasma antibody titers to mycobacterial antigens. *Clin Vaccine Immunol.* 2011 Jan;18(1):173-5. doi: 10.1128/CVI.00325-10. Epub 2010 Nov 3. PMID: 21047999

496. Bergman A, **Casadevall A** (2010) Mammalian endothermy optimally restricts fungi and metabolic costs. *mBio* r00212-10.

Featured in Science News

http://www.sciencenews.org/view/generic/id/67029/title/Just_warm_enough

Featured in Scientific American <http://www.scientificamerican.com/podcast/episode.cfm?id=986-trades-metabolic-cost-for-funga-10-12-27>

497. Biron CA, **Casadevall A**. (2010) On immunologists and microbiologists: ground zero in the battle for interdisciplinary knowledge. *MBio.* Nov 2;1(5). pii: e00260-10. doi: 10.1128/mBio.00260-10. PMID: 21103040

498. Miller JF, McFall-Ngai M, **Casadevall A** (2010) A new design for the ASM general meeting. *MBio.* 2010 Nov 23;1(5). pii: e00240-10. doi: 10.1128/mBio.00240-10. PMID:21151775

499. Jesus M, Nicola AM, Chow S, Lee IR, Nong S, Spech CA, Levitz SM, **Casadevall A** (2010). Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of *Cryptococcus neoformans*. *Virulence* 1:500-8.
500. Cordero RJB, Frases S, Guimaraes AJ, Rivera J, **Casadevall A** (2011) Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. *Mol. Micro* 79;1101-17.
501. Chow, S, **Casadevall A** (2011) Evaluation of a *Cryptococcus neoformans* galactoxylomanna-protein conjugate vaccine candidate against murine cryptococcosis. *Vaccine* 29:1891-8.
502. Harris M, Wang X-G, Jiang X, Goldberg GL, **Casadevall A** and Dadachova E. (2011). Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. *Head Neck Oncol.* 3;9.
This paper was highlighted in the Jan. 2011 Journal of Nuclear Medicine
503. Fang FC, **Casadevall A** (2011) Reductionistic and Holistic Science. *Infect. Immun.* 79:1401-4.
504. Oliveira DL, Nakayasu ES, Joffe LS, Guimaraes AJ, Sobreira TJ, Nosanchuk JD, Cordero RJ, Frases S, **Casadevall A**, Almeida IC, Nimrichter L, Rodrigues ML. (2011) Biogenesis of extracellular vesicles in yeast: many questions with few answers. *Commun. Intergr Biol.* 3:533-535.
505. Prados-Rosales R, Baena A, Martinez L, Luque-Garcia J, Kalscheuer R, Veeraraghavan U, Camara C, Nosanchuk JD, Guryal SB, Chen B, Jimenez J, Glatman-Freedman A, Jacobes WR, Porcelli SA, **Casadevall A** (2011). Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner. *J. Clin. Invest.* 121;1471-83.
506. Liu, T, Wang Y, Stukes S, Chen Q, **Casadevall A**, Xue C (2011) The F-box protein Fbp1 regulates sexual reproduction and virulence in *Cryptococcus neoformans*. *Eukaryotic Cell* 10:791-802.
507. Kmetzsch L, Joffe LS, Staats CC, de Oliveira DL, Fonseca FL, Cordero RJB, **Casadevall A**, Nimrichter L, Schrank A, Vainstein MH, Rodrigues ML (2011). Role for Golgi reassembly and stacking protein (Grasp) in polysaccharide secretion and fungal virulence. *Mol. Microbiol.* 81:206-18.
508. Turick CE, Milliken C, Ekechukwu, A, **Casadevall A**, Dadachova E. (2011) Gamma Radiation Interacts with Melanin to Alter its oxidation-reduction potential and results in electric current production. *Bioelectrochemistry* 82:69-73.
509. Chrisman CJ, Andrade PA, Guimaraes AJ, **Casadevall A** (2011) Phospholipids trigger *Cryptococcus neoformans* capsular enlargement during interactions with amoebae and macrophages. *PLOS Pathogens* e1002047.
510. Eisenman H, Chow S, **Casadevall A** (2011) The effect of L-DOPA on *Cryptococcus neoformans* growth and gene expression. *Virulence* 2:329-36.
511. Dadachova E, **Casadevall A** (2011) *Cryptococcus neoformans* as a model for radioimmunotherapy of infections. *Interdisciplinary Perspectives on Infectious Diseases* 2011:830286.
512. **Casadevall A**, Fang FC, Pirofski L (2011) Microbial Virulence as an emergent property: consequences and opportunities. *PLoS Pathogens* e1002136

513. Fang FC, **Casadevall A** (2011) Retracted Science and the Retraction Index. *Infect. Immun.* 79:3855-9.

This paper was featured in Science News of the Week and several online magazines

<http://www.timeshighereducation.co.uk/story.asp?sectioncode=26&storycode=417226&c=1>

Paper was featured in Science Magazine News of the week

<http://www.sciencemag.org/content/333/6045/923.2.full.pdf?sid=4fb4481d-9df8-427e-bffb-15e01e1b0634>

The Scientist News and Opinion

<http://the-scientist.com/2011/08/11/qa-the-impact-of-retractions/>

514. Nicola AM, Robertson EJ, Albuquerque P, Silveira-Derongowski L, **Casadevall A** (2011) Non-lytic exocytosis of *Cryptococcus neoformans* from macrophages occurs in vivo and is influenced by phagosomal pH. *mBio* 2, e00167-11.

515. Vecchiarelli A, Pericolini E, Gabrielli E, Chow SK, Bistoni F, Cenci E, **Casadevall A** (2011) *Cryptococcus neoformans* galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory therapy. *Immunotherapy* 3:997-1005

516. Rodrigues ML, Nimrichter L, Cordero RJ, **Casadevall A** (2011) Fungal polysaccharides: biological activity beyond the usual structural properties. *Front Microbiol.* 2:171.

517. Garcia-Rodas R, **Casadevall A**, Rodrigues-Tudela JL, Cuenca-Estrella M, Zaragoza O (2011) *Cryptococcus neoformans* capsular enlargement and cellular gigantism during *Galleria mellonella* infection. *Plos ONE* 6(9) e24485.

518. Del Poeta M, **Casadevall A** (2011). Ten Challenges on *Cryptococcus* and cryptococcosis. *Mycopathologia* 173(5-6):303-10.

519. Khajo A, Bryan RA, Friedman M, Burger RM, Levitsky Y, **Casadevall A**, Magliozzo RS, Dadachova E (2011) Protection of melanized *Cryptococcus neoformans* from lethal dose gamma radiation involves changes in melanin's chemical structure and paramagnetism. *PLoS One* 6:e25092.

520. Tsirilakis K, Kim C, Vicencio AG, Andrade C, **Casadevall A**, Goldman DL (2012) Methylxanthine inhibit Fungal Chitinases and exhibit antifungal activity. *Mycopathologia* 172:83-91.

521. Cordero RJB, Pontes B, Guimaraes AJ, Martinez LR, Rivera J, Fries BC, Nimrichter L, Rodrigues ML, Viana NM, **Casadevall A** (2011) Chronological aging is associated with biophysical and biochemical changes in the capsule of *Cryptococcus neoformans*. *Infect. Immun.* 79:4990-5000. *This paper was the highlighted in the journal Infection and Immunity*

522. Jiang Z, Bryan RA, Morgenstern A, Bruchertseifer F, **Casadevall A**, Dadachova E (2011) Treatment of early and established *Cryptococcus neoformans* infection with radiolabeled antibodies in immunocompetent mice. *Antimicrob Agents Chemother.* 56:552-4.

523. Frases S, Viana NB, **Casadevall A** (2011) Biophysical methods for the study of microbial surfaces. *Front Microbiol* 2:207

524. Imperiale MJ, **Casadevall A** (2011) Bioterrorism: lessons learned since the anthrax mailings. *mBio* 2, e00232.

525. Bryan RA, Guimaraes AJ, Hopcraft S, Jiang Z, Bonilla K, Morgenstern A, Bruchertseifer F, Del Poeta M, Torosantucci A, Cassone A, Nosanchuk KD, **Casadevall A**, Dadachova E. (2011) Toward developing a universal strategy for fungal disease using radioimmunotherapy targeting common fungal antigens. *Mycopathologia* 173(5-6):463-71.

526. Rodrigues ML, Nosanchuk JD, Schrank A, Vainstein MH, **Casadevall A**, Nimrichter L (2011) Vesicular transport systems in fungi. *Future Microbiol.* 2011;6:1371-81.

527. **Casadevall A**, Pirofski L (2011) A new synthesis for antibody mediated immunity. *Nature Immunology* 13:21-8.

F1000 recommended <http://f1000.com/prime/13578958#recommendations>

528. Goldman DL, Li X, Tsirilakis K, Andrade C. **Casadevall A**, Vicencio AG (2012) Increased chitinase expression and fungal-specific antibodies in the bronchoalveolar lavage fluid of asthmatic children. *Clin Exp Allergy* 42(4):523-30.

529. **Casadevall A** (2012) Amoeba can provide insight into the origin of virulence in pathogenic fungi. *Adv Exp Med Biol* 710:1-10.

530. Yu X, Prados-Rosales R, Jenny-Avital ER, Sosa K, **Casadevall A**, Achkar JM. (2012) Comparative evaluation of antibody profiles to mycobacterial capsular polysaccharides in tuberculosis patients and controls stratified by HIB status. *Clin. Vaccine Immunol.* 19:198-208.

531. Eisenman HC, **Casadevall A** (2012). Synthesis and assembly of fungal melanin. *Appl. Microbiol. Biotechnol.* 93:931-40.

532. **Casadevall A**, Fang FC. (2012) Reforming Science I. Methodological and cultural reforms. *Infect. Immun.* 80(3):891-6.

533. Fang FC, **Casadevall A** (2012). Reforming Science II. Structural reforms. *Infect. Immun.* 80(3):897-901.

The above two papers led to a New York Times article by Carl Zimmer

<http://www.nytimes.com/2012/04/17/science/rise-in-scientific-journal-retractions-prompts-calls-for-reform.html>

These efforts led to Drs. Casadevall and Fang being profiled in Science magazine:

<http://www.ncbi.nlm.nih.gov/pubmed/23349264>

534. Coelho C, Tesfa L, Zhang J, Rivera J, Gongalves T, **Casadevall A** (2012). Analysis of cell cycle and replication of mouse macrophages after in vivo and in vitro *Cryptococcus neoformans* infection using laser scanning cytometry. *Infect. Immun* 80(4):1467-78.

535. Araujo GS, Fonseca FL, Pontes B, Torres A, Cordero RJ, Zoncope-Oliveria RM, **Casadevall A**, Viana NB, Nimrichter L, Rodrigues ML, Garcia ES, de Souza W, Frases S. (2012) Capsules from pathogenic and non-pathogenic *Cryptococcus* spp. Manifest significant differences in structure and ability to protect against phagocytic cells. *PLoS One* e29561.

536. Nicola AM, **Casadevall A** (2012) In vitro measurement of phagocytosis and killing of *Cryptococcus neoformans* by macrophages. *Methods Mol. Biol* 844:189-197.

537. Albuquerque P, **Casadevall A** (2012). Quorum sensing in fungi – a review. *Med Mycol* 50(4):337-45.

538. Wolf J, Rivera J, **Casadevall A** (2012). Serum albumin disrupts *Cryptococcus neoformans* and *Bacillus anthracis* extracellular vesicles. *Cell Microbiol* 14(5):762-73.


539. Pirofski L, **Casadevall A** (2012). What is a pathogen? A question that begs the point. *BMC Biology* 10:6.

540. Berns KI, **Casadevall A**, Cohen MI, Ehrlich SA, Enquist LW, Fitch JP, Franz DR, Fraser-Liggett CM, Grant CM, Imperiale MJ, Kanabrocki J, Keim PS, Lemon SM, Levy SB, Lumpkin JR, Miller JF, Murch R, Nance ME, Osterholm MT, Relman DA, Roth JA, Vidaver AK (2012) Policy: Adaptations of avian flu virus are a cause for concern. *Nature* 482:153-154.

541. **Casadevall A**, Shenk T (2012) The H5N1 manuscript redaction controversy. *mBio* 3(1). pii: e00022-12.

542. Berns KI, **Casadevall A**, Cohen MI, Ehrlich SA, Enquist LW, Fitch JP, Franz DR, Fraser-Liggett CM, Grant CM, Imperiale MJ, Kanabrocki J, Keim PS, Lemon SM, Levy SB, Lumpkin JR, Miller JF, Murch R, Nance ME, Osterholm MT, Relman DA, Roth JA, Vidaver AK (2012) Public Health and biosecurity: Adaptation of Avian flu virus area cause for concern. *Science* 335(6069):660-1.

543. McClellan, EE, **Casadevall A** (2012). Strain-related differences in antibody-mediated changes gene expression are associated with differences in capsule and location of binding. *Fungal Gen Bio* 149(3):227-34.



544. **Casadevall A**, Nakouzi A, Crippa PR, Eisner M (2012) Fungal melanins differ in planar stacking distances. *PLoS One* 7(2):e30299. PMID:PMC3281024

545. **Casadevall A** and Shenk T (2012) Mammalian transmissible H5N1 virus: containment level and case fatality ratio. *mBio* 6;3(2):e00054-12.


546. Dadachova E, Kitchen SG, Bristol G, Baldwin GC, Revskaya E, Empig C, Thornton GB, Gorny MK, Zolla-Pazner S, **Casadevall A**. (2012) Pre-Clinical evaluation of a Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. *PLoS One* 7(3):e31866.

547. **Casadevall A** (2012) The future of biological warfare. *Microbial Biotechnology* 5(5):584-7 .

548. Muhammed M, Feldmesser M, Shubitz LJ, Lionakis MS, Sil A, Wang Y, Glavis-Blom, Lewis RE, Galgiani J, **Casadevall A**, Konoyannis DP, Mylonakis E. (2012) Mouse models for the study of fungal pneumonia: a collection of detailed protocols for the study of *Coccidioides*, *Cryptococcus*, *Fusarium*, *Histoplasma* and combined infection due to *Aspergillus-Rhizopus*. *Virulence* 3(3):329-38.

549. Ramos C, Fonseca F, Rodrigues J, Guimaraes A, Cinelli L, Miranda K, Nimrichter L, **Casadevall A**, Travassos L, Rodrigues M (2012) Chitin-like molecules associate with *Cryptococcus neoformans*

glucuronoxylomannan to form a glycan complex with previously unknown properties. *Eukaryotic Cell* 11(9):1086-94.



550. Cassone A, **Casadevall A** (2012) Recent progress in vaccines against fungal diseases. *Current Opin. Microbiol.* 15(4):427-33.

551. **Casadevall A** and Pirofski L (2012) Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. *Cell Host and Microbe* 11:445-56.

552. Nicola AM, Albuquerque P, Martinez LR, Dal-Rosso RA, Saylor C, De Jesus, M, Nosanchuk JD, **Casadevall A** (2012) Macrophage autophagy in immunity to *Cryptococcus neoformans* and *Candida albicans*. *Infect. Immun.* 80(9):3065-76.

553. Chatterjee S, Prados-Rosales R, Frases S, Itin B, **Casadevall A**, Stark RE (2012). Using solid-state NMR to monitor the molecular consequences of *Cryptococcus neoformans* melanization with different catecholamine precursors. *Biochem.* 7;51(31):6080-8 PMID:PMC3448835

554. Chow S, **Casadevall A** (2012) Monoclonal antibodies and toxins – a perspective on function and isotype. *Toxins* 4(6):430-54.

555. **Casadevall A**, Janda A (2012) Immunoglobulin isotype influences affinity and specificity. *PNAS* 109(31):12272-3.

556. Xia Y, Rawar R, Nokouz AS, Monestier M, Fan M, Wang L, **Casadevall A**, Putterman C (2012) The constant region contributes to the antigenic specificity and renal pathogenicity of anti-DNA antibodies. *J. Autoimmunity* 56(1-2):28-37.

557. **Casadevall A**, Fang FC (2012) Winner takes all. *Scientific American* 307(2):13.

558. **Casadevall A** (2012) Fungi and the rise of mammals. *PLoS Pathogens* Aug;8(8):e1002808
F1000 recommended: <http://f1000.com/prime/718006239#recommendations>

559. Janda A, Eryilmaz E, Nakouzi A, Cowburn D, **Casadevall A** (2012) Variable region identical immunoglobulins differing in isotype express different paratopes. *J Biol Chem.* 287(42):35409-17.

560. Robertson EJ, Wolf JM, **Casadevall A** (2012) EDTA inhibits *Cryptococcus neoformans* biofilm formation, extracellular vesicular secretion and shedding of the capsular polysaccharide glucuronoxylomannan. *Appl Environ Microbiol* 78(22):7977-84.

561. Albuquerque PC, B Cordero RJ, Fonseca FL, Peres R, Ramos CL, Miranda KR, **Casadevall A**, Puccia R, Nosanchuk JD, Nimrichter L, Guimaraes AJ, Rodrigues ML. (2012) A *Paracoccidioides brasiliensis* glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan. *Fungal Genet Biol.* (11):943-54.

562. **Casadevall A**, Shenk T (2012) The H5N1 moratorium controversy and debate. *Mbio* e00379-12

563. Fang FC, Steen RC, **Casadevall A** (2013) Misconduct accounts for the majority of retracted scientific publications. *PNAS* 109(42):17028-33.

F1000 Recommended <http://f1000.com/prime/4145956#recommendations>

This paper received intense media coverage. Here are some links

<http://news.sciencemag.org/scienceinsider/2012/10/misconduct-not-mistakes-causes-m.html>

http://www.sciencenews.org/view/generic/id/345465/description/Misconduct_prompts_most_retractions

<http://www.the-scientist.com/?articles.view/articleNo/32687/title/Fraud-Breeds-Retractions/>

<http://www.guardian.co.uk/science/2012/oct/01/tenfold-increase-science-paper-retracted-fraud>

http://carlzimmer.com/articles/index.php?subaction=showfull&id=1356631997&archive=&start_from=&ucat=15&

564. Revskaya E, Chu P, Howell RC, Schweitzer AD, Bryan RA, Harris M, Gerfen G, Jiang Z, Jandl T, Kim K, Ting LM, Sellers RS, Dadachova E, **Casadevall A** (2013) Compton scattering by internal shields based on melanin-containing mushrooms provides protection of gastrointestinal tract from ionizing radiation. *Cancer Biother Radiopharm* 27(9):570-6. PMID:PMC3484786.

This paper was covered by ASM blog Small things considered:

<http://schaechter.asmblog.org/schaechter/2013/11/radiation-ahead-eat-a-black-mushroom.html>

Also covered by This Week in Microbiology

TwIM #67 (<http://www.microbeworld.org/podcasts/this-week-in-microbiology/archives/1501-twim-67>)

565. Jandl T, Revskaya E, Jiang Z, Harris M, Dorokhova O, Tsukrov D, **Casadevall A**, Dadachova E. (2013) Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy. *Nucl Med Biol.* 40(2):177-81.

566. Fang, FC, **Casadevall A**. (2013). Why We Cheat. *Scientific American Mind*, 24(2), 30-37.



567. Cordero RBJ, Pontes B, Frases S, Nakouzi AS, Nimrichter L, Rodrigues ML, Viana NB, **Casadevall A** (2013) Antibody binding to *Cryptococcus neoformans* impairs budding by altering capsular mechanical properties. *J. Immunol.* 190(1):317-23.

568. Pericolini E, Alunno A, Gabrielli E, Bartoloni E, Cenci E, Chow SK, Bistoni G, **Casadevall A**, Gerli R, Vecchiarelli A (2013). The Microbial Capsular Polysaccharide Galactoxylomannan Inhibits IL-17A Production in Circulating T Cells from Rheumatoid Arthritis Patients. *Plos One* 8(1):e53336.

569. Fang FC, Bennett JW, **Casadevall A**. (2013) Males are overrepresented among life science researchers committing scientific misconduct. *Mbio* 4(1):e00640-12.

This paper received considerable media coverage. Here are some links

<http://www.sciencedaily.com/releases/2013/01/130122101905.htm>

<http://news.sciencemag.org/2013/01/male-scientists-more-prone-misconduct-study-concludes>

<http://www.biotechniques.com/news/Men-Commit-More-Misconduct/biotechniques-339315.html>

<http://www.nature.com/scitable/forums/women-in-science/do-men-commit-more-scientific-misconduct-102166616>

570. Klein M, Lotem M, Peretz T, Zwas ST, Mizrahi S, Liberman Y, Chisin R, Schachter J, Ron IG, Iosilevsky G, Kennedy JA, Revskaya E, de Kater AW, Banaga E, Klutzaritz V, Friedmann N, Galun E, Denardo GL, Denardo SJ, **Casadevall A**, Dadachova E, Thornton GB. (2013) Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. *J. Skin. Cancer* 2013:828329

571. **Casadevall A**, Pirofski L (2013) Exserohilum rostrum fungal meningitis associated with methylprenilolone injections. *Future Microbiol.* 8:135-7.

572. Harris M, Wang XG, Jiang Z, Phaeton R, Koba W, Goldberg GL, **Casadevall A**, Dadachova E. (2013) Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. *Br. J. Cancer.* 108(4):859-65.

573. Achkar J, **Casadevall A** (2013) Antibody-mediated immunity against tuberculosis: implications for vaccine development. *Cell Host Microbe* 13;13(3):250-62.

574. Pohl MA, Rivera J, Nakouzi A, Chow SK, **Casadevall A** (2013) Combinations of antibodies to anthrax toxin manifest new properties in neutralization assays. *Infect. Immun.* 81(6):1880-8.

575. Derengowski L, Costa Paes H, Tavares AHFP, Albuquerque P, Fernandes L, Silva-Pereira I, **Casadevall A** (2013) The transcriptional response of *Cryptococcus neoformans* to *Acanthamoeba castellanii* and macrophages provides insights into the evolutionary adaptation to the mammalian host. *Eukaryotic Cell* 12(5):761-74.


F1000 Recommended <http://f1000.com/prime/717992089#recommendations>

576. Jandl T, Revskaya E, Jiang Z, Bryan RA, **Casadevall A**, Dadachova E (2013) Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma. *Immunotherapy* 5(4):357-64.

577. Ziegenbalg A, Prados-Rosales R, Jenny-Avital ER, Kim RS, **Casadevall A**, Achkar JM (2013) Immunogenicity of mycobacterial vesicles in humans: identification of a new biomarker. *Tuberculosis* S1472-9792(13)00061-9.

578. Jain N, Cordero RJB, **Casadevall A**, Fries BC (2013) Allergen1 Regulates Polysaccharide Structure in *Cryptococcus neoformans*. *Mol. Micro* 88(4):713-27.

579. Chow SK, Smith C, MacCarthy T, Pohl MA, Bergman A, **Casadevall A**. (2013) Disease-enhancing antibodies improve the activity of toxin-neutralizing antibodies. *Cell Host Microbe* 13(4):417-28.



580. Fonseca FL, Guimarães AJ, Kmetzsch L, Dutra FF, Silva FD, Taborda CP, Araujo GD, Frases S, Staats CC, Bozza MT, Schrank A, Vainstein MH, Nimrichter L, **Casadevall A**, Rodrigues ML (2013) Binding of the wheat germ lectin to *Cryptococcus neoformans* chitoooligomers affects multiple mechanisms required for fungal pathogenesis. *Fungal Genet Biol.* ;60:64-73.

581. Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, **Casadevall A**, Dadachova E, and Gravekamp C (2013) Non-toxic radioactive *Listeria* is a highly effective therapy against metastatic pancreatic cancer. *PNAS* 110(21):8668-73.

This manuscript received considerable media attention and was the object of an NIH Press release

<http://www.nih.gov/researchmatters/may2013/05062013radioactive.htm>

<http://www.sciencedaily.com/releases/2013/04/130422154753.htm>

<http://www.nature.com/news/radioactive-bacteria-attack-cancer-1.12841>

<http://news.sciencemag.org/sciencenow/2013/04/radioactive-microbes-nuke-tumor-.html>

The paper was also accompanied by an editorial in *PNAS*

<http://www.ncbi.nlm.nih.gov/pubmed/23667150>

582. Garcia-Solache MA, Izquierdo-Garcia D, Smith C, Bergman A, **Casadevall A**. (2013) Fungal virulence in a lepidopteran model is an emergent property with deterministic features. *MBio.* 2013 Apr 30;4(3). pii: e00100-13.

This paper was chosen for the journal 'Editor picks'

F1000 recommended <http://f1000.com/prime/718006239#recommendations>

583. Xia Y, Janda A, Eryilmaz E, **Casadevall A**, Putterman C. (2013). The constant region affects antigen binding of antibodies to DNA by altering secondary structure. *Mol. Immunol* 56(1-2):28-37.

584. Kania G, Siegert S, Behnke S, Prados-Rosales R, **Casadevall A**, Lüscher TF, Luther SA, Kopf M, Eriksson U, Blyszczuk P (2013) Innate Signalling Promotes Formation of Regulatory Nitric Oxide-Producing Dendritic Cells Limiting T Cell Expansion in Experimental Autoimmune Myocarditis. *Circulation* 127(23):2285-94

585. McClelland EE, Hobbs LM, Rivera J, **Casadevall A**, Potts WK, Smith JM, Ory JJ (2013) The Role of Host Gender in the Pathogenesis of *Cryptococcus neoformans* Infections. *PLoS One.* 2013 May 31;8(5):e63632.

586. Steen RG, **Casadevall A**, Fang FC. (2013) Why has the number of scientific retractions increased? *PLoS One* e68397.

587. Eryilmaz E, Janda A, Kim J, Cordero RJ, Cowburn D, **Casadevall A**. (2013) Global structures of IgG isotypes expressing identical variable regions. *Mol. Immunol.* 56(4):588-598.

588. **Casadevall A** (2013) Progress in understanding fungal pathogenesis. *Curr Opin Microbiol.* 16(4):375-6.
589. Cordero RJ, Bergman A, **Casadevall A** (2013). Temporal Behavior of Capsule Enlargement for *Cryptococcus neoformans*. *Eukaryot Cell* 12(10):1383-8.
590. **Casadevall A**, Fang FC (2013) Is the Nobel Prize good for Science? *FASEB J.* 27(12):4682-90. <http://www.laborjournal.de/blog/?p=8514>
591. Andes D, **Casadevall A** (2013) Insights into fungal pathogenesis from the iatrogenic epidemic of *Exserohilum rostratum* fungal meningitis. *Fungal Genet Bio*161:143-5 .
592. Bryan RA, Jiang Z, Morgenstern A, Bruchertseifer F, **Casadevall A**, Dadachova E. (2013) Radioimmunotherapy of *Cryptococcus neoformans* spares bystander mammalian cells. *Future Microbiol. Sep*;8(9):1081-9.
593. Coelho C, Bocca A, **Casadevall A.** (2013) The Intracellular Life of *Cryptococcus neoformans*. *Annu Rev Pathol.* 2014 9:219-38. doi: 10.1146/annurev-pathol-012513-104653,
594. **Casadevall A** (2013) Progress in understanding fungal pathogenesis. *Curr Opin Microbiol.* 16(4):375-6.
595. Rath P, Huang C, Wang T, Wang T, Li H, Prados-Rosales R, Elemento O, **Casadevall A** and Nathan C. (2013) Genetic Regulation of Vesiculogenesis and Immunomodulation in *Mycobacterium tuberculosis*. *PNAS* 110(49):E4790-7.
596. Silva BMA, Prados-Rosales R, Espadas-Moreno J, Wolf JM, Luque-Gracia JL, Gongalves T, **Casadevall A** (2013) Characterization of *Alternaria infectoria* extracellular vesicles. *Med Mycol*, 52(2):202-10.
597. **Casadevall A**, Enquist L, Imperiale MJ, Keim P, Relman DA (2013) Redaction of Sensitive Data in the Publication of Dual Use Research of Concern. *mBio* e00991-13 .
598. Albuquerque P, Nicola AM, Nieves E, Williamson PR, **Casadevall A** (2013) Quorum Sensing Mediated-Cell-Density Dependent Regulation of Growth and Virulence in *Cryptococcus neoformans*. *mBio* e00986-13.
599. Alunno A, Pericolini E, Gabrielli E, Bistoni O, Caterbi S, Bartoloni E, Terenzi R, Valentini E, La Paolia E, Chow SK, **Casadevall A**, Vechiarelli A, Gerli R (2014) Purified microbial capsular polysaccharide Galactoxylomannan (GalXM) inhibits the effector T lymphocyte arm and potentiates the regulatory counterpart in rheumatoid arthritis. *Ann Rheum Dis.* 2014;73:Suppl 1 A71.
600. Prados-Rosales R, Brown L, **Casadevall A**, Montalvo-Quirós S, Luque-Garcia JL. (2014) Isolation and identification of membrane vesicle-associated proteins in Gram-positive bacteria and mycobacteria. *MethodsX.* Aug 19;1:124-9. doi: 10.1016/j.mex.2014.08.001. eCollection 2014. PMID: PMC4472924
601. Rivera J, Morgenstern A, Bruchertseifer F, Kearney JF, Turnbough CL Jr, Dadachova E, **Casadevall A.** (2014) Microbicidal power of alpha radiation in sterilizing germinating *Bacillus anthracis* spores. *Antimicrob. Agents Chemotheap.* 58(3):1813-5. doi: 10.1128/AAC.01266-13.

602. Brotjatsch J, **Casadevall A**, Goldman DL (2014) Molecular determinants for a cardiovascular collapse in anthrax. *Front Biosci (Elite Ed)* 6:139-47.

603. **Casadevall A**, Handelsman J (2014) The presence of women conveners correlates with a higher proportion of female speakers at scientific symposia. *mBio* 5(1):e00846-13.

This article attracted considerable media attention and was featured in *The Scientist*, *Nature*, *The Atlantic*, *The chronicle of higher education* and numerous other journals and sites.

<http://www.theatlantic.com/technology/archive/2014/01/the-easiest-possible-way-to-increase-female-speakers-at-conferences/282858/>

<http://www.the-scientist.com/?articles.view/articleNo/38795/title/Speaker-Selection-Bias/>

<http://www.livescience.com/42362-encouraging-women-science.html>

<http://chronicle.com/blogs/ticker/include-women-on-meeting-teams-to-help-careers-of-female-scientists-study-suggests/71045>

<http://www.nature.com/naturejobs/science/articles/10.1038/nj7483-445a>

http://www.huffingtonpost.com/2014/01/08/women-in-science-stem-leaky-pipeline_n_4561084.html

604. Bournazos S, Chow S, Abboud N, **Casadevall A**, Ravetch JV (2014) Human IgG Fc domain engineering enhances anti-toxin neutralizing antibody activity. *J. Clin. Invest* 124(2):725-9. doi: 10.1172/JCI72676.

JV Ravetch and A Casadevall shared senior authorship

605. Prados-Rosales R, Weinrick BC, Pique DG, Jacobs WR Jr, **Casadevall A**, Rodrigues GM (2014) Role for *Mycobacterium tuberculosis* vesicles in iron acquisition. *J. Bacteriol.* 196:1250-6.

606. **Casadevall A**, Fang FC (2014) Specialized Science. *Infect. Immun* 82(4):1355-60. doi: 10.1128/IAI.01530-13.


607. Rivera J, Sellers RS, Zeng W, van Rooijen N, **Casadevall A**, Goldman DL (2014) Platelet-activating factor contributes to *Bacillus anthracis* lethal toxin-associated damage. *J. Biol. Chem* 289(10):7131-41. *DL Goldman and A Casadevall shared senior authorship.*

608. Albuquerque PC, Fonseca FL, Dutra FF, Bozza MT, Frases S, **Casadevall A**, Rodrigues ML (2014) *Cryptococcus neoformans* glucuronoxylomannan fractions of different molecular masses are functionally distinct. *Future Microbiol.* 2014 Feb;9(2):147-61. PMID: PMC4294706

609. Coelho C, Bocca AL, **Casadevall A** (2014). The tools for virulence of *Cryptococcus neoformans*. *Adv Appl Microbiol.* 2014;87:1-41. doi: 10.1016/B978-0-12-800261-2.00001-3. PMID: PMC4132287

610. Brown GD, Meintjes G, Kolls JK, Gray C, Horsnell W; Working Group from the EMBO-AIDS Related Mycoses Workshop, Achan B, Alber G, Aloisi M, Armstrong-James D, Beale M, Bicanic T, Black J, Bohjanen P, Botes A, Boulware DR, Brown G, Bunjun R, Carr W, **Casadevall A**, Chang C, Chivero E, Corcoran C, Cross A, Dawood H, Day J, De Bernardis F, De Jager V, De Repentigny L, Denning D, Eschke M, Finkelman M, Govender N, Gow N, Graham L, Gryschek R, Hammond-Aryee K, Harrison T, Heard N, Hill M, Hoving JC, Janoff E, Jarvis J, Kayuni S, King K, Kolls J, Kullberg BJ, Laloo DG, Letang E, Levitz S, Limper A, Longley N, Machiridza TR, Mahabeer Y, Martinsons N, Meiring S, Meya D, Miller R, Molloy S, Morris L, Mukaremera L, Musubire AK, Muzoora C, Nair A, Nakiwala Kimbowa J, Netea M, Nielsen K, O'hern J, Okurut S, Parker A, Patterson T, Pennap G, Perfect J, Prinsloo C, Rhein J, Rolfes MA, Samuel C, Schutz C, Scriven J, Sebolai OM, Sojane K, Sriruttan C, Stead D, Steyn A, Thawer NK, Thienemann F, Von Hohenberg M, Vreulink JM, Wessels J, Wood K, Yang YL. (2014) AIDS-related mycoses: the way forward. *Trends Microbiol.* Mar;22(3):107-9. doi: 10.1016/j.tim.2013.12.008. PMID: PMC4129449

611. Stukes S, Cohen HW, **Casadevall A** (2014) Temporal Kinetics and Quantitative Analysis of *Cryptococcus neoformans* Non-Lytic Exocytosis. *Infect. Immun.* 82(5):2059-67.
612. **Casadevall A**, Fang FC. (2014) Causes for the persistence of impact factor mania. *MBio.* 5(2):e00064-14. doi: 10.1128/mBio.00064-14.
613. **Casadevall A**, Dermody TS, Imperiale MJ, Sandri-Goldin RM, Shenk T. (2014) On the need for a national board to assess dual use research of concern (DURC). *J Virol.* 88(12):6535-7.
614. Chaskes S, Cammer M, Nieves E, **Casadevall A** (2014) Pigment Production on L-Tryptophan Medium by *Cryptococcus gattii* and *Cryptococcus neoformans*. *PLOS One* 9(4):e91901.
615. Olaya-Abril A, Prados-Rosales R, McConnell MJ, Martín-Peña R, González-Reyes JA, Jiménez-Munguía I, Gómez-Gascón L, Fernández J, Luque-García JL, García-Lidón C, Estévez H, Pachón J, Obando I, **Casadevall A**, Pirofski LA, Rodríguez-Ortega MJ (2014). Characterization of protective extracellular membrane-derived vesicles produced by *Streptococcus pneumoniae*. *J Proteomics.* 106:46-60.
616. Park Y-D, Shin S, Panepinto J, Ramos J, Qiu J, Frases S, Albuquerque P, Cordero RJB, Himmelreich W, Beenhouwer D, Bennett JE, **Casadevall A**, Williamson PR (2014) A role for LHC1 in higher order structure and complement binding of the *Cryptococcus neoformans* capsule. *PLOS Pathogens* 10(5):e1004037.
617. Brown L, Kessler A, Cabezas-Sanchez P, Luque-Garcia JL, **Casadevall A.** (2014) Extracellular vesicles produced by the Gram-positive bacterium *Bacillus subtilis* are disrupted by the lipopeptide surfactin. *Mol Microbiol.* 93(1):183-98. doi: 10.1111/mmi.12650
618. Wolf J, Espadas-Moreno J, Luque-Garcia JL, **Casadevall A** (2014) Interaction of *Cryptococcus neoformans* extracellular vesicles with the cell wall. *Eukaryotic Cell* 13:1484-93. doi: 10.1128/EC.00111-14.



619. **Casadevall A**, Steen RG, Fang FC (2014) Sources of error in the retracted scientific literature. *FASEB J* 28(9):3847-55.
620. García-Rodas R, Cordero RJ, Trevijano-Contador N, Janbon G, Moyrand F, **Casadevall A**, Zaragoza O. (2014) Capsule Growth in *Cryptococcus neoformans* Is Coordinated with Cell Cycle Progression. *mBio* 5(3):e00945-14. doi: 10.1128/mBio.00945-14.

630. **Casadevall A**, Howard D, Imperiale MJ. (2014) Reply to "Can limited scientific value of potential pandemic pathogen experiments justify the risks?". MBio. Oct 14;5(5):e02053-14. doi: 10.1128/mBio.02053-14. PMCID: PMC4205797

631. **Casadevall A**, Howard D, Imperiale MJ. (2014) Reply to "Valuing knowledge: a reply to the epistemological perspective on the value of gain-of-function experiments". MBio. Oct 14;5(5):e02054-14. doi: 10.1128/mBio.02054-14. PMCID: PMC4205798

632. **Casadevall A**, Howard D, Imperiale MJ (2014) The Apocalypse as a Rhetorical Device in the Influenza Virus Gain-of-Function Debate. MBio. 2014 Oct 14;5(5). pii: e02062-14. PMCID: PMC4205799

633. Pericolini E, Gabrielli E, Alunno A, Bartoloni Bocci E, Perito S, Chow SK, Cenci E, **Casadevall A**, Gerli R, Vecchiarelli A. (2014) Functional improvement of regulatory T cells from rheumatoid arthritis subjects induced by capsular polysaccharide glucuronoxylomannogalactan. PLoS One Oct 22;9(10):e111163. doi: 10.1371/journal.pone.0111163. eCollection 2014. PMCID: PMC4206502

634. Stukes S, **Casadevall A** (2014) Visualizing non-lytic exocytosis of *Cryptococcus neoformans* from macrophages using digital light microscopy. J Vis Exp. 2014 Oct 21;(92). doi: 10.3791/52084. PMCID: PMC4353314

635. Kohler JR, **Casadevall A**, Perfect JR (2014) The spectrum of pathogenic fungi. Cold Spring Harb Perspect Med. 2014 Nov 3. pii: a019273. doi: 10.1101. PMCID: PMC4292074

636. Vargas G, Rocha JD, Oliveira D, Albuquerque PC, Frases S, Santos SS, Nosanchuk JD, Soares Medeiros LC, Miranda KR, Sobreira T, Nakayasu ES, Agiri EA, Almeida IC, **Casadevall A**, Rodrigues M, Freire-de-Lima CG, Nimrichter L (2015) Compositional and immunobiological analyses of extracellular vesicles released by *Candida albicans* Cell Microbiol. Mar;17(3):389-407. doi: 10.1111/cmi.12374. PMID: 25287304

637. **Casadevall A**, Pirofski L (2015) What is a host? Incorporating the microbiota to the 'damage response framework' of microbial pathogenesis. Infect. Immun. Jan;83(1):2-7. doi: 10.1128/IAI.02627-14. PMCID: PMC4288903

638. Chan J, Mehta S, Bharrhan S, Chen Y, Achkar JM, **Casadevall A**, Flynn J. (2014) The role of B cells and humoral immunity in *Mycobacterium tuberculosis* infection. Semin Immunol. 2014 Oct 28;26(6):588-600. doi: 10.1016/j.smim.2014.10.005. PMCID: PMC4314354

639. Wolf JM, **Casadevall A** (2014) Challenges posed by extracellular vesicles from eukaryotic microbes. Curr Opin Microbiol. 2014 Oct 17;22C:73-78. doi: 10.1016/j.mib.2014.09.012. PMCID: PMC4359756

640. **Casadevall A**, Pirofski LA (2014) Microbiology: Ditch the term pathogen. Nature 516(7530):165-6. doi: 10.1038/516165a. PMID: 25503219

641. Imperiale MJ, **Casadevall A** (2014) Vagueness and Costs of the Pause on Gain-of-Function (GOF) Experiments on Pathogens with Pandemic Potential, Including Influenza Virus. MBio pii: e02292-14. doi: 10.1128/mBio.02292-14. PMCID: PMC4278541

642. Duprex WP, **Casadevall A** (2014) Falling down the Rabbit Hole: aTRIP Toward Lexiconic Precision in the "Gain-of-Function" Debate. MBio pii: e02421-14. doi: 10.1128/mBio.02421-14. PMCID: PMC4271557

643. **Casadevall A**, Shenk T. (2014) mBio addresses the pause in gain-of-function (GOF) experiments involving pathogens with pandemic potential (PPP). MBio. Dec 12;5(6). pii: e02434-14. doi: 10.1128/mBio.02434-14. PMID: PMC4271558
644. Dadachova E, **Casadevall A**. (2014) Radiolabeled antibodies for therapy of infectious diseases. Microbiol Spectr. 2014 Nov;2(6):0023. PMID: PMC4294273
645. Fang FC, **Casadevall A** (2015) Competitive Science: Is Competition Ruining Science. Infect. Immun. Jan 20. pii: IAI.02939-14. PMID: PMC4363426
646. Coelho C, Oliveira Souza AC, Derengowski L, de Leon-Rodriguez C, Wang B, Leon-Rivera R, Bocca, AL, Gonçalves T, **Casadevall A** (2015) Macrophage mitochondrial and stress response to ingestion of *Cryptococcus neoformans*. J. Immunol. 194(5):2345-57. PMID: PMC3647765
647. Majlessi L, Prados-Rosales R, **Casadevall A**, Brosch R. (2015) Release of mycobacterial antigens. Immunol Rev. 264(1):25-45. PMID: 25703550
648. Achkar JM, Chan J, **Casadevall A** (2015) B cells and antibodies in the defense against *Mycobacterium tuberculosis* infection. Immunol. Rev. 264(1):167-81. PMID: PMC4629253
649. Imperiale MJ, **Casadevall A** (2015) The importance of virology at a time of great need and great jeopardy. mBio 6(2). pii: e00236-15. doi: 10.1128/mBio.00236-15. PMID: PMC4453524
650. Robert V, Cardinali G, **Casadevall A** (2015) Distribution and impact of yeast thermal tolerance permissive for mammalian infection. BMC Biology Feb 26;13:18. doi: 10.1186/s12915-015-0127-3. PMID: PMC4381509
651. Janda A, Eryilmaz E, Nakouzi A, Pohl MA, Bowen A, **Casadevall A** (2015) Variable region identical IgA and IgE to *Cryptococcus neoformans* capsular polysaccharide manifest specificity differences. J. Biol. Chem 290(19):12090-100. PMID: PMC4424345
652. Chatterjee S, Prados-Rosales R, Itin B, **Casadevall A**, Stark RE (2015) Solid-state NMR Reveals the Carbon-based Molecular Architecture of *Cryptococcus neoformans* Fungal Eumelanins in the Cell Wall. J. Biol. Chem 290(22):13779-90. PMID: PMC4447955
653. Imperiale MJ, **Casadevall A** (2015) A new synthesis for dual use research of concern. PLoS Med. Apr 14;12(4):e1001813. doi: 10.1371/journal.pmed.1001813. PMID: PMC4397073
654. Pirofski L, **Casadevall A** (2015) What is infectiveness? BMC Immunology Mar 26;16:13. doi: 10.1186/s12865-015-0076-1. PMID: PMC4374184
655. **Casadevall A**, Pirofski L (2015) The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases. Plos Pathogens 11(4):e1004717. PMID: PMC4408073
656. Zolla V, Nizamutdinova IT, Scharf B, Clement CC, Maejima D, Akl T, Nagai T, Luciani P, Leroux JC, Halin C, Stukes S, Tiwari S, **Casadevall A**, Jacobs WR Jr, Entenberg D, Zawieja DC, Condeelis J, Fooksman DR, Gashev AA, Santambrogio L (2015). Aging-related anatomical and biochemical changes in lymphatic collectors impair lymph transport, fluid homeostasis, and pathogen clearance. Aging Cell. May 15. doi: 10.1111/ace.12330. PMID: PMC4531072

657. Wolf JM, Espadas J, Luque-Garcia J, Reynolds T, **Casadevall A** (2015) Lipid biosynthetic genes affect *Candida albicans* extracellular vesicle morphology, cargo, and immunostimulatory properties. Eukaryotic Cell May 29. pii: EC.00054-15. PMCID: PMC4519749

658. Martinez LR, **Casadevall A** (2015) Biofilm formation by *Cryptococcus neoformans*. Microbiol Spectr. 2015 Jun;3(3). doi: 10.1128/microbiolspec.MB-0006-2014. PMID: 26185073

659. **Casadevall A** (2015) Achieving gender equity at the American Society for Microbiology General Meeting. mBio doi: 10.1128/mBio.01146-15. PMCID:PMC4526716

This study received media coverage

http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articles/2015_07_29/caredit.a1500189

<https://www.insidehighered.com/news/2015/08/05/microbiologists-show-its-possible-achieve-gender-equity-scholarly-presentations>

<http://mbioblog.asm.org/mbiosphere/2015/08/toward-gender-parity-in-conference-presentation.html>

<https://www.genomeweb.com/scan/asm-reports-near-gender-parity-speakers-meeting>

660. Prados-Rosales R, Toriola S, Nakouzi A, Chatterjee S, Stark R, Gerfen G, Tumpowsky P, Dadachova E, **Casadevall A**. (2015) Structural Characterization of Melanin Pigments from Commercial Preparations of the Edible Mushroom *Auricularia auricula*. J Agric Food Chem 26;63(33):7326-32. doi: 10.1021/acs.jafc.5b02713. PMCID: PMC4862413

661. **Casadevall A**, Dermody TS, Imperiale MJ, Sandri-Goldin RM, Shenk T (2015) Dual-Use Research of Concern (DURC) Review at American Society for Microbiology Journals. MBio. 2015 Aug 11;6(4). pii: e01236-15. doi:10.1128/mBio.01236-15. PMCID: PMC4542189

662. Bowen A, **Casadevall A** (2015) Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research. PNAS 112(36):11335-40. PMCID: PMC4568675

Article feature in 'this issue' in PNAS

<http://www.pnas.org/content/112/36/11139.full>

This study received media coverage

<http://www.washingtonpost.com/news/wonkblog/wp/2015/08/17/scientists-are-trying-to-figure-out-the-best-ways-to-spend-money-on-science/>

<http://www.sciencedaily.com/releases/2015/08/150817160617.htm>

<http://news.yahoo.com/more-money-fewer-cures-us-medical-research-faces-201526110.html>

<http://news.sciencemag.org/scientific-community/2015/08/effort-c-impact-u-s-biomedical-research-study-concludes>

See also correspondence:

663. **Casadevall A**, Shenk T. (2015) The Justification for the Academy Track in mBio. MBio. Aug 18;6(4). pii: e01222-15. doi: 10.1128/mBio.01222-15. PMCID: PMC4542184

664. García-Rodas R, Trevijano-Contador N, Román E, Janbon G, Moyrand F, Pla J, **Casadevall A**, Zaragoza O (2015) Role of Cln1 during melanization of *Cryptococcus neoformans* Frontiers Microbiol. 6:798. doi: 10.3389/fmicb.2015.00798. PMCID: PMC4532930

665. Brown L, Wolf JM, Prados-Rosales R, **Casadevall A** (2015) Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nature Micro Rev 13(10):620-30. PMCID: PMC4860279

666. **Casadevall A**, Fang FC (2015) Field Science: The Nature and Utility of Scientific Fields. *Mbio* e01259-15. doi: 10.1128/mBio.01259-15. PMCID: PMC4600110
667. **Casadevall A**, Fang FC (2015) A Historical Science. *Infect. Immun.* 83(12):4460-4. PMCID: PMC4645372
668. Frank GM, Adalja A, Barbour A, **Casadevall A**, Dormitzer PR, Duchin J, Hayden FG, Hirsch MS, Hynes NA, Lipsitch M, Pavia AT, Relman DA (2015) Infectious Diseases Society of America and Gain-of-Function Experiments With Pathogens Having Pandemic Potential. *J. Infect. Dis.* 213(9):1359-61. doi: 10.1093/infdis/jiv474. PMID: 26416656
669. Fang FC, **Casadevall A**. (2015) Correction for Fang and Casadevall, Competitive Science: Is Competition Ruining Science? *Infect. Immun.* 2015 Nov;83(11):4452. doi: 10.1128/IAI.01031-15. PMCID:PMC4598405
670. Almeida F, Wolf JM, **Casadevall A** (2015) Virulence-Associated Enzymes of *Cryptococcus neoformans*. *Eukaryotic Cell* 14(12):1173-85. PMCID: PMC4664877
671. **Casadevall A**, Fang FC (2015) Impacted science: impact is not importance. *mBio* e01593-15. doi: 10.1128/mBio.01593-15. PMCID:PMC4620476
672. Bowen A, **Casadevall A**. (2015) Reply to Fiscella: the phases of biomedical science should be studied to optimize health outcomes. *Proc Natl Acad Sci U S A*. Nov 24;112(47):E6413. PMCID: PMC4664302
673. Fernandes C, Prados-Rosales R, Silva BM, Nakouzi-Naranjo A, Zuzarte M, Chatterjee S, Stark RE, **Casadevall A**, Gonçalves T. (2015) Activation of Melanin Synthesis in *Alternaria infectoria* by Antifungal Drugs. *Antimicrob Agents Chemother.* Dec 28;60(3):1646-55. PMCID: PMC4775914
674. Nosanchuk JD, Stark RE, **Casadevall A**. (2015) Fungal Melanin: What do We Know About Structure? *Front Microbiol.* 6:1463. doi: 10.3389/fmicb.2015.01463. PMCID: PMC4687393
675. Fang FC, **Casadevall A** (2016) The illusion of self correction. *Chemistry World* <http://www.rsc.org/chemistryworld/2015/12/self-correction-illusion-misconduct-retraction>
676. Janda A, Bowen A, Greenspan NS, **Casadevall A** (2016) Ig Constant Region Effects on Variable Region Structure and Function. *Front Microbiol.* 4;7:22. doi: 10.3389/fmicb.2016.00022. PMCID: PMC4740385
677. Fang FC, Bowen A, **Casadevall A**. (2016) NIH peer review percentile scores are poorly predictive of grant productivity (2016). *Elife pii: e13323*. doi: 10.7554/eLife.13323. PMCID: PMC4769156
The Scientist <http://www.the-scientist.com/?articles.view/articleNo/45379/title/NIH-Grant-Reviews-Don-t-Predict-Success/>
F1000 <http://f1000.com/prime/726150583>
678. Cordero RJ, Liedke SC, de S Araújo GR, Martinez LR, Nimrichter L, Frases S, Peralta JM, **Casadevall A**, Rodrigues ML, Nosanchuk JD, Guimaraes AJ (2016). Enhanced virulence of *Histoplasma capsulatum* through transfer and surface incorporation of glycans from *Cryptococcus neoformans* during co-infection. *Sci Rep.* 6:21765. doi: 10.1038/srep21765. PMCID: PMC4764860

679. DeLeon-Rodriguez CM, **Casadevall A.** (2016) *Cryptococcus neoformans*: Tripping on Acid in the Phagolysosome. *Front Microbiol.* doi: 10.3389/fmicb.2016.00164. PMID: PMC4756110

680. **Casadevall A**, Fang FC. (2016) Revolutionary Science. *mBio.* pii: e00158-16. doi: 10.1128/mBio.00158-16. PMID: PMC4810483

681. Coelho C, **Casadevall A** (2016) Cryptococcal therapies and drug targets: the old, the new and the promising. *Cell Microbiol.* 18(6):792-9. doi: 10.1111/cmi.12590. PMID: 26990050

682. Chen T, Blanc C, Eder AZ, Prados-Rosales R, Souza AC, Kim RS, Glatman-Freedman A, Joe M, Bai Y, Lowary TL, Tanner R, Brennan MJ, Fletcher HA, McShane H, **Casadevall A**, Achkar JM (2016) Association of Human Antibodies to Arabinomannan with enhanced mycobacterial Opsonophagocytosis and intracellular growth reduction. *J. Infect. Dis.* 241(2):300-10 doi: 10.1093/infdis/jiw141. Epub April 7. PMID: PMC4918826

683. Fang FC, **Casadevall A.** (2016) Research funding: the case for a modified lottery. *mBio* e00422-16. doi: 10.1128/mBio.00422-16. PMID: PMC4959526

684. Collier RJ, **Casadevall A.** (2016) The Holobiont/Hologenome Concept Series. *MBio.* Apr 14;7(2). pii: e00605-16. doi: 10.1128/mBio.00605-16. PMID: PMC4850271

685. Fang FC, **Casadevall A** (2016) Grant funding – playing the odds. *Science.* 352(6282):158. doi: 10.1126/Science 352.6282.158-a. PMID: 27124444

686. **Casadevall A** (2016) Thermal restriction as an antimicrobial function of fever. *PLoS Pathog.* 2016 May 5;12(5):e1005577. doi: 10.1371/journal.ppat.1005577. PMID: PMC4858228

687. Fang FC, **Casadevall A.** (2016) Erratum for Fang and Casadevall, Research Funding: the Case for a Modified Lottery *MBio.* May 17;7(3). pii: e00694-16. doi: 10.1128/mBio.00694-16. PMID: PMC4895113

688. Prados-Rosales R, Carreño LJ, Weinrick B, Batista-Gonzalez A, Glatman-Freedman A, Xu J, Chan J, Jacobs WR Jr, Porcelli SA, **Casadevall A** (2016) The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against *Mycobacterium tuberculosis*. *J. Infect. Dis.* 214(3):426-37. PMID: PMC4936643

689. Bik EM, **Casadevall A**, Fang FC (2016). The Prevalence of Inappropriate Image Duplication in Biomedical Research Publications. *mBio* pii: e00809-16. doi: 10.1128/mBio.00809-16. (AC and FCF contributed equally). PMID: PMC4941872

This article received wide coverage:

Retraction watch

<http://retractionwatch.com/2016/04/19/one-in-25-papers-contains-inappropriately-duplicated-images-screen-finds/>

The Scholarly Kitchen

<https://scholarlykitchen.sspnet.org/2016/05/02/image-manipulation-cleaning-up-the-scholarly-record/>

Nature <http://www.nature.com/news/problematic-images-found-in-4-of-biomedical-papers-1.19802>

Stat News <https://www.statnews.com/2016/04/29/duplicated-images-research-papers/>

690. Imperiale MJ, **Casadevall A** (2016) Zika virus focuses the gain-of-function debate (2016) *mSphere* DOI: 10.1128/mSphere.00069-16. PMID: PMC4894681

691. Matos Baltazar LM, Nakayasu ES, Sobreira TJP, Choi H, **Casadevall A**, Nimrichter L, Nosanchuk JD (2016) Antibody Binding Alters the Characteristics and Contents of Extracellular Vesicles Released by *Histoplasma capsulatum*. *mSphere* DOI: 10.1128/mSphere.00085-15. PMID: PMC4894687

692. Cordero RJB, De Leon-Rodriguez C, Alvarado-Torres J, Rodz A, **Casadevall A** (2016) Life Science's Average Publishable Unit (APU) has increased over the past two decades. *PLOS One* 11(6):e0156983. doi: 10.1371/journal.pone.0156983. PMID: PMC4911092

693. Stukes S, Coelho C, Rivera J, Jedlicka AE, Hajjar KA, **Casadevall A** (2016) The Membrane Phospholipid Binding Protein Annexin A2 Promotes Phagocytosis and Non-lytic Exocytosis of *Cryptococcus neoformans* and Impacts Survival in Fungal Infection. *J Immunol.* Jul 1. pii: 1501855. [Epub ahead of print]. PMID: PMC5160961

694. **Casadevall A**, Bertuzzi S, Buchmeier MJ, Davis RJ, Drake H, Fang FC, Gilbert J, Goldman BM, Imperiale MJ, Matsumura P, McAdam AJ, Pasetti MF, Sandri-Goldin RM, Silhavy T, Rice L, Young JA, Shenk T. (2016) ASM Journals Eliminate Impact Factor Information from Journal Websites. *MBio.* Jul 11;7(4). pii: e01150-16. doi: 10.1128/mBio.01150-16. PMID: PMC5069964

This article was published simultaneously by the following ASM journals: Antimicrobial Agents and Chemotherapy, Applied and Environmental Microbiology, Clinical Microbiology Reviews, Infection and Immunity, Journal of Clinical Microbiology, mBio, mSphere, and mSystems.

Media coverage

<http://www.nature.com/news/beat-it-impact-factor-publishing-elite-turns-against-controversial-metric-1.20224>

<http://europeanscienceediting.eu/articles/good-practice-asm-journals-eliminate-impact-factor-information-from-their-journals-websites/>

695. **Casadevall A**, Ellis LM, Davies EW, McFall-Ngai M, Fang FC. (2016) A Framework for Improving the Quality of Research in the Biological Sciences. *MBio.* Aug 30;7(4). pii: e01256-16. doi: 10.1128/mBio.01256-16.

Related correspondence:

Casadevall A, Ellis LM, Davies EW, McFall-Ngai M, Fang FC. (2016) Reply to "Improving Microbiology Research: the Problems Are Less Statistical and More Biological". *MBio.* 2016 Oct 18;7(5). pii: e01680-16. doi: 10.1128/mBio.01680-16. PMID: PMC5082904

696. **Casadevall A**, Fang FC. (2016) Moonshot Science-Risks and Benefits. *MBio.* Aug 30;7(4). pii: e01381-16. doi: 10.1128/mBio.01381-16. PMID: PMC4999559

697. **Casadevall A**, Fang FC. (2016) Reply to "Funding by Lottery: Political Problems and Research Opportunities". *MBio.* Aug 30;7(4). pii: e01401-16. doi: 10.1128/mBio.01401-16. PMID: PMC27578762

698. McClelland EE, Ramagopal UA, Rivera J, Cox J, Nakouzi A, Prabu MM, Almo SC, **Casadevall A**. (2016) A Small Protein Associated with Fungal Energy Metabolism Affects the Virulence of *Cryptococcus neoformans* in Mammals. *PLoS Pathog.* Sep 1;12(9):e1005849. doi: 10.1371/journal.ppat.1005849. PMID: PMC5008624

699. Bowen A, **Casadevall A**. (2016) Revisiting the Immunoglobulin Intramolecular Signaling Hypothesis. *Trends Immunol.* Sep 14. pii: S1471-4906(16)30118-1. doi: 10.1016/j.it.2016.08.014. PMID: PMC5287420

700. **Casadevall A.** (2016) To Be or Not Be a (Functional) Antibody Against TB. *Cell*. Oct 6;167(2):306-307. doi: 10.1016/j.cell.2016.09.041. PMID: 27716502

701. Tsukrov D, McFarren A, Morgenstern A, Bruchertseifer F, Dolce E, Gorny MK, Zolla-Pazner S, Berman JW, Schoenbaum E, Zingman BS, **Casadevall A**, Dadachova E. (2016) Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals. *Front Med (Lausanne)*. Sep 26;3:41. PMCID: PMC5035742

702. da Silva TA, Roque-Barreira MC, **Casadevall A**, Almeida F. (2016) Extracellular vesicles from *Paracoccidioides brasiliensis* induced M1 polarization in vitro. *Sci Rep*. Oct 24;6:35867. doi: 10.1038/srep35867. PMCID: PMC5075875

703. Saks MJ, Albright T, Bohan TL, Bierer BE, Bowers CM, Bush MA, Bush PJ, **Casadevall A**, Cole SA, Denton MD, Diamond SS, Dioso-Villa R, Epstein J, Faigman D, Faigman L, Fienberg SE, Garrett BL, Giannelli PC, Greely HT, Imwinkelried E, Jamieson A, Kafadar K, Kassirer JP, Koehler JJ, Korn D, Mnookin J, Morrison AB, Murph E, Peerwani N, Peterson JL, Risinger DM, Sensabaugh GF, Spiegelman C, Stern H, Thompson WC, Wayman JL, Zabell S, Zumwalt RE (2016) Forensic bite mark identification: weak foundations, exaggerated claims. *Journal of Law and the Biosciences*, 1–38. doi:10.1093/jlb/lsw045

704. **Casadevall A**, Fang FC. Rigorous Science: a how to guide. *MBio*. 2016 Nov 8;7(6). pii: e01902-16. doi: 10.1128/mBio.01902-16. PMCID: PMC5111411

705. Bowen A, Wear MP, Cordero R, Oscarson S, **Casadevall A** (2016) A monoclonal antibody to *Cryptococcus neoformans* glucuronoxylomannan manifests hydrolytic activity for both peptides and polysaccharides. *J Biol Chem*. Nov 21. pii: jbc.M116.767582. PMCID: PMC5241721

706. Grossman NT, **Casadevall A.** (2016) Physiological Differences in *C. neoformans* in vitro versus in vivo and Their Effects on Antifungal Susceptibility. *Antimicrob Agents Chemother*. Dec 28. pii: AAC.02108-16. doi: 10.1128/AAC.02108-16. PMCID: PMC5328578

707. **Casadevall A** (2016) Acknowledgment of Reviewers. *MBio* Dec 30;8(1). pii: e02303-16. doi: 10.1128/mBio.02303-16. PMID: 28039306

708. Saks MJ, Albright T, Bohan TL, Bierer BE, Bowers CM, Bush MA, Bush PJ, **Casadevall A**, Cole SA, Denton MB, Diamond SS, Dioso-Villa R, Epstein J, Faigman D, Faigman L, Fienberg SE, Garrett BL, Giannelli PC, Greely HT, Imwinkelried E, Jamieson A, Kafadar K, Kassirer JP, Koehler J, Korn D, Mnookin J, Morrison AB, Murphy E, Peerwani N, Peterson JL, Risinger DM, Sensabaugh GF, Spiegelman C, Stern H, Thompson WC, Wayman JL, Zabell S, Zumwalt RE (2016) Forensic bite mark identification: weak foundations, exaggerated claims. *J Law Biosci*. 6 Nov 23;3(3):538-575. doi: 10.1093/jlb/lsw045. PMID: 28852538

709. Prados-Rosales R, Carreño L, Cheng T, Blanc C, Weinrick B, Malek A, Lowary TL, Baena A, Joe M, Bai Y, Kalscheuer R, Batista-Gonzalez A, Saavedra NA, Sampedro L, Tomás J, Anguita J, Hung SC, Tripathi A, Xu J, Glatman-Freedman A, Jacobs WR Jr, Chan J, Porcelli SA, Achkar JM, **Casadevall A.** (2017) Enhanced control of *Mycobacterium tuberculosis* extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine. *PLoS Pathog*. Mar 9;13(3):e1006250. doi: 10.1371/journal.ppat.1006250. PMCID: PMC5360349

710. **Casadevall A**, Cordero RJ, Bryan R, Nosanchuk J, Dadachova E. (2017) Melanin, Radiation, and Energy Transduction in Fungi. *Microbiol Spectr*. Mar;5(2). doi: 10.1128/microbiolspec.FUNK-0037-2016. PMID: 28256187

711. **Casadevall A.** (2017) The Pathogenic Potential of a Microbe. *mSphere*. Feb 22;2(1). pii: e00015-17. doi: 10.1128/mSphere.00015-17. PMCID: PMC5322344

712. Chandra D, Selvanesan BC, Yuan Z, Libutti SK, Koba W, Beck A, Zhu K, **Casadevall A**, Dadachova E, Gravekamp C. (2017) 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. *Oncotarget*. Feb 6. doi: 10.18632/oncotarget.15117. [Epub ahead of print] PMCID: PMC5400540

713. **Casadevall A**, Shenk T. (2017) The mBio American Academy of Microbiology Submission Track in 2017. *MBio*. Feb 7;8(1). pii: e00050-17. doi: 10.1128/mBio.00050-17. PMCID: PMC5296597

714. Fang FC, **Casadevall A.** (2017) Reply to "On the Impact Factor and the ASM Editorial Policy". *Infect Immun*. 2017 Jan 26;85(2). pii: e00989-16. doi: 10.1128/IAI.00989-16. PMCID: PMC5278168

715. Kwon-Chung KJ, Bennett JE, Wickes BL, Meyer W, Cuomo CA, Wollenburg KR, Bicanic TA, Castañeda E, Chang YC, Chen J, Cogliati M, Dromer F, Ellis D, Filler SG, Fisher MC, Harrison TS, Holland SM, Kohno S, Kronstad JW, Lazera M, Levitz SM, Lionakis MS, May RC, Ngamskulrongsroj P, Pappas PG, Perfect JR, Rickerts V, Sorrell TC, Walsh TJ, Williamson PR, Xu J, Zelazny AM, **Casadevall A.** (2017) The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. *mSphere*. Jan 11;2(1). pii: e00357-16. doi: 10.1128/mSphere.00357-16. PMCID: PMC5227069

716. **Casadevall A.** (2017) Antibodies to *Mycobacterium tuberculosis*. *N Engl J Med*. Jan 19;376(3):283-285. doi: 10.1056/NEJMcibr1613268. PMID: 28099836

717. Grossman NT, **Casadevall A.** (2017) Physiological Differences in *Cryptococcus neoformans* Strains *In Vitro* versus *In Vivo* and Their Effects on Antifungal Susceptibility. *Antimicrob Agents Chemother*. Feb 23;61(3). pii: e02108-16. doi: 10.1128/AAC.02108-16. Review. PMCID: PMC5328578

718. Bowen A, Wear MP, Cordero RJ, Oscarson S, **Casadevall A.** (2017) A Monoclonal Antibody to *Cryptococcus neoformans* Glucuronoxylomannan Manifests Hydrolytic Activity for Both Peptides and Polysaccharides. *J Biol Chem*. Jan 13;292(2):417-434. doi: 10.1074/jbc.M116.767582. PMCID: PMC5241721

719. Grossman NT, **Casadevall A.** (2017) Physiological Differences in *Cryptococcus neoformans* Strains *In Vitro* versus *In Vivo* and Their Effects on Antifungal Susceptibility. *Antimicrob Agents Chemother*. Feb 23;61(3). pii: e02108-16. doi: 10.1128/AAC.02108-16. PMCID: PMC5328578

720. Kwon-Chung KJ, Bennett JE, Wickes BL, Meyer W, Cuomo CA, Wollenburg KR, Bicanic TA, Castañeda E, Chang YC, Chen J, Cogliati M, Dromer F, Ellis D, Filler SG, Fisher MC, Harrison TS, Holland SM, Kohno S, Kronstad JW, Lazera M, Levitz SM, Lionakis MS, May RC, Ngamskulrongsroj P, Pappas PG, Perfect JR, Rickerts V, Sorrell TC, Walsh TJ, Williamson PR, Xu J, Zelazny AM, **Casadevall A.** (2017) The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. *mSphere*. Jan 11;2(1). pii: e00357-16. doi: 10.1128/mSphere.00357-16. eCollection Jan-Feb. PMCID: PMC5227069

721. Fang FC, **Casadevall A.** (2017) Reply to "On the Impact Factor and the ASM Editorial Policy". *Infect Immun*. Jan 26;85(2). pii: e00989-16. doi: 10.1128/IAI.00989-16. Print Feb. PMCID: PMC5278168

722. **Casadevall A**, Shenk T. (2017) The mBio American Academy of Microbiology Submission Track in 2017. MBio. Feb 7;8(1). pii: e00050-17. doi: 10.1128/mBio.00050-17. PMCID: PMC5296597
723. Chandra D, Selvanesan BC, Yuan Z, Libutti SK, Koba W, Beck A, Zhu K, **Casadevall A**, Dadachova E, Gravekamp C. (2017) 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. Oncotarget. Mar 28;8(13):20729-20740. doi: 10.18632/oncotarget.15117. PMCID: PMC5400540
724. **Casadevall A**. (2017) The Pathogenic Potential of a Microbe. mSphere. Feb 22;2(1). pii: e00015-17. doi: 10.1128/mSphere.00015-17. eCollection Jan-Feb. PMCID: PMC5322344
725. **Casadevall A**, Cordero RJ, Bryan R, Nosanchuk J, Dadachova E. (2017) Melanin, Radiation, and Energy Transduction in Fungi. Microbiol Spectr. Mar;5(2). doi: 10.1128/microbiolspec.FUNK-0037-2016. PMID: 28256187
726. Prados-Rosales R, Carreño L, Cheng T, Blanc C, Weinrick B, Malek A, Lowary TL, Baena A, Joe M, Bai Y, Kalscheuer R, Batista-Gonzalez A, Saavedra NA, Sampedro L, Tomás J, Anguita J, Hung SC, Tripathi A, Xu J, Glatman-Freedman A, Jacobs WR Jr, Chan J, Porcelli SA, Achkar JM, **Casadevall A**. (2017) Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine. PLoS Pathog. Mar 9;13(3):e1006250. doi: 10.1371/journal.ppat.1006250. eCollection Mar. PMCID: PMC5360349
727. **Casadevall A**. (2017) Crisis in Infectious Diseases: 2 Decades Later. Clin Infect Dis. Apr 1;64(7):823-828. doi: 10.1093/cid/cix067. PMID: 28362950
728. **Casadevall A**. (2017) Acknowledgment of Invited Editors. MBio. Apr 4;8(2). pii: e00455-17. doi: 10.1128/mBio.00455-17. PMCID: PMC5380845
729. **Casadevall A**, Freij JB, Hann-Soden C, Taylor J. (2017) Continental Drift and Speciation of the Cryptococcus neoformans and Cryptococcus gattii Species Complexes. mSphere. Apr 19;2(2). pii: e00103-17. doi: 10.1128/mSphere.00103-17. eCollection Mar-Apr. PMCID: PMC5397565
730. Kohler JR, Hube B, Puccia R, **Casadevall A**, Perfect JR (2017) Fungi that infect humans. Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.FUNK-0014-2016. PMID: 28597822
731. **Casadevall A**, Freij JB, Hann-Soden C, Taylor J. (2017) Reply to Engelthaler and Meyer, "Furthering the Continental Drift Speciation Hypothesis in the Pathogenic Cryptococcus Species Complexes". mSphere Jun 14;2(3). pii: e00242-17. doi: 10.1128/mSphere.00242-17. PMID: 28635996 PMCID: PMC5471351
732. Bowen A, Wear M, **Casadevall A** (2017) Antibody-mediated Catalysis in Infection and Immunity. Infect Immun. Jul 3. pii: IAI.00202-17. doi: 10.1128/IAI.00202-17. PMCID: PMC5563562
733. **Casadevall A** (2017) Don't forget the fungi when considering global catastrophic biorisks. Health Secur Jul 25. doi: 10.1089/hs.2017.0048. PMCID: PMC5576259
734. Cordero RJB, Vij R, **Casadevall A** (2017) Microbial melanins for radioprotection and bioremediation. Microb Biotechnol. Aug 14. doi: 10.1111/1751-7915.12807. PMCID: PMC5609342
735. Coelho C, Oliveira Souza AC, da Silveira Derengowski L, de Leon-Rodriguez C, Wang B, Leon-Rivera R, Bocca AL, Gonçalves T, **Casadevall A** (2017) Correction: Macrophage Mitochondrial and Stress

Response to Ingestion of *Cryptococcus neoformans*. *J Immunol.* Sep 1;199(5):1944. doi: 10.4049/jimmunol.1700948. PMID: 28827389

736. Saks MJ, Albright T, Bohan TL, Bierer BE, Bowers CM, Bush MA, Bush PJ, **Casadevall A**, Cole SA, Denton MB, Diamond SS, Dioso-Villa R, Epstein J, Faigman D, Faigman L, Fienberg SE, Garrett BL, Giannelli PC, Greely HT, Imwinkelried E, Jamieson A, Kafadar K, Kassirer JP, Koehler J', Korn D, Mnookin J, Morrison AB, Murphy E, Peerwani N, Peterson JL, Risinger DM, Sensabaugh GF, Spiegelman C, Stern H, Thompson WC, Wayman JL, Zabell S, Zumwalt RE. (2017) Forensic bite mark identification: weak foundations, exaggerated claims. *J Law Biosci.* Nov 23;3(3):538-575. doi: 10.1093/jlb/lsw045. PMID: PMC5570687

737. Nolan SJ, Fu MS, Coppens I, **Casadevall A** (2017) Lipids affect the *Cryptococcus neoformans*-macrophage interaction and promote non-lytic exocytosis. *Infect Immun.* Sep 25. pii: IAI.00564-17. doi: 10.1128/IAI.00564-17. PMID: PMC5615203

738. Schloss PD, Johnston M, **Casadevall A** (2017) Support Science by Publishing in Scientific Society Journals. *MBio.* Sep 26;8(5). pii: e01633-17. doi: 10.1128/mBio.01633-17.

739. Luo R, Zimin A, Workman R, Fan Y, Pertea G, Grossman N, Wear MP, Jia B, Miller H, **Casadevall A**, Timp W, Zhang SX, Salzberg SL. (2017) First Draft Genome Sequence of the Pathogenic Fungus *Lomentospora prolificans* (formerly *Scedosporium prolificans*). *G3 (Bethesda).* Sep 29. pii: g3.300107. doi: 10.1534/g3.117.300107. [Epub ahead of print] PMID: PMC5677167

740. Camacho E, Chrissian C, Cordero RJB, Liporagi-Lopes L, Stark RE, **Casadevall A** (2017) N-acetylglucosamine affects *Cryptococcus neoformans* cell-wall composition and melanin architecture. *Microbiology* Oct 18. doi: 10.1099/mic.0.000552. [Epub ahead of print] PMID: PMC5775898

741. Sah S, **Casadevall A**, Bell S, Gates SJ, Albright TD, Denton MB (2017) Forensic science must be scientific: A body created to set national standards is now in danger. *Scientific American* Oct. 317:12.

742. **Casadevall A**, Pirofski LA (2017) What is a host II: The attributes of individual susceptibility. *Infect Immun.* 2017 Oct 30. pii: IAI.00636-17. doi: 10.1128/IAI.00636-17. [Epub ahead of print] PMID: PMC5778373

743. Fu MS, **Casadevall A** (2017) Divalent metal cations potentiate the predatory capacity of amoeba for *Cryptococcus neoformans*. *Appl Environ Microbiol.* Nov 17. pii: AEM.01717-17. doi: 10.1128/AEM.01717-17. PMID: PMC5772251

744. Schloss PD, Johnston M, **Casadevall A** (2017) Erratum for Schloss et al., "Support Science by Publishing in Scientific Society Journals". *MBio.* Nov 21;8(6). pii: e01926-17. doi: 10.1128/mBio.01926-17. PMID: PMC5698558

745. Almeida F, Wolf JM, da Silva TA, DeLeon-Rodriguez CM, Rezende CP, Pessoni AM, Fernandes FF, Silva-Rocha R, Martinez R, Rodrigues ML, Roque-Barreira MC, **Casadevall A** (2017) Galectin-3 impacts *Cryptococcus neoformans* infection through direct antifungal effects. *Nat Commun.* Dec 6;8(1):1968. doi: 10.1038/s41467-017-02126-7. PMID: PMC5719036

746. Pirofski LA, **Casadevall A** (2017) Immune-Mediated Damage Completes the Parabola: *Cryptococcus neoformans* Pathogenesis Can Reflect the Outcome of a Weak or Strong Immune Response. *MBio.* Dec 12;8(6). pii: e02063-17. doi: 10.1128/mBio.02063-17. PMID: PMC5727418

747. Bosch G, **Casadevall A** (2017) Graduate Biomedical Science Education Needs a New Philosophy. MBio. Dec 19;8(6). pii: e01539-17. doi: 10.1128/mBio.01539-17. PMCID: PMC5736909

748. **Casadevall A**, Fang FC (2017) Reply to Argüelles and Argüelles-Prieto, "Are the Editors Responsible for Our Obsession with the Impact Factor?" MBio. Dec 19;8(6). pii: e02079-17. doi: 10.1128/mBio.02079-17. PMCID: PMC5736916

749. Rizzo J, Colombo AC, Zamith-Miranda D, Silva VKA, Allegood JC, **Casadevall A**, Del Poeta M, Nosanchuk JD, Kronstad JW, Rodrigues ML. (2017) The putative flippase Apt1 is required for intracellular membrane architecture and biosynthesis of polysaccharide and lipids in *Cryptococcus neoformans*. Biochim Biophys Acta. Dec 29;1865(3):532-541. doi: 10.1016/j.bbamcr.2017.12.007. PMCID: PMC6052768

750. Dragotakes Q, **Casadevall A** (2017) Automated Measurement of Cryptococcal Species Polysaccharide Capsule and Cell Body. J Vis Exp. 2018 Jan 11;(131). doi: 10.3791/56957. PMCID: PMC5908552

751. **Casadevall A**, Coelho C, Cordero RJB, Dragotakes Q, Jung E, Vij R, Wear MP (2018) The Capsule of *Cryptococcus neoformans*. Virulence Feb 13:0. doi: 10.1080/21505594.2018.1431087. PMID: 29436899

752. Walker L, Sood P, Lenardon MD, Milne G, Olson J, Jensen G, Wolf J, **Casadevall A**, Adler-Moore J, Gow NAR (2018) The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles. MBio. Feb 6;9(1). pii: e02383-17. doi: 10.1128/mBio.02383-17. PMCID:PMC5801470

753. Fanelli D, Costas R, Fang FC, **Casadevall A**, Bik EM (2018) Testing Hypotheses on Risk Factors for Scientific Misconduct via Matched-Control Analysis of Papers Containing Problematic Image Duplications. Sci Eng Ethics. Feb 19. doi: 10.1007/s11948-018-0023-7. PMID: 29460082

754. **Casadevall A**, Fang FC (2018) Elegant Science. MBio. Feb 20;9(1). pii: e00043-18. doi: 10.1128/mBio.00043-18. PMCID: PMC5821082

755. **Casadevall A**. (2018) Melanin triggers antifungal defences. Nature. Mar 15;555(7696):319-320. doi: 10.1038/d41586-018-02370-x. PMID: 29542711

756. Gonçalves DS, Ferreira MDS, Liedke SC, Gomes KX, de Oliveira GA, Leão PEL, Cesar GV, Seabra SH, Cortines JR, **Casadevall A**, Nimrichter L, Domont GB, Junqueira MR, Peralta JM, Guimaraes AJ (2018) Extracellular vesicles and vesicle-free secretome of the protozoa *Acanthamoeba castellanii* under homeostasis and nutritional stress and their damaging potential to host cells. Virulence Mar 21:0. doi: 10.1080/21505594.2018.1451184. PMID: 29560793

757. Jung EH, Meyers DJ, Bosch J, **Casadevall A** (2018) Novel Antifungal Compounds Discovered in Medicines for Malaria Venture's Malaria Box. Sphere Mar 14;3(2). pii: e00537-17. doi: 10.1128/mSphere.00537-17. eCollection 2018 Mar-Apr. PMCID: PMC5853493

758. Imperiale MJ, **Casadevall A** (2018) A New Approach to Evaluating the Risk-Benefit Equation for Dual-Use and Gain-of-Function Research of Concern. Front Bioeng Biotechnol. Mar 8;6:21. doi: 10.3389/fbioe.2018.00021. eCollection 2018. PMCID: PMC5853790

759. **Casadevall A**, Gow N (2018) Using Preprints for Journal Clubs. MBio. Apr 3;9(2). pii: e00516-18. doi: 10.1128/mBio.00516-18. PMCID: PMC5885029

760. Nosanchuk JD, Jeyakumar A, Ray A, Revskaya E, Jiang Z, Bryan RA, Allen KJH, Jiao R, Malo ME, Gómez BL, Morgenstern A, Bruchertseifer F, Rickles D, Thornton GB, Bowen A, **Casadevall A**, Dadachova E (2018) Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. *Sci Rep.* Apr 3;8(1):5466. doi: 10.1038/s41598-018-23889-z. PMCID: PMC5882926
761. Bell S, Sah S, Albright TD, Gates SJ Jr., Denton MB, **Casadevall A**. (2018) A call for more science in forensic science. *Proc Natl Acad Sci U S A.* Apr 12. pii: 201712161. doi: 10.1073/pnas.1712161115. PMCID:PMC5939058
762. **Casadevall A**. (2018) Acknowledgment of Invited Editors. *MBio.* Apr 24;9(2). pii: e00731-18. doi: 10.1128/mBio.00731-18. PMCID:PMC5915734
763. **Casadevall A**, Pirofski LA (2018) A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis. *Clin Infect Dis.* 2018 Apr 25. doi: 10.1093/cid/ciy188. PMID: 29697770
764. **Casadevall A** (2018) Antibody-based vaccine strategies against intracellular pathogens. *Curr Opin Immunol.* Apr 25;53:74-80. doi: 10.1016/j.coi.2018.04.011. PMID: 29704764
765. Freij JB, Fu MS, De Leon Rodriguez CM, Dziedzic A, Jedlicka AE, Dragotakes Q, Rossi DCP, Jung EH, Coelho C, **Casadevall A** (2018) Conservation of Intracellular Pathogenic Strategy among Distantly Related Cryptococcal Species. *Infect Immun.* Jun 21;86(7). pii: e00946-17. doi: 10.1128/IAI.00946-17. PMCID:PMC60143651
766. **Casadevall A**, Coelho C, Alanio A (2018) Mechanisms of *Cryptococcus neoformans*-Mediated Host Damage. *Front Immunol.* Apr 30;9:855. doi: 10.3389/fimmu.2018.00855. PMCID: PMC5936990
767. Hommel B, Mukaremera L, Cordero RJB, Coelho C, Desjardins CA, Sturny-Leclère A, Janbon G, Perfect JR, Fraser JA, **Casadevall A**, Cuomo CA, Dromer F, Nielsen K, Alanio A (2018) Titan cells formation in *Cryptococcus neoformans* is finely tuned by environmental conditions and modulated by positive and negative genetic regulators. *PLoS Pathog.* May 18;14(5):e1006982. doi: 10.1371/journal.ppat.1006982. PMCID: PMC5959062
768. Martinez LR, Boucaud DW, **Casadevall A**, August A (2018) Factors Contributing to the Success of NIH-Designated Underrepresented Minorities in Academic and Nonacademic Research Positions. *CBE Life Sci Educ.* Jun;17(2):ar32. doi: 10.1187/cbe.16-09-0287. PMCID:PMC5998319
769. De Leon-Rodriguez CM, Rossi DCP, Fu MS, Dragotakes Q, Coelho C, Guerrero Ros I, Caballero B, Nolan SJ, **Casadevall A** (2018) The Outcome of the *Cryptococcus neoformans*-Macrophage Interaction Depends on Phagolysosomal Membrane Integrity. *J Immunol.* Jun 1. pii: ji1700958. doi: 10.4049/jimmunol.1700958. PMID: 29858266
770. Fu MS, Coelho C, De Leon-Rodriguez CM, Rossi DCP, Camacho E, Jung EH, Kulkarni M, **Casadevall A** (2018) *Cryptococcus neoformans* urease affects the outcome of intracellular pathogenesis by modulating phagolysosomal pH. *PLoS Pathog.* Jun 15;14(6):e1007144. doi: 10.1371/journal.ppat.1007144. PMCID:PMC6021110
771. Perez-Dulzaides R, Camacho E, Cordero RJB, **Casadevall A** (2018) Cell-wall dyes interfere with *Cryptococcus neoformans* melanin deposition. *Microbiology.* Jun 25. doi: 10.1099/mic.0.000682. PMID: 29939127

772. Goldman DL, Nieves E, Nakouzi A, Rivera J, Phyu EE, Win TH, Achkar JM, **Casadevall A** (2018) Serum-Mediated Cleavage of *Bacillus anthracis* Protective Antigen Is a Two-Step Process That Involves a Serum Carboxypeptidase. *mSphere* Jun 27;3(3). pii: e00091-18. doi: 10.1128/mSphere.00091-18. PMID: PMC6021598
773. Bik EM, Fang FC, Kullas AL, Davis R, **Casadevall A** (2018) Analysis and Correction of Inappropriate Image Duplication: The *Molecular and Cellular Biology* Experience. *Mol Cell Biol.* Jul 23. pii: MCB.00309-18. doi: 10.1128/MCB.00309-18. PMID: 30037982
774. Camacho E, **Casadevall A** (2018) Cryptococcal Traits Mediating Adherence to Biotic and Abiotic Surfaces. *J Fungi (Basel).* Jul 29;4(3). pii: E88. doi: 10.3390/jof4030088. PMID: 30060601
775. Cordero RJB, Robert V, Cardinali G, Arinze ES, Thon SM, **Casadevall A** (2018) Impact of Yeast Pigmentation on Heat Capture and Latitudinal Distribution. *Curr Biol.* Aug 20;28(16):2657-2664.e3. doi: 10.1016/j.cub.2018.06.034. Epub 2018 Aug 2. PMID: 30078567
776. Rodrigues ML, **Casadevall A** (2018) A two-way road: novel roles for fungal extracellular vesicles. *Mol Microbiol.* 2018 Aug 5. doi: 10.1111/mmi.14095. [Epub ahead of print]. PMID: 30079549
777. Pirofski LA, **Casadevall A** (2018) The Damage-Response Framework as a Tool for the Physician-Scientist to Understand the Pathogenesis of Infectious Diseases. *J Infect Dis.* Aug 14;218(suppl_1):S7-S11. doi: 10.1093/infdis/jiy083. PMID: PMC6093430
778. Vij R, Cordero RJB, **Casadevall A** (2018) The Buoyancy of *Cryptococcus neoformans* Is Affected by Capsule Size. *mSphere.* Nov 7;3(6). pii: e00534-18. doi: 10.1128/mSphere.00534-18. PMID: PMC6222054
779. Chatterjee S, Prados-Rosales R, Tan S, Phan VC, Chrissian C, Itin B, Wang H, Khajo A, Magliozzo RS, **Casadevall A**, Stark RE (2018) The melanization road more traveled by: precursor substrate effects on melanin synthesis in cell-free and fungal cell systems. *J Biol Chem.* Nov 1. pii: jbc.RA118.005791. doi: 10.1074/jbc.RA118.005791. [Epub ahead of print] PMID: 30385508
780. De Leon-Rodriguez CM, Fu MS, Çorbali MO, Cordero RJB, **Casadevall A** (2018) The Capsule of *Cryptococcus neoformans* Modulates Phagosomal pH through Its Acid-Base Properties. *mSphere.* Oct 24;3(5). pii: e00437-18. doi: 10.1128/mSphere.00437-18. PMID: PMC6200979
781. May RC, **Casadevall A** (2018) In Fungal Intracellular Pathogenesis, Form Determines Fate. *MBio.* Oct 23;9(5). pii: e02092-18. doi: 10.1128/mBio.02092-18. PMID: PMC6199499
782. **Casadevall A**, Fang FC (2018) Making the scientific literature fail-safe. *J Clin Invest.* 2018 Oct 1;128(10): 4243-4244. doi: 10.1172/JCI123884. Epub 2018 Sep 4. PMID: PMC6159988
783. Paes HC, Frazão SO, Rosa CP, Albuquerque P, **Casadevall A**, Felipe MSS, Nicola AM (2018) Opsonin-free, real-time imaging of *Cryptococcus neoformans* capsule during budding. *Virulence* 9(1):1483-1488. doi: 10.1080/21505594.2018.1515610. PMID: PMC6177245
784. Imperiale MJ, Howard D, **Casadevall A** (2018) The Silver Lining in Gain-of-Function Experiments with Pathogens of Pandemic Potential. *Methods Mol Biol.* 1836:575-587. doi: 10.1007/978-1-4939-8678-1_28. PMID: 30151593

785. Paes HC, Frazão SO, Rosa CP, Albuquerque P, **Casadevall A**, Felipe MSS, Nicola AM (2018) Opsonin-free, real-time imaging of *Cryptococcus neoformans* capsule during budding. *Virulence*. 9(1):1483-1488. doi: 10.1080/21505594.2018.1515610. PMCID: PMC6177245

786. **Casadevall A**, Fang FC (2018) Making the scientific literature fail-safe. *J Clin Invest*. Oct 1;128(10):4243-4244. doi: 10.1172/JCI123884. Epub 2018 Sep 4. PMCID: PMC6159988

787. May RC, **Casadevall A** (2018) In Fungal Intracellular Pathogenesis, Form Determines Fate. *MBio*. Oct 23;9(5). pii: e02092-18. doi: 10.1128/mBio.02092-18. PMCID: PMC6199499

788. De Leon-Rodriguez CM, Fu MS, Çorbali MO, Cordero RJB, **Casadevall A** (2018) The Capsule of *Cryptococcus neoformans* Modulates Phagosomal pH through Its Acid-Base Properties. *mSphere*. Oct 24;3(5). pii: e00437-18. doi: 10.1128/mSphere.00437-18. PMCID: PMC6200979

789. Chatterjee S, Prados-Rosales R, Tan S, Phan VC, Chrissian C, Itin B, Wang H, Khajo A Magliozzo RS, **Casadevall A**, Stark RE (2018) The melanization road more traveled by: Precursor substrate effects on melanin synthesis in cell-free and fungal cell systems. *J Biol Chem*. Dec 28;293(52):20157-20168. doi: 10.1074/jbc.RA118.005791. Epub 2018 Nov 1. PMCID: PMC6311522

790. Vij R, Cordero RJB, **Casadevall A** (2018) The Buoyancy of *Cryptococcus neoformans* Is Affected by Capsule Size. *mSphere*. Nov 7;3(6). pii: e00534-18. doi: 10.1128/mSphere.00534-18. PMCID: PMC6222054

791. Guimarães AJ, de Cerqueira MD, Zamith-Miranda D, Lopez PH, Rodrigues ML, Pontes B, Viana NB, DeLeon-Rodriguez CM, Rossi DCP, **Casadevall A**, Gomes AMO, Martinez LR, Schnaar RL, Nosanchuk JD, Nimrichter L. (2018) Host membrane glycosphingolipids and lipid microdomains facilitate *Histoplasma capsulatum* internalisation by macrophages. *Cell Microbiol*. Nov 14:e12976. doi: 10.1111/cmi.12976. [Epub ahead of print] PMID: 30427108; DOI: 10.1111/cmi.12976

792. **Casadevall A** (2018) Fungal Diseases in the 21st Century: The Near and Far Horizons. *Pathog Immun*. 2018;3(2):183-196. doi: 10.20411/pai.v3i2.249. Epub Sep 25. PMCID: PMC6241320

793. Coelho C, Brown LC, Maryam M, Vij R, Smith DF, Burnet MC, Kyle JE, Heyman HM, Ramirez J, Prados-Rosales R, Lauvau G, Nakayasu ES, Brady NR, Hamacher-Brady A, Coppens I, **Casadevall A** (2018) *Listeria monocytogenes* virulence factors, including Listeriolysin O, are secreted in biologically active Extracellular Vesicles. *J Biol Chem*. Nov 30. pii: jbc.RA118.006472. doi: 10.1074/jbc.RA118.006472. [Epub ahead of print] PMCID: PMC6349127

794. Casadevall A (2018) Is the Pace of Biomedical Innovation Slowing? *Perspect Biol Med*. 61(4):584-593. doi: 10.1353/pbm.2018.0067. PMID: 30613040; DOI: 10.1353/pbm.2018.0067

795. **Casadevall A**, Fu MS, Guimaraes AJ, Albuquerque P (2019) The 'Amoeboid Predator-Fungal Animal Virulence' Hypothesis. *J Fungi (Basel)*. Jan 21;5(1). pii: E10. doi: 10.3390/jof5010010. PMID: 30669554; DOI: 10.3390/jof5010010

796. Broderick, NA, **Casadevall A** (2019) Gender inequalities among authors who contributed equally. *Elife*. Jan 29;8. pii: e36399. doi: 10.7554/eLife.36399. PMID: 30698140; DOI: 10.7554/eLife.36399

797. Dragotakes Q, Fu MS, **Casadevall A** (2019) Dragotcytosis: Elucidation of the Mechanism for *Cryptococcus neoformans* Macrophage-to-Macrophage Transfer. *J Immunol*. May 1;202(9):2661-2670. doi: 10.4049/jimmunol.1801118. Epub Mar 15.

798. Hawk CS, Coelho C, Oliveira DSL, Paredes V, Albuquerque P, Bocca AL, Correa Dos Santos A, Rusakova V, Holemon H, Silva-Pereira I, Felipe MSS, Yagita H, Nicola AM, **Casadevall A**. Integrin β 1 Promotes the Interaction of Murine IgG3 with Effector Cells. J Immunol. 2019 May 1;202(9):2782-2794. doi: 10.4049/jimmunol.1701795. Epub 2019 Mar 20.

799. Williams CL, **Casadevall A**, Jackson S. (2019) Figure errors, sloppy science, and fraud: keeping eyes on your data. J Clin Invest. Mar 25;129(5):1805-1807. doi: 10.1172/JCI128380. eCollection Mar 25.

800. Kumagai T, Palacios A, **Casadevall A**, García MJ, Toro C, Tiemeyer M, Prados-Rosales R (2019) Serum IgM Glycosylation Associated with Tuberculosis Infection in Mice. mSphere. Mar 27;4(2). pii: e00684-18. doi: 10.1128/mSphere.00684-18.

801. **Casadevall A**. (2019) Duke University's huge misconduct fine is a reminder to reward rigour. Nature Apr;568(7750):7. doi: 10.1038/d41586-019-01032-w.

802. Hatanaka O, Rezende CP, Moreno P, Freitas Fernandes F, Oliveira Brito PKM, Martinez R, Coelho C, Roque-Barreira MC, **Casadevall A**, Almeida F (2019) Galectin-3 Inhibits Paracoccidioides brasiliensis Growth and Impacts Paracoccidioidomycosis through Multiple Mechanisms. mSphere. Apr 24;4(2). pii: e00209-19. doi: 10.1128/mSphere.00209-19.

803. **Casadevall A**, Semenza GL, Jackson S, Tomaselli G, Ahima RS. (2019) Reducing bias: accounting for the order of co-first authors. J Clin Invest. Apr 29;129(6):2167-2168. doi: 10.1172/JCI128764. eCollection Apr 29.

804. Camacho E, Vij R, Chrissian C, Prados-Rosales R, Gil D, O'Meally RN, Cordero RJB, Cole RN, McCaffery JM, Stark RE, **Casadevall A** (2019) The structural unit of melanin in the cell wall of the fungal pathogen *Cryptococcus neoformans*. J Biol Chem. Jul 5;294(27):10471-10489. doi: 10.1074/jbc.RA119.008684. Epub May 22.

805. **Casadevall A** (2019) Global Catastrophic Threats from the Fungal Kingdom : Fungal Catastrophic Threats. Curr Top Microbiol Immunol. May 23. doi: 10.1007/82_161. [Epub ahead of print].

806. Maryam M, Fu MS, Alanio A, Camacho E, Goncalves DS, Faneuff EE, Grossman NT, **Casadevall A**, Coelho C (2019) The enigmatic role of fungal annexins: the case of *Cryptococcus neoformans*. Microbiology. Aug;165(8):852-862. doi: 10.1099/mic.0.000815. Epub May 29.

807. **Casadevall A**, Pirofski LA (2019) Benefits and Costs of Animal Virulence for Microbes. MBio. Jun 4;10(3). pii: e00863-19. doi: 10.1128/mBio.00863-19.

808. Gonçalves DS, Ferreira MDS, Gomes KX, Rodríguez-de La Noval C, Liedke SC, da Costa GCV, Albuquerque P, Cortines JR, Saramago Peralta RH, Peralta JM, **Casadevall A**, Guimarães AJ (2019) Unravelling the interactions of the environmental host *Acanthamoeba castellanii* with fungi through the recognition by mannose-binding proteins. Cell Microbiol. Oct;21(10):e13066. doi: 10.1111/cmi.13066. Epub Jun 19.

809. Smith DFQ, **Casadevall A** (2019) The Role of Melanin in Fungal Pathogenesis for Animal Hosts. Curr Top Microbiol Immunol. 422:1-30. doi: 10.1007/82_2019_173.

810. Coelho C, **Casadevall A** (2019) Answers to naysayers regarding microbial extracellular vesicles. Biochem Soc Trans. Aug 30;47(4):1005-1012. doi: 10.1042/BST20180252. Epub Jul 18.

811. **Casadevall A**, Kontoyiannis DP, Robert V (2019) On the Emergence of *Candida auris*: Climate Change, Azoles, Swamps, and Birds. *MBio*. Jul 23;10(4). pii: e01397-19. doi: 10.1128/mBio.01397-19.

812. Hommel B, Sturny-Leclère A, Volant S, Veluppillai N, Duchateau M, Yu CH, Hourdel V, Varet H, Matondo M, Perfect JR, **Casadevall A**, Dromer F, Alanio A (2019) *Cryptococcus neoformans* resists to drastic conditions by switching to viable but non-culturable cell phenotype. *PLoS Pathog*. Jul 29;15(7):e1007945. doi: 10.1371/journal.ppat.1007945. eCollection Jul.

813. Coelho C, Camacho E, Salas A, Alanio A, **Casadevall A** (2019) Intranasal Inoculation of *Cryptococcus neoformans* in Mice Produces Nasal Infection with Rapid Brain Dissemination. *mSphere*. Aug 7;4(4). pii: e00483-19. doi: 10.1128/mSphere.00483-19.

Editorials

Fang Fc, Casadevall A (2012) Why people cheat and what needs to change. *The Seattle Times* http://seattletimes.com/html/opinion/2020569681_ferricfangarturocasadevallopedxml.html

Casadevall A, Fang Fc (2013) Science Health Thyself. Carried by many newspapers <http://www.project-syndicate.org/commentary/using-science-to-address-threats-to-the-scientific-enterprise-by-arturo-casadevall-and-ferric-c--fang>

Fang Fc, Casadevall (2014) Taking the Powerball Approach to Funding Medical Research. Winning a government grant is already a crapshoot. Making it official by running a lottery would be an improvement. *The Wall Street Journal* <http://online.wsj.com/news/articles/SB10001424052702303532704579477530153771424>

Casadevall A (2015) Put the Ph back into PhD, *Johns Hopkins Public Health Magazine* <http://magazine.jhsph.edu/2015/summer/forum/rethinking-put-the-ph-back-in-phd/>

Casadevall A, Fang FC (2015) Is Science in Crisis? *The Baltimore Sun*. <http://www.baltimoresun.com/news/opinion/oped/bs-ed-science-crisis-20150725-story.html>

Casadevall A (2016) To fight superbugs, scientists are turning toward antibodies. *Newsweek*

Casadevall A, Fang FC (2017) Science is Society's best insurance policy. *Bloomberg*. <https://www.bloomberg.com/view/articles/2017-04-06/science-is-society-s-best-insurance-policy>

Book Chapters, Monographs

1. **Casadevall, A.** (2000). The return of antibody based therapies MDVista

1. Kobrin B, **Casadevall A**, Schiff C, Pirofski L, and Scharff MD (1990) Somatic Instability of Immunoglobulin Genes in Culture in Somatic Hypermutation in V-regions. Edited by J. Steele. CRC Critical Review in Immunology, II-24.

2. Goldman, D.G., **Casadevall A.** (1998) Experimental pulmonary *cryptococcus* infection in rats. *Handbook of Animal Models of Infection*. Academic Press, London, U.K.

3. **Casadevall, A.** Immunity to fungi *Encyclopedia of Live Sciences*

4. **Casadevall, A.** Fungal infections, systemic, by Opportunistic agents *Encyclopedia of Microbiology* 2nd Edition.

5. Nosanchuk, J. and **Casadevall**, A. (1998) Amphotericin B: activity beyond fungal sterols. *Recent Research Developments in Antimicrobial Agents & Chemotherapy* 3:7-15.
6. **Casadevall**, A., Goldman, D.G., Lee, S. (1999) Cryptococcal meningoencephalitis New Concepts on the Immunopathogenesis of CNS infections.
7. **Casadevall** A. Resistance and Immunization to Infectious Diseases (2000) *Immunology: A Short Course*, 4th Edition, John Wiley and Sons, Inc pp 421-454.
8. **Casadevall**, A. Immunotherapy for fungal infections in *Immunotherapy for Infectious Diseases*. Humana Press.
9. **Casadevall**, A. Humoral immunity and *Cryptococcus neoformans*. Dekker Press. *Fungal Pathogenesis* 2001-14:293-324
10. Pirofski, L. and **Casadevall**, A. Antibody therapy for infectious diseases: a progress report at the start of the 3rd millennium
11. **Casadevall**, A. Acquired immunity against fungi. (Chapter 16) In *Immunology of Infectious Diseases* (2001). S.H.E. Kaufman, Sher, A., and Ahmed, R. eds. ASM Press, Washington, DC.
12. Pirofski, L. and **Casadevall**, A. (2001). Traitement anti-infectieux par anticorps. *Annales de L'Institut Pasteur/Actualites - Le retour de la serotherapie*. Cohen, G.N. and Alonso, J. (eds) Elsevier, Paris.
13. **Casadevall** A. Resistance and Immunization to Infectious Diseases (2003) *Immunology: A Short Course*, 5th Edition, John Wiley and Sons, Inc.
14. **Casadevall** A (2002) Acquired Immunity against fungi (Chapter 16; p 223-234). In *Immunology of Infectious Diseases*. Edited by SHE Kaufman, A Sher, and R Ahmed ASM Press. Washington
15. **Casadevall** A (2002) Humoral Immunity and *Cryptococcus neoformans* (Chapter 14, p293-324). In *Fungal Pathogenesis – Principles and Clinical Applications*. Ed. by RA Calderone, RL Cihlar. Marcel Dekker NY
16. **Casadevall** A (2002) Immunotherapy for fungal infections (Chapter 18, p303-322). In *Immunotherapy for Infectious Diseases*. Ed. JM Jacobson. Humana Press, Totowa, NJ
17. Pirofski L, **Casadevall** A (2006). Acquired Immunity to Fungi, In *Molecular Principles of Fungal Pathogenesis*. Ed J Heitman, S Filler, A Mitchell ASM Press, Washington.
18. Steenbergen JN and **Casadevall** A (2005). The evolution of human fungal pathogens. In *The evolution of Human Fungal Pathogens*. Ed. HS Seifert. ASM Press, Washington.
19. **Casadevall**, A (2006). Amoebae and slime mold: host of virulence evolution. In *Molecular Principles of Fungal Pathogenesis*. Ed J Heitman, S Filler, A Mitchell, ASM Press, Washington.
20. Macura N, Zhang T, **Casadevall** A (2006) Developing a mathematical model of phagocytosis: a learning process.
21. McLelland E, Heisenman H, **Casadevall** A (2007) 'Pathogenesis of *Cryptococcus neoformans*' in *New Insights in Fungal Pathogenesis*.

22. Zaragoza, O, Frases S, **Casadevall A** (2007) Pathogenicity of *Cryptococcus neoformans*: an evolutionary perspective. In *Introduction to Evolutionary Biology of Bacterial and Fungal Pathogens*. Eds. Baquero F, Nombela C, Cassell GH, Gutierrez JA. ASM Press.
23. Pirofski L, **Casadevall A**. (2007) 'The Damage-response framework of microbial pathogenesis in GI Microbiota and Regulation of the Immune System Landes Bioscience
24. Dadachova K, **Casadevall A** (2010) Melanin and resistance to ionizing radiation in fungi. *Extremophiles handbook*. Koki Horikoshi (Ed). Springer, Japan.
25. Perfect JR, **Casadevall A** (2010) The history of *Cryptococcus* and cryptococcosis, in *Cryptococcus: from human pathogen to model yeast*. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, **Casadevall A** (Eds). ASM Press. Washington DC.
26. Rodrigues ML, **Casadevall A**, Zaragoza O (2010) The architecture and antigenic composition of the polysaccharide capsule, in *Cryptococcus: from human pathogen to model yeast*. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, **Casadevall A** (Eds). ASM Press. Washington DC.
27. Trofa D, **Casadevall A**, Nosanchuk JD (2010) Melanin: structure, function, and biosynthesis in *Cryptococcus*. in *Cryptococcus: from human pathogen to model yeast*. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, **Casadevall A** (Eds). ASM Press. Washington DC.
28. Coleman JJ, Chrisman CJ, **Casadevall A**, Mylanakis E. (2010) *Cryptococcus neoformans*: nonvertebrate hosts and the emergence of virulence. in *Cryptococcus: from human pathogen to model yeast*. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, **Casadevall A** (Eds). ASM Press. Washington DC.
29. Pirofski L, **Casadevall A** (2010) Acquired Humoral Immunity to *Cryptococcus neoformans*. in *Cryptococcus: from human pathogen to model yeast*. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, **Casadevall A** (Eds). ASM Press. Washington DC.
30. Dromer F, **Casadevall A**, Perfect J, Sorrell T (2010) *Cryptococcus neoformans*: Latency and Disease. in *Cryptococcus: from human pathogen to model yeast*. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, **Casadevall A** (Eds). ASM Press. Washington DC.
31. **Casadevall A**, Dadachova E, Pirofski L (2010) Vaccine and antibody therapies from *Cryptococcus neoformans* to melanoma. in *Cryptococcus: from human pathogen to model yeast*. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, **Casadevall A** (Eds). ASM Press. Washington DC.
32. **Casadevall A** (2011) Changing the Therapeutic Paradigm in Antibacterial Drug Discovery. Alita A. Miller and Paul F. Miller (Eds) Caister Academic Press. Norfolk UK.
33. **Casadevall A** (2011) *Cryptococcus* (Chapter 202) in *Harrison's Principles of Internal Medicine 18th Edition* Edited by D. Longo, A. Fauci, D. Kasper, S. Hauser, J. Jameson, J. Loscalzo. McGraw Hill.
34. Nicola AM, Fabricant SA, Albuquerque P, Soares Felipe MS, **Casadevall A** (2016) Host Autophagy in Antifungal Immunity in Autophagy M.A. Hayat (ed), Volume 9. 317-330.

Books, Textbooks

Cryptococcus neoformans. Written by A. Casadevall and J. Perfect. ASM Press, Washington DC, 1998

Cryptococcus neoformans: from human pathogen to model yeast. Edited by J. Heitman, TR Kozel, KJ Kwon-Chung, JR Perfect, and A, Casadevall. ASM Press 2011

Recent Advances on Model Hosts. Edited by Mylonakis E, Ausubel F.M., Casadevall A, Gilmore, M Springer Verlag/Springer Science & Business. 2011

Human Fungal Pathogens. Edited by A. Casadevall, Aaron P. Mitchell, Judith Berman, KJ Kwon-Chung, John R. Perfect and Joseph Heitman. Cold Spring Harbor Press 2014

Letters, correspondence

Casadevall, A, Spitzer, E.D. (1995) Involvement of multiple *Cryptococcus neoformans* strains in a single episode of cryptococcus and reinfection with novel strains in recurrent infection as demonstrated by random amplification of polymorphic DNA and DNA fingerprinting [Letter]. J.Clin.Microbiol. 33:1682-1683.

Casadevall, A. (1997) Changing the focus of infectious diseases to pathogen-specific therapy Clin.Infect.Dis. 25:349-350.

Nosanchuk, J.D., **Casadevall**, A. Separated at birth. N Engl J Med. 1999 Feb 4;340:395

Casadevall, A. and Pirofski, L. 'On the definition of virulence' ASM News 69(5) 217

Casadevall, A. and Pirofski, L. 'Anti-virulence genes - further muddling the lexicon?' Trends Microbiol. 11:413-4.

Fang FC, **Casadevall A** (2016) A modified lottery can reduce bias in the allocation of research funds. Science April issue.

Fang FC, **Casadevall A** (2016) Grant funding: Playing the odds. Science Apr 8:352(6282) 158. doi: 10.1126/science 352.6282.158-a. Epub 2016 Apr 7

Other media

National Public Radio - <http://www.npr.org/templates/story/story.php?storyId=94563054&ft=1&f=5>
Boston Globe

http://www.boston.com/news/globe/health_science/articles/2005/02/22/were_the_dinosaurs_done_in_by_fungus/

BBC Interview

<http://www.bbc.co.uk/programmes/p005w29s>

NPR talk of the Nation – Fungi: the good, the bad and the edible.

<http://www.npr.org/templates/story/story.php?storyId=94563054>

NYT interview on retracted publication

<http://www.nytimes.com/2012/04/17/science/rise-in-scientific-journal-retractions-prompts-calls-for-reform.html>

NPR Interview on problems with science

<http://www.yourpublicmedia.org/content/wnpr/getting-psyched-about-science>

NPR All Things Considered about new botulinum toxin

<http://www.npr.org/blogs/health/2014/04/21/305650796/whos-protecting-whom-from-deadly-toxin>

NPR Biologist choose sides in safety debate over lab made pathogens

<http://www.npr.org/blogs/health/2014/08/13/339854400/biologists-choose-sides-in-safety-debate-over-lab-made-pathogens>

NPR Interview on the pause involving GOF experiments with pathogens of pandemic potential

<http://www.npr.org/blogs/health/2014/10/23/358122198/scientists-fight-for-superbug-research-as-u-s-pauses-funding>

Voice of America interview on science fraud and misconduct

<http://www.voanews.com/audio/2969854.html>

Inventions, Patents, Copyrights

US Patent 6,509,325. Nosanchuk Joshua D, Casadevall Arturo, Ovalle; Rafael. Method for inhibiting melanogenesis and uses thereof.

US Patent 6,545,130. Glatman-Freedman; Aharon, Casadevall; Arturo. Monoclonal antibodies to mycobacterium tuberculosis and a modified ELISA assay

US Patent 7,402,385 B2 E. Dadachova, J.D. Nosanchuk and A. Casadevall Radiolabeled antibodies and peptides for treatment of tumors.

US Patent 7,651,689 E. Dadachova, A. Casadevall and A. Nakouzi Methods of applying ionizing radiation for therapy of infections

US Patent 7,402,385 E. Dadachova, J.D. Nosanchuk and A. Casadevall Radiolabeled antibodies for treatment of tumors

Canadian Patent No. 2,606,022; European Patent No. 1868639 (validated in France, Germany, Italy, United Kingdom; Hong Kong Patent No. HK1117035; South African Patent No. 2007/08539) E.

Dadachova, A. Casadevall and H. Goldstein. Methods of applying ionizing radiation for therapy of HIV infection.

US Patent 8,187,611 B2 N. Abboud and A. Casadevall. Anti-peptide antibodies that cross react with protective antigen of *Bacillus anthracis* and uses thereof.

US Patent 8,652,827 E. Dadachova, R. A. Bryan and A. Casadevall Radiosynthesis as an alternative energy utilization process in melanized organisms and uses thereof.

US Patent 8,586,090 E. Dadachova and A. Casadevall Melanin nanoshells for protection against radiation and electronic pulses.

Applications pending

J. Achkar, A. Casadevall, R. Rosales and A. Ziegenbalg Serologic test for the rapid diagnosis of tuberculosis.

E. Dadachova, A. Casadevall, H. Strickler and R.D. Burk Radioimmunotherapy and imaging of tumor cells that express viral antigens.

E. Dadachova, A. Casadevall, M.A. Sesay, H. Damania, P.E. Smariga Radiolabeled monoclonal antibodies, methods of preparation using TCEP and uses thereof.

E. Dadachova, A. Casadevall, M.A. Sesay, H. Damania, P.E. Smariga Disposable column system for purification of radiolabeled antibodies.

E. Dadachova and A. Casadevall Methods for increasing efficacy of radioimmuno-therapy of melanoma.

JM Friedman, AJ Friedman, G. Han, MS Navati, KP Davies, MT Tar, AA Alfieri, A Casadevall, E Dadachova, HC Eisenman, Jasmin and D Spray Versatile nanoparticulate biomaterial for controlled delivery and/or containment of therapeutic and diagnostic material.

E. Dadachova, C. Gravekamp, A. Casadevall. Radiobacteria for therapy of cancer.

E. Dadachova and A. Casadevall. Oral administration of melanin for protection against radiation.

TEACHING

Mentoring

Advisees (predoctoral PhD advisor)

1996 Yulin Wang Ph.D.

1997 Sarah Franzot Ph.D.

1998 Lin Chen Ph.D.

1999	Wendy Cleare	Ph.D.
1999	Nikoletta Lendvai	Ph.D.
2000	Neely Mozaffarian	Ph.D.
2000	Angel Rosas	Ph.D.
2002	Johanna Rivera	Ph.D.
2002	Reid Schwebach	Ph.D.
2003	Judith Steenbergen	Ph.D.
2004	Javier Garcia-Rivera	Ph.D.
2006	Marcela Torres	Ph.D.
2006	Luis Martinez	Ph.D.
2007	Yong Luo	Ph.D.
2008	Mauricio Alvarez	Ph.D.
2009	Magdia DeJesus	Ph.D.
2009	Carolyn Saylor	Ph.D.
2010	Cara Chrisman	Ph.D.
2011	Patricia Andrade	Ph.D.
2011	Andres Nicola	Ph.D. (University of Brasilia)
2012	Radames Cordero	Ph.D.
2012	Alena Janda	Ph.D.
2013	Jacky Chow	Ph.D.
2013	Carolina Coelho	Ph.D. (University of Coimbra)
2014	Sabriya Stukes	Ph.D.
2015	Lisa Brown	Ph.D.
2016	Anthony Bowen	Ph.D.
2017	Carlos de Leon Rodriguez	Ph.D.
2017	Eric Jung	Ph.D.
2018	Joudeh Freiji	M.D.

Postdoctoral Fellows (Name, Years, Current Position)

Brian Currie, M.D., M.P.H. 1992-1993 Assist. Dean, Clinical Research, Montefiore Med. Center;
Professor, Dept. Med., Dept. Epidemiology & Population Health, Albert Einstein College
of Medicine, Bronx, NY

Sushovita Mukherjee, M.D. 1992-1996 Not Available

Jean Mukherjee, D.V.M., Ph.D. 1996-1997 Assist. Prof., Dept. Biomed. Sci. (Infectious Diseases),
Cummings Sch. Vet Med., Tufts University, North Grafton, MA

Aharona Freedman, M.D. 1993-1998 Assist. Clinical Prof., Dept. Pediatrics (Infectious Diseases), Albert
Einstein College of Medicine, Bronx, NY

Joshua Nosanchuk, M.D. 1996-1998 Prof., Dept. Med. (Infectious Diseases), Dept. Microbio. & Immuno.,
Albert Einstein College of Medicine, Bronx, NY

Bettina Fries, M.D. 1997-1999 Prof., Dept. Med. (Infectious Diseases), Stony Brook University, NY

Marta Feldmesser, M.D. 1994-2001 Assoc. Prof., Dept. Med. (Infectious Diseases), Dept. Obstetrics &
Gynecology and Women's Health, Dept. Microbio. & Immuno., Albert Einstein College
of Medicine, Bronx, NY

Carlos Taborda, Ph.D. 1999-2002 Assoc. Prof., Dept Microbio., Institute Biomed. Sci., University of Sao
Paulo, Sao Paulo, Brazil

David Goldman, M.D. 1996-2003 Assoc. Prof., Dept. Med. (Infectious Diseases), Dept. Pediatrics, Dept.
Microbio. & Immuno., Albert Einstein College of Medicine, Bronx, NY

Stephanie Tucker, Ph.D. 1999-2003 Not Available

Oscar Zaragoza, Ph.D. 2001-2006 Principal Investigator, Dept. Microbio., Instituto de Salud Carlos III,
Marid, Spain

Diane McFadden, Ph.D. 1999-2006 Assoc. Director, Northeast Biodefense Center, Columbia University, New York, NY

Marcela Torres, Ph.D. 2006-2007 Scientist, Regeneron Pharmaceuticals Inc., Tarrytown, NY

Helene Eisenman, Ph.D. 2003-2008 Assist. Prof., Dept. Microbio., Baruch College, New York, NY

Erin McClelland, Ph.D. 2003-2008 Assist. Prof., Dept. Basic Sci. (Microbio. & Immuno.), The Commonwealth Medical College, Scranton, PA

Susana Frases-Carvajal, Ph.D. 2004-2009 Scientist, Biotech. Lab., National Institute of Metrology, Rio de Janeiro, Brazil

Yong Luo, M.D., Ph.D. 2007-2009 Residency, Long Island Jewish Medical Center, New Hyde Park, NY

Aviva Diamond, Ph.D. 2009-2010 Post-doc with Ian Willis, Albert Einstein College of Medicine, Bronx, NY

Emma Robertson, Ph.D. 2008-2011 Post-doc with Kirsten Nielsen, University of Minnesota, Minneapolis, MN

Andre Nicola, M.D., Ph.D. 2006-2011 Prof. and Researcher, Graduate Program in Genomic Sciences and Biotechnology, Catholic University of Brasilia, Brazil

Nareen Abboud, Ph.D. 2009-2011 Research Program Manager, Montefiore Medical Center, Bronx, NY

Monica Garcia-Solache, M.D., Ph.D. Postdoctoral fellow with Louis Rice, Brown University.

Rafael Prados, Ph.D. 2009-2014 Assist. Prof., Albert Einstein College of Medicine, New York, NY

Mary Pohl, Ph.D. 2011-2014 Senior Scientist, Oncobiologics, Inc.

Julie Wolf, Ph.D. 2010-2015 ASM, Washington, DC

Radames Cordero, Ph.D. 2015-2017, Research Associate, Johns Hopkins University

Coelho, Carolina, Ph.D. 2015-2018, MRC Centre for Medical Mycology, University of Exeter

Maggie Wear, Ph.D. 2016-2019, Assistant Scientist, Johns Hopkins University

Awards for junior scientists in Dr. Casadevall laboratory

1995-2000	David Goldman MD	NIH Physician Scientist Award
1996-99	Rona Freedman MD	Aaron Diamond Scholarship
1999-2004	Rona Freedman MD	NIH Physician Scientist KO8 Award
1993	Wendy Cleare	American Heart Minority Scholarship
1994	Wendy Cleare	NIH Minority Award Supplement
1996-2001	Marta Feldmesser MD	NIH Physician Scientist KO8 Award
1995-97	Sarah Piancastelli Franzot (PhD student)	Fulbright Scholarship
1997-99	Joshua Nosanchuk MD	Mycology IDSA Award
1997-2002	Joshua Nosanchuk MD	NIH Physician Scientist KO8 Award
	Johanna Rivera	NIH Marc Graduate Student Fellowship.
1998-2000	Bettina Fries MD	Mycology IDSA Award (Declined due overlap)
1998-2001	Bettina Fries MD	Howard Hughes Postdoctoral Award
	Bettina Fries MD	NIH Physician Scientist KO8 Award
2001-03	Dianne McFadden PhD	Life Sciences Postdoctoral Fellowship Award
	Dianne McFadden PhD	NIH F32 Postdoctoral Award (Declined due to overlap)
	Javier Garcia	NIH Marc Graduate Student Fellowship
	Helene Eisenman PhD	NIH F32 Postdoctoral Award
	Erin McClelland PhD	Revson Fellowship
2007-12	Jacqueline Achkar MD	NIH K23 Award

Thesis committees

I have participated in dozens of PhD committees and defenses but did not keep track of these

Training grant participation

9/1/97-5/31/13 Molecular Pathogenesis of Infectious Diseases 5T32AI007506-09

NIH/NIADD

PI: Casadevall

Until 06 (training faculty) after 06 (PI)

9/1/94-6/30/21 The Molecular and Cellular Basis of Infectious Diseases (MCBID) Program
2T32AI007417-21A1
NIH/NIADD
PI: Casadevall

Teaching

Course Leader for **GRADUATE MICROBIAL PATHOGENESIS**; 6 credit graduate school course at the Albert Einstein College of Medicine Sue Golding Graduate Division which teaches the fundamentals of microbial pathogenesis. 1996 and 1999.

2000-present	Lecturer in Graduate Pathology Course - Albert Einstein College of Medicine
	Lecturer in Graduate Critical Reading Course- Albert Einstein College of Medicine
2001-present	Lecturer in Immunology Medical School Module - Albert Einstein College of Medicine
2000-2014	Lecturer in Graduate Immunology Course - Albert Einstein College of Medicine
2000-14	Lecturer in Infectious Disease Course - Albert Einstein College of Medicine
1999	Lecturer at Rockefeller Microbial Pathogenesis course
2000-14	Lecturer at NYU Microbial Pathogenesis course
2013-present	Lecturer at Columbia Ethics Course
2015	Lecturer in IBS course, Johns Hopkins Sch of Public Health
2015	Lecturer in Graduate Immunology Course, Johns Hopkins Sch of Public Health
2015	Lecturer in Biology of Parasitism, Johns Hopkins Sch of Public Health
2016	Lecturer in Graduate Immunology Course, Johns Hopkins Sch of Public Health
2016	Lecturer in Public Health Biology Course, Johns Hopkins Sch of Public Health
2016	Lecturer in Biomedical Sciences, Johns Hopkins Sch of Public Health
2017	Lecturer in Biology of Parasitism, Johns Hopkins Sch of Public Health
2017	Lecturer in Bacterial Pathogenesis course, Johns Hopkins Sch of Public Health
2017	Lecturer in Responsible Conduct of Research course, Columbia University
2017	Lecturer in Biophysics course, Johns Hopkins University
2017	Lecturer in Current Issues in Public Health, Johns Hopkins Sch of Public Health
2017	Lecturer in Evolution of Infectious Diseases, Johns Hopkins Sch of Public Health
2017	Lecturer in Graduate Immunology, Johns Hopkins Sch of Public Health
2017	Lecturer in Introduction to the Biomedical Sciences, Johns Hopkins Sch of Public Health
2017	Lecturer in Pathobiology of Disease, Johns Hopkins Sch of Medicine
2017	Lecturer in Pediatric Ground Rounds, Johns Hopkins Sch of Medicine
2017	Lecturer in Public Health Biology, Johns Hopkins Sch of Public Health
2018	Lecturer in Biology of Parasitism, Johns Hopkins Sch of Public Health
2018	Lecturer in Bacterial Pathogenesis course, Johns Hopkins Sch of Public Health
2018	Lecturer in Responsible Conduct of Research course, Columbia University
2018	Lecturer in Biophysics course, Johns Hopkins University
2018	Lecturer in Current Issues in Public Health, Johns Hopkins Sch of Public Health
2018	Lecturer in Evolution of Infectious Diseases, Johns Hopkins Sch of Public Health
2018	Lecturer in Graduate Immunology, Johns Hopkins Sch of Public Health
2018	Lecturer in Introduction to the Biomedical Sciences, Johns Hopkins Sch of Public Health
2018	Lecturer in Pathobiology of Disease, Johns Hopkins Sch of Medicine
2018	Lecturer in Parasitology, Johns Hopkins Sch of Public Health
2018	Lecturer in Public Health Biology, Johns Hopkins Sch of Public Health
2019	Lecturer in R3 Course, Johns Hopkins Sch of Public Health
2019	Lecturer in Responsible Conduct of Research course, Columbia University
2019	Lecturer in Biophysics course, Johns Hopkins University
2019	Lecturer in Current Issues in Public Health, Johns Hopkins Sch of Public Health

2019	Lecturer in Evolution of Infectious Diseases, Johns Hopkins Sch of Public Health
2019	Lecturer in Graduate Immunology, Johns Hopkins Sch of Public Health
2019	Lecturer in Introduction to the Biomedical Sciences, Johns Hopkins Sch of Public Health
2019	Lecturer in Pathobiology of Disease, Johns Hopkins Sch of Medicine
2019	Lecturer in Parasitology, Johns Hopkins Sch of Public Health
2018	Lecturer in Public Health Biology, Johns Hopkins Sch of Public Health

PART II

RESEARCH GRANT PARTICIPATION

Current Grants:

Period of Performance: 04/01/2015–01/31/2020

Title of Grant: Biology of Fungal Melanin

Grant Number: 5 R01 AI052733-13

Sponsoring Agency: NIH/NIAID

Direct Costs/yr: \$131,898

PD/PI: Casadevall

Objective: The specific aims of this grant are to establish the mechanism by which melanin promotes the virulence of *C. neoformans in vivo*, to establish the protective efficacy of antibody to *Cryptococcus neoformans* melanin and laccase and the mechanism of antibody action, to investigate the molecular events of *C. neoformans* melanin biosynthesis.

Period of Performance: 08/01/2015–05/31/2020 (NCE)

Title of Grant: Synergy of Host Defense Mechanisms in the Lung

Grant Number: 5 R01 HL059842-17

Sponsoring Agency: NIH/NHLBI

Direct Costs/yr: \$250,000

PD/PI: Casadevall

Objective: The goal of this project is to establish the relationship between macrophage damage and CN non-lytic exocytosis, to establish the mechanism by which host annexins contribute to CN non-lytic exocytosis, and to identify the fungal components that facilitates non-lytic exocytosis.

Period of Performance: 11/01/2016 – 10/31/2021

Title of Grant: Host inositol regulation of AIDS-Associated *Cryptococcus* brain infection

Grant Number: R01 AI123315

Sponsoring Agency: NIH

Direct Costs/yr: \$60,000

PD/PI: Xue

Objective: Performing detailed GXM analysis using physical chemistry approaches, including using monoclonal antibody and light scattering; detection and isolation of different polysaccharide fractions under conditions with different carbon sources (inositol or glucose) for their role in BBB crossing in vitro; and potential development of protective antibody for inositol transporters.

ACADEMIC SERVICE

Institutional Administrative Appointments

1995-7	Member, Graduate Committee, Albert Einstein College of Medicine
1998-9	Member, Assistant Professor Promotion Committee, Albert Einstein College of Medicine
2005-6	Member, Search committee Dean, Albert Einstein College of Medicine
2012-3	Member, Search Committee Chair of Pediatrics, Albert Einstein College of Medicine
2013-4	Member, Search committee Chair of Medicine, Albert Einstein College of Medicine

- 2015 Member, Search Committee for Bloomberg Distinguished Professor, Johns Hopkins Sch Med
- 2015 Member, Committee Department of Biochemistry & Molecular Biology review site visit
- 2015 Member, Committee Sidney Kimmel Medical College of Thomas Jefferson University,
Department of Microbiology & Immunology External Review

PRESENTATIONS

INVITED PRESENTATIONS (Partial List)

- 1992 Grand Rounds. Downstate Department of Medicine
Grand Rounds. New York University Department of Medicine
Dept of Pathology. Stony Brook University

- 1993 2nd International Conference on Cryptococcus and Cryptococcosis Milan, Italy

- 1994 Dept of Med. Grand Rounds. Newark School of Medicine
Systemic antifungals: discovery, development and applied therapeutics. New York City
Dept of Medicine. Mount Sinai School of Medicine
Dept of Medicine. Memorial Sloan-Kettering Hospital
Medical Mycology Society of the Americas, Las Vegas Meeting
New York University. Update on Fungal Infections Symposia, NY
Dept of Rheumatology. New York University, NY
Infectious Disease Society of America, Orlando, FL
International Congress of Mycology-Vancouver, Canada
2nd NIAID Workshop on Medical Mycology, Flagstaff, Az.
Dept of Medicine. Boston University.

- 1995 Dept of Structural Biology. Public Health Res. Institute, NYC
Dept of Medicine. Torrance-UCLA Med. Ctr., Los Angeles, CA
Dept of Medicine. Cincinnati School of Medicine. Cincinnati, OH
Dept of Microbiology. Georgetown School of Med., Georgetown, MD
Div. of Infectious Diseases. Memorial Sloan-Kettering Hospital, NYC
3rd NIAID Workshop on Medical Mycology. Big Ski, Montana
International Workshop on Molecular Pathogenesis of Fungal Infections. Wurzburg,
Germany
Infectious Diseases, Duke University, Durham, NC
Dept of Chemistry, Queens College, CUNY

- 1996 Medical Mycology Society of the Americas, New Orleans
3rd International Conference on Cryptococcus and Cryptococcosis, Paris, France
Spanish Mycology Association, Valencia, Spain
Cuban Medical Convention, Miami Beach, Fla.
Dept of Biology, Hunter College, CUNY
ESATYBC Conference, Catskills, NY
Hunter College, NYC
NIH Workshop on The role of humoral immunity in the treatment and prevention of
Infectious Diseases Washington, DC
Dept of Microbiology. Medical College of Ohio, Toledo
Merck Pharmaceuticals, Rahway, NJ
Medical Mycology Society of New York Lecture

1997 13th Congress of the International Society of Human and Medical Mycology, Parma Italy. Convener of symposium titled: Cell-mediated versus antibody mediated-protection mechanisms in fungal diseases: an ongoing dilemma.
 American Society of Microbiology General Meeting Symposium, Miami, Fla.
 FASEB conference, Colorado
 New York Academy of Sciences Lecture
 Rockefeller University
 IDSA Symposium on new therapeutic strategies for fungal infections
 Department of Microbiology, Oklahoma Health Sciences Center
 Mount Sinai School of Medicine-Molecular Medicine Seminar Series
 Woods Hole Mycology Course Lecturer
 NIAID Workshop: Bridging the gap for Underrepresented Minority Research Scientists

1998 Wistar Institute
 Grand Rounds Beth Israel Hospital
 Department of Microbiology, Medical College of Ohio
 Division of Infectious Diseases, Columbia University
 Society for Industrial Microbiology Annual Meeting, Denver, Co
 Department of Health, State of New York, Albany, NY
 Department of Microbiology, Stony Brook University, NY
 Anderson Lecture, Charlottesville, Va
 Woods Hole Mycology Course Lecturer

1999 ASM Division F Divisional Lecture
 Cold Spring Harbor Symposium on Microbial Pathogenesis and Host Response.
 1999 Joint Committee Meeting of the US-Japan Cooperative Medical Science Program
 Nelson Lecture at the University of Montana in Bozeman
 Santa Fe symposia on Defense of the Brain
 International Meeting on Tuberculosis, Stockholm, Sweden
 ASM Symposium Millennial Challenges to Vaccines
 Trudeau Institute
 NHLBI Symposium on Pulmonary Immunobiology and Inflammation, NIH
 U.S.-Japan Cooperative Science Program Joint Committee, Bethesda, MD
 Woods Hole Mycology Course Lecture
 NIAID Workshop: Bridging the gap for underrepresented Minority Research Scientists

2000 Boston University
 14th Congress of the International Society of Human and Medical Mycology, Buenos Aires, Argentina. Convener of symposium titled: Vaccines and Preventive Antibodies; Also speaker on symposium on Fungal Morphogenesis and Virulence
 1st Japanese Mycology Forum, Tokyo, Japan, Keynote Speaker
 Foundation Lecture British Mycology Society Meeting, Stratford-upon-Avon, England
 Gordon Conference on Fungal Pathogenesis
 New York University - Division of Infectious Diseases
 40th ICAAC. Toronto. Vaccines for the 21st Century: New disease Targets on Horizon.
 Ritterson Memorial Lecture, University of Rochester Medical Center
 Genome Therapeutics Corporation, Waltham, MA
 Immunology for nonviral infections, Trudeau Institute, Saranac Lake
 Yale University

- 2001 ASM Symposium Host defense against fungi: application toward therapeutics and vaccine development, Orlando, FL
 New York Medical College (Division of Infectious Disease)
 University of Minnesota (Department of Microbiology)
 Elli Lilly, Indianapolis, IN
 CSH Symposium on Microbial Pathogenesis and Host Response
 22nd International Conference Chemotherapy (Amsterdam)
 Fungal Therapy, NJ Medical School Symposium
 Dept of Microbiology, University of Pennsylvania
 National Institute of Health
 Department of Microbiology, Charleston
 Newark School of Medicine
- 2002 Keystone Symposia on Molecular and Cellular Biology
 5th Conference on Cryptococcus and Cryptococcosis, Adelaide Australia
 Gordon Conference on Fungal Pathogenesis
 IUMS Symposium, Paris
 ASM Symposium New Concepts in Physiology and Biochemistry of Pathogenic Fungi Salt Lake City, UT
 Woods Hole Mycology Course Lecture
 Dept of Microbiology, University of Michigan
 Dept of Microbiology, University of Wisconsin
 Dept of Microbiology, University of Louisiana
 Division of Infectious Diseases, Albany
 2nd Conference on Vaccines, Istituto Superiore di Sanita, Rome
 Division of Infectious Diseases, Columbia University
- 2003 Dept of Genetic Medicine, Cornell University
 Dept of Immunology and Virology, U. Mass Medical School
 9th Congress of the European Confederation of Medical Mycology, Amsterdam, Netherlands
 15th Congress of the International Society of Human and Animal Mycology
 Duke University Medical School
 Participant, Banbury Conference. Toward a More Unified Understanding of Infectious Disease
 CSH Symposium on Microbial Pathogenesis and Host Response
 15th Congress of the International Society of Human and Medical Mycology, San Antonio. Convener of symposium titled: Protective Antibodies; Also speaker on symposium on Fungal Morphogenesis and Virulence
 Keynote Speaker, Mount Sinai Medical Resident Forum
 NABI Pharmaceuticals, Rockville, MD
 South Dakota Health Research Foundation
 ACS Glycobiology Symposium, ACS Meeting, New York.
 Washington University School of Medicine
 Miami University, Oxford Ohio
 New York University Division of Infectious Diseases
 Grand Rounds Memorial Sloan Kettering
- 2004 Immune Compromised Host Society - Grenada, Spain
 Keystone Symposia on Bioterrorism and Emerging Infectious Diseases, Keystone, CO.

Mathematical Biosciences Inst. 'Disease Models of Host-Pathogen Interactions'
 Columbus OH
 Public Health Research Institute, Newark, NJ
 ASM Meeting Symposium: 'Immune Mechanisms in Polymicrobial Infections', New Orleans
 Keynote Speaker, Candida Meeting, Austin. TX
 11th International Congress of Infectious Diseases, Cancun, Mexico
 Mycology Unit, Pasteur Institute
 Coexistence and Collisions at the Host/Microbe Interface, Burroughs Wellcome Fund, Miami, FL.
 American Phytopathological Society Mycology Committee, Anaheim, CA
 New York University – Department of Microbiology
 FASEB Summer Research Conference on Polysaccharides, Tucson, AZ
 University of Iowa – Division of Infectious Diseases
 University of Gainesville, FL -- Department of Oral Biology
 Wyeth Vaccine Division, Pearl River, NY
 University of Colorado Health Science Center – Dept of Microbiology
 Biodefense Regional Center of Excellence meeting in Bethesda, MD
 Environmental Protection Agency workshop on Virulence Factor-Activity Relationships
 American Society of Tropical Medicine and Hygiene
 5th Louis Pasteur Conference on Infectious Diseases, Pasteur Institute

2005 Plenary Session, Mycology Division of IUMS, San Francisco
 La Jolla Institute of Allergy and Immunology
 Scripps Institute
 Keynote Speaker – 6th International Conference on Cryptococcus and Cryptococcosis
 Focus on Fungal Infections 15, Miami, FL
 ASM Biodefense Workshop
 ASM Meeting Symposium, Atlanta, GA
 IUMS Meeting, San Francisco
 CDC Distinguished Lecturer
 Koch Centennial Postulates Workshop, Berlin
 Keynote Speaker, University of Michigan Public Health Retreat
 New York Hospital in Queens
 Maimonides Hospital
 NIH, Biodefense Clinical Research Branch
 FDA, Immunology Section
 JASON General Meeting, San Diego
 Monoclonal Antibody Meeting, Rome, Italy
 Eastern Pennsylvania Branch of the American Society for Microbiology
 Thaler Lecture, Aeras Global TB Vaccine Foundation
 Koch's postulate - Centennial Workshop
 University of Kansas, Department of Microbiology
 New York Academy of Sciences
 NIAID scientists from the Division of AIDS (DAIDS)

2006 Biodefense clinical research workshop (poxvirus meeting) Bethesda, MD
 ASM 2006 Biodefense meeting. Panel Discussion
 Grand Rounds, University of Virginia
 Department of Microbiology, Drexel University
 ASM 2006 Candida Meeting

International Conference on Emerging Infectious Disease, Atlanta
International Society for Human and Animal Mycoses, Paris
Maxwell L. Littman Award Lecture – New York Society for Medical Mycology
ASM General Meeting in Orlando, FL
B cell workshop Trudeau Institute
New York Medical College
Maxwell L. Littman Award Lecture – New York Society for Medical Mycology

2007
University of Texas Southwestern Medical School
University of Connecticut
Keynote speaker, XIII Fungal Genetics Conference
Berkeley U
University of California San Francisco
University of Illinois – Urbana Champaign
ASM General Meeting Toronto Canada
Princeton U - Program on Science and Global Security's Carnegie Biodefense Seminar
Keynote Speaker Second FEBS Advanced Lecture Course Human Pathogens
U. Louisville Distinguished Speaker Lecture
Harold C. Neu Conference (Chicago)
University of Wisconsin – Graduate Student Invited Speaker
University of Alabama
Keynote Speaker Merck Retreat
APUA Congress - Boston

2008
IDSA Kass Lecture
U Mass Worcester
ISDA/ICAAC
Schimelbureau Amsterdam
Gordon Conference
EPA conference on emerging threats
Brooklyn College Dept Biology Keynote Retreat Speaker
St. Louis University
VA ASM Branch Lectureship speaker
NIAID Biodefense Network Meeting
University of Minnesota

2009
Aztra Zeneca, MA, Waltham
University of Buffalo
Rio Grande ASM Branch Keynote speaker
UAB Program in Immunology
Puerto Rico ASM Branch Keynote Speaker
Critical Path for ID Therapeutics Targeting Host NIAID/DMID/OBRA Workshop
Forum on Microbial Threats (IOM)
Rinat-Pfizer, SF
IOM Committee on Science, Technology and Law
Semmering Vaccine Symposium, Vienna
University of Wurzburg symposium on Living with Pathogens
University of Pittsburgh
Merck
Medical Mycology Society of New York
Novartis

Tufts University
Wadsworth Center
Intermountain ASM Branch Keynote Speaker
Southeastern ASM Branch Keynote Speaker
Florida ASM Branch Keynote Speaker
Hawaii Branch ASM Keynote Speaker
Farness Lecture, Tucson, AZ
Duke University, Dept of Genetics

2010 Keynote Speaker, First International Conference on Model Hosts, Crete Greece
Keynote Speaker European Fungal Genetics Conference, Amsterdam, Netherlands
Distinguished Faculty Seminar in Infectious Diseases, Medical College of Wisconsin
Association of Medical School Microbiology and Immunology Chairs
Forum on Microbial Threats (IOM)
Vienna Biocenter, Vienna, Austria.
Columbia University Dept of Microbiology and Immunology
Mount Sinai Dept of Infectious Diseases
8th World Congress on Trauma, Shock, Inflammation and Sepsis, Munich, Germany
ASM General Meeting, San Diego
ICCAC, Boston
IDSA, Vancouver
Ann Arbor, MI
University of Rio de Janeiro
IOM Forum on Fungal diseases
2010 Nelson Lecture, Bozeman, Montana
2010 Theobald Smith Lecture at Albany
2010 Arthur White Lecture, U Indiana

2011 Scripps Institute, La Jolla
Stanford University
Naval Research Laboratory, Washington DC
GRC Immunology of Fungal Infections (Galveston)
Mark Wilson Conference, San Juan
Keystone Symposia on Lung Immunity
University of Pennsylvania, Philadelphia
Keynote Speaker, Annual Pew Scholars Meeting, Cozumel
Keynote Speaker, GRC on Chemical and Bioterrorism Threats
Department of Microbiology and Immunology, Loyola University
Inter Urban Clinical Club
National Biodefense RCE Meeting, Denver
Cryptococcus and cryptococcosis meeting
Weinstein Lecture, Tufts
Keynote Speaker, Brazilian Microbiology Society
Keynote Speaker, Australian Microbiology Society
Bacterial Toxins Meeting, Oslo Norway
Brown University
Massachusetts General Hospital
Merck Vaccine Symposium (Toronto)
ICAAC Boston
Brown University
University of North Carolina

National Plant Diagnostic Network
Harvard University

2012

Bard College
Keystone meeting on Fungal pathogenesis and drug discovery, Santa Fe
University of Calgary
University of Tennessee
University of Puerto Rico
Pasteur Institute
2012 Pugwash Conference
Symposium on fungal pathogenesis, Oviedo, Spain
ICAAC Lecture 2012
Translational Science 2012 Meeting, Washington DC
University of Arkansas
International Conference of Emerging Infectious Diseases (Emerging Fungal Diseases)
Atlanta
Keynote speaker, 8th National Symposium on Recent Advances in Carbohydrate Sci.
Banff, Alberta
Vanderbilt University
Duke Mycology Symposium
NYAS Symposium 'Discovering antibacterial and anticancer therapeutics in unexpected places'
Keynote speaker – Tularemia meeting, Breckenridge CO
Keynote Speaker – U Cleveland Immunology retreat
Health Research Alliance, Washington DC
Jenner Lecture, St. Georges Hospital, London

2013

Human Fungal Pathogens 2013 Nice, France
NIH Immunology Program, Bethesda MD
GRC Fungal Infections – Galveston, TX
Ohio State University, Columbus, OH
ASM Biodefense and Emerging Infectious Meeting, Washington, DC
Virginia Commonwealth University, Richmond, VA
Columbia University (Responsible conduct of research course)
Texas A&M, College Station, TX
University of Texas at San Antonio
University of Texas at Austin
University of Jena
American Society for Microbiology General Meeting, Denver, CO
BWF Meeting in Calgary, Canada
Swiss Society for Microbiology, Interlaken
Capetown, South Africa
Human Fungal Pathogens Course, Nice, France
Keynote Speaker, Donaghue Foundation
Rheumatology Division, Beth Israel Medical Center
Snowmass Microbial Pathogenesis Meeting
Kynnon Lecture, NIAID

2014

Association of American Law Schools (AALS) Annual Meeting, New York
Bridging Lecture, International Union of Microbiological Societies 2014 meeting,
Montreal, Canada

Department of Microbiology and Immunology, UC Davis
 2014 Keystone Symposium on Prophylactic and Therapeutic Antibodies
 Keynote Speaker, Israeli Society of Microbiology 2014 meeting
 Keynote Speaker 17th Upstate NY Immunology Conference
 Keynote Speaker International Life Sciences Institute Annual meeting, Bermuda
 Keynote Speaker, The 2nd Annual Infection, Inflammation, and Immunity Summer Symposium, U Utah
 Benard Fields Memorial Lecture, The Scripps, La Jolla
 2014 American Association of Immunology Minority Affairs Guest Lecturer
 Student Invited Speaker, Graduate Biosciences Society at the University of Virginia, Charlottesville
 Invited speaker, GRC Cellular and Molecular Fungal Biology
 Group on Research Advancement and Development (GRAND), AAM Colleges
 San Antonio Vaccine Development Center Conference titled "Infections, Immunity and Vaccines"
 Keynote Speaker Department of Microbiology and Molecular Genetics Retreat, UTHSCenter, Houston
 Keynote Speaker Upstate NY Immunology Conference, Lake George
 Keynote Speaker ASM Eastern NY Branch, Albany, NY
 Symposium on Microbes in Health and Disease at Weill Medical College
 Keynote Speaker XII International Meeting on Paracoccidioidomycosis, Brasilia, Brasil.

2015 14th Annual St. Jude/PIDS Pediatric Infectious Diseases Research Conf., Memphis, TN
 Invited Speaker, Icahn School of Medicine at Mount Sinai, New York, NY
 Invited Speaker, Albert Einstein, New York, NY
 Invited Speaker, Princeton University, Princeton, NY
 Invited Speaker, Baylor College, Houston, TX
 Invited Speaker and Organizer, Model Host Conference, Crete, Greece
 Invited Speaker, Universidad de la Republica, Montevideo, Uruguay
 Invited Speaker, North Dakota State University, Fargo, ND
 Invited Workshop Speaker, National Diversity Equity Workshop, Arlington, VA
 Invited Speaker, Merck, East Brunswick, NJ
 Invited Speaker, University of Kentucky, Lexington, KY
 Invited Speaker, University of Maryland, Baltimore, MD
 Invited Speaker, Nationwide Children's Hospital, Columbus, Ohio
 Invited Speaker, ASM Maryland Branch, Hunt Valley, MD
 McCollum Colloquium, Dartmouth, Hanover, NH
 Columbia University ethics course, New York, NY
 NIH Director's Wednesday Afternoon Lecture Series, NIH, Bethesda, MD
 Invited Speaker, East Tennessee University, Johnson City, TN
 Keynote Speaker, New York Hospital Queens, New York, NY
 Douglas McGregor Keynote Address, Cornell University, Ithaca, NY
 McGinnis Memorial Lecture, Duke University, Durham, NC
 Annual Microbial Sciences Symposium, Harvard University, Cambridge, MA
 Keynote Speaker, University of California Irvine, Lake Arrowhead, CA
 3rd Conference on Model Hosts, Crete, Greece

2016 Plenary Speaker, ASM Biodefense Conference, Arlington VA
 Microbiology 2016, Liverpool, UK
 Medoff Lecture, Washington University, St. Louis
 Department of Biomedical Sciences, East Tennessee University, TN

Naff Lecture, Case Western Reserve
 McGhee Lecture, University of Arkansas
 National Library of Medicine
 Keynote Speaker, Canadian Society of Microbiology, Toronto
 Microbe 2016, American Society of Microbiology, Boston, NY
 Karling Lecture, The Mycological Society of Americas, Berkeley, CA.
 Emerging Infectious Disease Workshop, Madrid, Spain
 15th CRG-Centre for Genomic Regulation Symposium, Barcelona, Spain
 Keynote Speaker, MSGERC Meeting, Asilomar, CA
 Society for Glycobiology, New Orleans
 Retreat Keynote Speaker, Department of Microbiology, U Maryland
 Student Invited Speaker, McMaster University, Ontario, Portland
 Reed College, Portland, Oregon
 Merck Sharp and Dohme
 Keynote Speaker (student invited), McMaster University, Ontario, Canada
 Reed College, Portland, Oregon
 Merck Sharp and Dohme
 Boston University, Boston, MA
 Plenty Speaker, 2016 Society for Glycobiology, New Orleans, LA
 University of Pittsburgh, Pittsburgh, PA

2017 Westmere Lecture, Birmingham UK
 Harry Smith Lecture, Birmingham UK
 Boston University, Boston, MA
 Queens College, New York, NY
 University of Wisconsin-Madison, Madison, WI
 University of Kansas, Manhattan, KS
 Plenary Speaker, 2017 International Mtg of Microbiological Society of Korea, Seoul
 5th International Symposium of the Collaborative Research Centre, Tübingen, Germany
 GAP Summit 2017, Georgetown University, Washington, DC
 Food & Drug Administration, Silver Spring, MD
 Keynote Speaker, 2017-2018 Icahn SOM at Mount Sinai Annual Retreat, Ellenville, NY
 Mahmoud Ghannoum 20th Anniversary Symposium, University Hospitals Cleveland
 Medical Ctr, Ohio
 Middle Tennessee State University, Murfreesboro, TN
 National Research Council of the Swiss Nation, Berne, Switzerland
 Columbia Law School, New York, New York

2018 SPRIG Speaker, National Institutes of Health, Bethesda, MD
 Columbia Law School, New York, New York
 Plenary Speaker, 14th European Conference on Fungal Genetics, Haifa, Israel
 Speaker, Biosecurity Luncheon, The National Academies of Science, Engineering and
 Medicine, Washington, DC
 Speaker, Israel Society for Medical Mycology, Tel Aviv, Israel
 Speaker, United States Uniformed Health Services, Bethesda, MD
 Speaker, University of Connecticut, Storrs, CT
 Speaker, Signals of Trust Science Communication, Cold Spring Harbor, Lloyd Harbor, NY
 Speaker, University of Nebraska Medical Center, Omaha, NE
 Speaker, Broad Institute, Cambridge, MA
 Keynote Speaker, Kelsey Lecture, The University of Texas MD Anderson Cancer
 Center, Houston, Texas

Keynote Speaker, Van Andel Institute, Grand Rapids, MI
Speaker, Gordon Research Conference Extracellular Vesicles, Newry, ME
Speaker, Duke University MGM annual retreat, Durham, NC
Speaker, 8th BMMC Conference, Dublin, Ireland
Speaker Fungal CIFAR Workshop, Toronto, Canada
Speaker, Center for Valley Fever Symposium, Sacramento, California
Speaker, Tulane University School of Medicine, New Orleans, LA
Speaker, University of Pittsburgh, Pittsburgh, PA
Speaker, Columbia Law, New York, NY
Speaker, Albert Einstein College of Medicine, New York, NY

2019

Speaker, University of Alabama, Birmingham, Alabama
Speaker, University of Maryland Baltimore, Baltimore, Maryland
Speaker, Johns Hopkins School of Medicine, Baltimore, Maryland
Speaker, Columbia Law, New York, NY
Speaker, University of Arizona, Tucson, Arizona
Speaker, Baruch College CUNY, New York, NY
Speaker, APSA, Chicago, IL
Speaker, World Vaccine Congress, Washington, DC
Speaker, University of Buffalo, Buffalo, New York
Speaker, UT Southwestern Medical Center, Dallas, TX
Speaker, Merck Research Laboratories, Boston, MA
Speaker, Rocky Mountain Laboratories, Hamilton, MT
Speaker, Melanin Workshop, Silver Spring, MD
Speaker, Cancer Biology Training Consortium, Baltimore, MD
Keynote Speaker, Queen's University of Belfast, Belfast
Speaker, Cornell University, New York, New York
Speaker, NASA Glenn Research Center, Cleveland, Ohio
Speaker, National Academies of Sciences, Engineering and Medicine, Washington, DC
Speaker, Rockefeller University, New York, New York